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 1 
PURPOSE 
Benign prostate hypertrophy (BPH) and prostate cancer (PC) are highly common 
among aging men causing bothersome symptoms or developing into life-threatening diseases. 
Both disorders become clinically manifest after 50 years of age, however, preliminary stages 
in their development can be recognized many years earlier. Aging is, therefore, a risk factor 
for the diseases. Disease of the prostate has generally been perceived as being associated with 
particular voiding problems considered by many men to be merely features of the aging 
process. The past decade has witnessed a major change in the attitude towards the various 
diseases of the prostate gland. The increasing incidence of BPH and PC has been related to 
the identification of a large number of prevalent, but previously undetected cases in the 
population through widespread screening using the prostate-specific antigen-test.
1
 
Consequently, the overall prognosis for prostate cancer patients has dramatically improved 
over the years. Unfortunately, whereas the treament and relief of BPH has noticeably 
progressed, the treatment of invasive PC has remained elusive. In an era of increasing life 
expectation, the prevention of diseases affecting the aging population has gained momentum 
and a lot of research is being carried out on the potential of chemopreventive agents present in 
the diet. 
Epidemiological data show that the mortality risk associated with prostate cancer is 
much higher in European and American countries compared to Asian countries, even though 
the incidences are comparable. Migrants, who move from areas of low risk for particular 
cancers to areas where the risk is higher, have an increased risk for developing clinical PC 
and this suggests that environmental factors such as diet rather than genetical factors are 
involved. It has been recognized that certain constituents of the Asian diet and of the 
Mediterranean region protect against the development of PC and the lack of these constituents 
in the Western diet seems most important in the observed risk differences. Because diet seems 
associated with a lower mortality risk of PC in Asian people and because the consumption of 
soy is one of the most striking differences between Western and Eastern diets, an association 
with phytoestrogens that are present in signficant amounts in soy has been suggested. 
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Phytoestrogens are plant-derived compounds that possess weak estrogenic activities. 
In contrast to the notion that estrogens are essential in female hormonal regulations, the role 
of estrogens in the male neuro-endocrine system has only recently been accepted. The 
detection of the estrogen receptors ER and ER in the male gonads and the prostate has been 
crucial in this respect. Phytoestrogens could influence hormone-dependent diseases including 
BPH and PC by their varying bioactivities such as roles in production, metabolization and 
biological activities of endogene hormones, the activities of intracellular enzymes, growth 
factors, protein synthesis, cell proliferation, differentiation and adhesion and processes such 
as angiogenesis.  
In view of the prevention of the development and progression of benign and malign 
prostate disorders by altering dietary habits or by the intake of food supplements, it seems 
timely to study phytoestrogen-containing plants for their chemopreventive activities regarding 
BPH and PC. Hop (Humulus lupulus L.) is a rich source of prenylflavonoids and, in 
particular, 5 compounds are most interesting for their bioactivities including estrogenicity. 8-
Prenylnaringenin proved to be the most potent phytoestrogen known to date, while 
xanthohumol is devoid of any estrogenicic properties. 6-Prenylnaringenin, isoxanthohumol 
and desmethylxanthohumol demonstrated very weak estrogenic activities.  
This Ph. D. project deals with investigations into the chemopreventive or therapeutic 
potential of hop-derived prenylflavonoids with respect to prostate diseases, in particular PC. 
We aimed to get insights in how the hop-derived prenylflavonoids xanthohumol (X), 
desmethylxanthohumol (DMX), isoxanthohumol (IX), 8-prenylnaringenin (8PN) and 6-
prenylnaringenin (6PN) influence the pathogenesis of PC and in how the underlying 
mechanisms operate. Therefore, we investigated the antiproliferative and cytotoxic properties 
in order to determine the relative potencies of the individual hop-derived prenylflavonoids in 
inhibiting the growth of human prostate cancer cells LNCaP.FGC, PC-3, and DU145, and to 
assess the sensitivities of the different cell lines to these compounds. LNCaP.FGC are unique 
androgen-sensitive human prostate carcinoma cells derived from a supraclavicular lymph 
node, that have retained functional differentiation of prostatic epithelial cells.
2
 PC-3 and 
DU145 are androgen-insensitive prostate cancer cells derived from brain metastases of an 
untreated prostate cancer patient and from bone metastases of a patient with androgen-
independent prostate cancer, respectively.
3,4
 These cell lines have been widely used as models 
for prostate cancer in both basic research and chemopreventive studies.  
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As the antiproliferative effects of the prenylflavonoids on cancer cells may be 
mediated through hormonal - in particular estrogenic - mechanisms, we additionally assessed 
the estrogenic activity by a growth stimulatory experiment and an estrogen-inducible yeast 
screening assay (yeast estrogen screen; YES). 
 Agents with potential antiangiogenic properties could be promising anticancer drugs. 
Therefore, we investigated the hop-derived prenylflavonoids in vitro for their antiangiogenic 
activities using a human bone marrow endothelial cell line (HBME). 
Finally, more research was performed to get insights into the underlying mechanisms 
by which the hop-derived prenylflavonoids influence cell proliferation by investigating the 
kinetics of their time-dependent antiproliferative activities and the morphological changes of 
the treated cells for typical apoptotic features.  
 
                                                
 
 
1
 Carter HB, Coffey DS. The prostate: an increasing medical problem. Prostate, 1990, 16: 39-48. 
2
 Horozewicz JS, Leong SS, Kawinski E, Karr JP, Rosenthal H, Chu TM, Mirand EA, Murphy GP. LNCaP 
model of human prostatic carcinoma. Cancer Res, 1983, 43: 1809-1818. 
3
 Stone KR, Mickey DD, Wunderli H, Mickey GH, Paulson DF. Isolation of a human prostate carcinoma cell 
line (DU145). Int J Cancer, 1978, 21: 274-281. 
4
 Kaighn ME, Shankar N, Ohnuki Y, Lechner F, Jones LW. Establishment and characterization of a human 
prostatic carcinoma cell line (PC-3). Investig Urol, 1979, 17: 16-23. 
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1 Hop (Humulus lupulus L.) 
1.1 Botanical overview 
1.1.1 Taxonomy and ethymology 
According to the most recent International Code of Botanical Nomenclature (St Louis 
Code) adopted by the 16th International Botanical Congress in 2000, the current name for the 
family, comprised only of the two genera Humulus L. and Cannabis L., is Cannabaceae. 
Other names still applied to this family are Cannabinaceae and Cannabidaceae.1 The name of 
the genus, Humulus, is thought to originate from humus (ground, earth) referring to the rich 
ground in which the plant flourishes. Others believe that it refers to the manner of growing 
close to the ground when the plant is not supported. And even others assert that Humulus 
comes from umidus or moist because of the preferential growth in moist earth. Undoubtedly, 
lupulus is derived from the Latin lupus or wolf, because of the characteristic of hops to 
strangle neighbouring plants while climbing up, in an analogous way as a wolf strangles his 
prey. The word hops has been used since the 8th century and it is believed to be deduced 
either from the Anglo-Saxon hoppan, which means ‘to climb’ or from the old-german hopfo, 
which means ‘to raise’, thus both referring to the growing characteristics. 
The genus Humulus L. comprises three species: Humulus lupulus L., Humulus 
japonicus Sieb. & Zucc. (Humulus scandens (Lour.) Merr.), and Humulus yunnanensis Hu. 
Humulus lupulus L. is the most common species with approximately 40 varieties (cultivars). 
It was first domesticated in central Europe and is currently naturalized throughout the 
northern temperate regions of the world as well as some temperate regions in Australia, 
South-Africa, and South-America. Humulus japonicus Sieb. & Zucc. is grown as an 
ornamental plant and is of no economical use. It is endemic to East-Asia. Humulus 
yunnanensis Hu. can only be found in the Yunnan Province in China and, apart from the 
botanical description, no data are available about this species, which is due to its very limited 
occurrence, but also because this species is very often wrongly identified as Humulus lupulus 
L. 
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 Wild hops are found ubiquitously. There are accounts by early European settlers in 
North-America of wild hops being present when they arrived there.2,3 Wild American hops 
readily interbred with European cultivars brought by the settlers.3 
The names H. americanus Nutt., H. neomexicanus Rydb., H. volubilis Salisb., H. 
vulgaris Gilib., Lupulus communis Gaertn., and L. humulus Mill. are probably synonyms for 
various H. lupulus varieties including var. lupulus (European hops), var. cordifolius (Miq.) 
Maxim in Franch. Et Sav. (H. cordifolius Miq.) native to East-Asia, var. lupuloides E. Small, 
native to the Missouri-Mississippi river basin, var. brachystachyus Zapalowicz and var. 
neomexicanus Nelson et Cockerell (H. neomexicanus Rydberg) native to South-West United 
States. Over 100 hop cultivars have been selected, mainly for their high contents of  bitter 
acids, while others were selected for many generations primarily for their contents of volatile 
oil.2,3 
1.1.2 Botanical description 
 
 
Figure 1.1 Humulus lupulus L. (Photo copyright Henriette Kress, http://www.henriettesherbal.com). 
The hop plant is a tall dioecious perennial climbing vine growing very fast from spring 
through summer.4 It can reach heights from 3 m up to 10 m sometimes growing up to 30 cm 
per day. In autumn and winter, the aboveground annual parts of the plant die. Every year, in 
early spring, numerous shoots are produced from the remaining expanding rootstock, from 
which new plants can sprout having a rough square to hexagonal stem that swings clockwise 
around trees and attaches by fine two-pointed hairs. Most of these shoots are removed by 
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pruning and only 3 to 6 are trained-up strings, when they have reached a length of about 1 m. 
As the root system of adult plants can extend to more than 1.5 m in depth and 2 m laterally, 
rich and deep soils are required for efficient growing. The vigorous and fast growth from 
April to July requires large amounts of fertilizer and a regular supply of water either by 
natural rainfall or via irrigation systems.  
The leaves of the hop plant are rough, pale-
green, tri- to pentalobate or heart-shaped with a 
long stalk and sawed edges. They can grow up to 
15 cm long, are singular, cross-wise opposed, with 
a hand-shaped nervure and they possess little 
supportive leaves that are single-lobed. During July 
and August, the male plants carry small flowers 
(stamens) standing in groups in the axil of the 
leaves. The flowers of the female plants, appearing 
from the 3rd growing season, develop into greenish-yellow, ovoid catkins formed of 
membranous scales (bract and bracteoles), which partially overlap, and they have fine veins. 
When at the end of the summer the stalks wither, the female inflorescence have reached 
ripening and can be harvested as ovoid, brownish, scaled hop cones or strobiles. The inside of 
bract and bracteoles contains oleoresin glands that 
appear as small yellow-orange granules and 
constitute lupulin, a resinous, yellow-orange powder. 
Lupulin contains numerous compounds that are of 
economical interest especially in the beer brewing 
industry and, therefore, only the female hop plants 
are being cultivated. In some hop growing areas, 
particularly England, male plants are cultivated 
together with the females in order to produce seeds 
in the hop cones following pollination and, accordingly, to improve crop yields. However, in 
other parts of the world, it is forbidden to cultivate a male plant, and, in Belgium, wild males 
must be removed within 5 km from a female plant, because fertilized hop cones contain hard 
greasy seeds that adversely influence the beer quality.  
Figure 1.2 Humulus  lupulus L. Stamens on 
the male plant (Photo copyright Henriette 
Kress, http://www.henriettesherbal.com). 
Figure 1.3 Humulus  lupulus L. Hop cones 
from the female plant  (Photo copyright 
Henriette Kress, 
http://www.henriettesherbal.com). 
LIES DELMULLE 155x240 - 148 blz - INDESIGN.indd   18 05-11-2007   15:54:38
 7 
When the hop cones are harvested, they have a moisture content of 75% to 80% (w/w) 
and, in order to prevent deterioration before storage or processing, reduction to less than 12% 
(w/w) is necessary. This moist reduction, achieved by hot air dryers, is very critical with 
respect to the hop quality. High temperatures, especially above 65°C, may accelerate 
oxidative decomposition of major constituents. Dried hops are recommended to be stored at 
low temperatures prior to processing or further use. The hop plant is commercially productive 
between 12 and 20 years. 
1.1.3 Plant origin 
Hop originates very likely from East-Europe. The plant has been cultivated for more 
than a millenium. At present, it grows wild in the hedges and wood skirts of the northern 
temperate climate zones of the world including Europe, North-America, and West-Asia, 
extending roughly from 35 to 55 degrees of latitude in humus-rich, moist soils. The material 
of commerce comes exclusively from female plants cultivated primarely in the United States, 
Germany, Great Britain, Czech Republic, China, but also in South-Africa and Australia3. 
1.2 Use of hops 
1.2.1 Traditional use 
Hops have been reputed for their bioactivities since ancient times. This was expressed 
in the treatment of a variety of diseases and in the widespread use as a health-promoting plant. 
In the 1st century after Christ, Plinius mentioned the breeding of hops in the roman gardens 
for the culinary use of the shoots, which were served as a delicacy in spring. Today, the 
shoots are still eaten and prepared in many different ways as kind of special asparagus, in 
soups or even raw in salads, but they are very expensive. The young leaves can also be eaten 
usually mixed in salads.  
There was presumptive evidence of the use of hops for its calming, sleep-inducing, 
and libido-diminishing effects already during early medieval times. The pillows of restless 
children were stuffed with hop cones to induce sleep, give pleasant dreams or to reduce pain 
as they suffered from ear or nerve pains. Early medieval texts mention the use of hops for 
their diuretic, blood-purifying, and menstruation-promoting effects. In the 12th century, 
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Hildegard von Bingen stated that barley beers should be prepared with hops. She asserted that 
hops used as a spice cause a sad and melancholic mood. The North-American Indians used 
hops successfully for sleeplessness and pain and as a gyneacological remedy against breast 
and uterus problems. 
Since the 14th century in the Netherlands and in Belgium, and since the 16th century in 
England, hops became one of the most important ingredients for beer brewing, because of the 
contributions to the bitter taste and overall flavor, and the natural preservative effects. 
However, in England, the use of hops in brewing was initially barred and the parlement stated 
that hops was ‘a wicked weed that would spoil the taste of the drink and endanger the people’. 
In the 17th century, hops were advized by Culpeper for the treatment of jaundice, liver 
and stomach diseases, headache, and infections of the skin, and as a blood-purifyer. The 
digestion-enhancing effect of hops had been described earlier by Paracelsus (2nd century) and 
hops had been used as a stomach tonic since then. 
The calming and sleep-inducing activities of hops that were well-known among hop 
pickers could have been caused by transferring the hop resins from hand to mouth or by 
inhalation of hop essential oils. Among female hop pickers, menstrual disturbances were 
commonly reported, while male pickers could suffer from gyneacomasty.2,4 
1.2.2 Modern use 
Nowadays, the main use of hops is for beer brewing. Hops are responsible for the 
bitter taste of beer and the typical ‘hoppy’ aroma. Barley malts often have a sweety, 
unpleasant flavor and the hop bitterness is of the utmost importance for beer to balance this 
sweetness. However, at first, this use was not really appreciated. Originally, hop was only 
added for its natural preservative value protecting beer against microorganisms and 
deterioration of taste stability, thereby enhancing the keeping quality of beer when brewing 
became an industry. Another advantage of the use of hops in beer brewing refers to the beer 
foam-stabilising properties. The hop constituents responsible for these beneficial effects in the 
process of beer brewing have been studied extensively.  
Due to its prominent mild sedative and weak hypnotic effects, a great number of hop-
containing preparations are on the market, mostly in combination with other sedative herbs 
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such as Valeriana officinalis (valerian), Melissa officinalis (lemon balm), Passiflora 
incarnata (passion flower). These preparations are used for anxiety, nervousness, and 
insomnia, which stems from the anecdotal evidence of sleepiness among hops pickers in the 
past. The German Commission E Monograph lists hops as an approved herb for “mood 
disturbances such as restlessness and anxiety and for sleep disturbances”.5 Although there 
have been no meaningful clinical trials to support hops as a sedative, several studies have 
demonstrated that formulas combining hops with other sedative herbs are effective for 
insomnia.6,7 Combinations of hops with valerian and passion flower or lemon balm are also 
approved by the German Commission E as sedative and sleep-promoting formulas. Reports 
have indicated that preparations of hops have sedative-like activity in frogs, pigeons, mice, 
goldfish, and golden carp.8 Clear understanding of the biochemical mechanism and the 
conclusive identification of compounds responsible for such activity have not yet been 
achieved. Sikorski and Rusiecki9 reported that both humulone and lupulone were “strongly 
sedative to pigeons and small birds, and somewhat less active on mice”. Most attention has 
been given to volatile constituents of the hop essential oil. A degradation product of 
humulone and lupulone, 2-methylbut-3-en-2-ol, has been suggested as the active compound 
and it was shown to be sedative in mice.10,11 Wohlfart et al. could not detect this compound in 
fresh hops and they observed that it reaches a maximum concentration after 2 years of storage 
at room temperature. Thus, if this compound can fully explain the sedative activity attributed 
to hops, it must be formed from hop constituents such as bitter acids that would then be 
considered as “pro-drugs”. Hänsel and Wohlfart12 asserted that the sedative effect of hops was 
not due to its content of myrcene, which was since shown to have an analgetic activity in 
mice.13 As mentioned above, hops also has its use in the culinary field as well as in cosmetics 
being an ingredient for relaxing bath oils and others.  
Hop extracts and/or compounds have been reported to be active in the following 
assays: antioxidant and/or chemoprevention, antimicrobial (particularly against Gram-positive 
bacteria), antigonadotropic, and cytotoxic. Recently, a lot of attention has been given to the 
health-beneficial effects of hop polyphenols. Research carried out on the alleged hormonal 
activity from hops has led to the identification in 1999 of a strong estrogenic compound, 8-
prenylnaringenin.14 The discovery of this compound provided the explanation for the reported 
hormonal disturbances in female hop pickers in the past. 8-Prenylnaringenin was shown to be 
one of the most potent phytoestrogens currently known. Our laboratory has expanded its 
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research on the possible beneficial activities of hop polyphenols, especially of prenylated 
chalcones and flavanones.  
1.3 Hop chemistry 
Several hundreds of constituents have been identified in hops15,16 as secondary 
metabolites that are concentrated in the lupulin glands. Among the many different classes of 
compounds present in lupulin, hop bitter acids, hop essential oil, and hop polyphenols are the 
most important ones, not only for the commercial uses of hops, but also as chemical markers 
to distinguish between different hop cultivars.17  
Table 1.1 Average composition of dried hop cones 
Compounds Percent (w/w)
_-Acids 2-19
_-Acids 2-10
Hop oil 0.5-3.0 (v/w)
Polyphenols 3-6
Monosaccharides 2
Amino acids 0.1
Proteins 15
Lipids and fatty acids 1-5
Pectins 2
Ash - salts 10
Cellulose - lignins 40-50
Water 8-12  
1.3.1 Presence of hop-derived prenylflavonoids 
A mixture of prenylated, geranylated, oxidized, and/or cyclized chalcones, is secreted 
by the lupulin glands along with the hop bitter acids and the hop essential oil.14,18,19,20,21,22,23 
The chalcone xanthohumol (X, Figure 1.4, 1) is the most abundant prenylated flavonoid in 
fresh and properly preserved hops present in concentrations exceeding 1%.20,21,22 A majority 
of the known flavonoids from hops can be considered as derivatives of 2’,4,4’,6’-
tetrahydroxy-3’-prenylchalcone, commonly known as desmethylxanthohumol (DMX, Figure 
1.4, 3), which is found in hops in much smaller amounts compared to X. With the exception 
of two geranylated compounds, which have only be detected by MS,20,21 all known 
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constituents of hops from this series are prenylated at either the 6-position or the 8-position or 
both. X isomerizes readily by an intramolecular Michael-type addition to the flavanone 
isoxanthohumol (IX, Figure 1.4, 2), the reaction reportedly proceeding more rapidly with 
increasing pH.19,20,21 Isomerization of the chalcone DMX to a mixture of 6-prenylnaringenin 
(6PN, Figure 1.4, 4) and 8-prenylnaringenin (8PN, Figure 1.4, 5) is the so-called conversion 
of Nastainczyk,24,25 which may occur spontaneously during hop storage.  
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Figure 1.4  Hop-derived prenylflavonoids. (*Intramolecular Michael-type addition). 1, Xanthohumol (X); 
2, Isoxanthohumol (IX); 3, Desmethylxanthohumol (DMX); 4, 8-Prenylnaringenin (8PN); 5, 6-
Prenylnaringenin (6PN). 
It must be stressed that the name of the compound 8PN used in the English hop 
literature is misleading for a variety of reasons. Naringenin is a chiral natural product usually 
with a S-configuration at the stereocenter C-2. The prenylated flavanone 8PN from hops is a 
racemate, which should be noted as (±)-8PN.22,24 The natural chiral compound 8PN has been 
identified in Sophora flavescens Ait., a fabaceous shrub native to Asia, and this compound is 
known in the literature as 8-isopentenylnaringenin26 or sophoraflavanone B.18 To prevent 
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misunderstanding, it may be preferable to use the name ‘hopein’ coined by Prof. Dr. D. De 
Keukeleire27 when referring to the hop constituent 8PN. 
1.3.2 Biosynthesis of hop-derived prenylflavonoids 
The lupulin glands of hops produce exclusively free flavonoids of the chalcone type. 
Furthermore, the lupulin glands are able to transfer methyl and prenyl functions to phenolic 
rings like chalconaringenin and phloroglucinol. Prenylflavanones such as IX, 8PN, and 6PN 
are formed in the absence of chalcone isomerase. The type of reaction resulting in ring closure 
of the chalcone structures to form flavanones is referred to as an intramolecular Michael-type 
addition. This isomerization may occur in any chalcone containing a free 2’- or 6’-hydroxy 
group and, when hydroxyls are present both at the 2’-position and the 6’-position, two 
regioisomers are produced. 
1.3.3 Biological activities of hop-derived prenylflavonoids 
A wide range of biological activities such as antiallergenic, antiinflammatory, 
antiviral, antifungal, antibacterial, antioxidative, antiproliferative, and anticarcinogenic effects 
have been observed with various natural flavonoids.28 Recent interest in hop polyphenols 
stems from the results of research on other beverages, especially wine, in which scientifically 
based arguments have highlighted the beneficial effects of consumption of polyphenols 
during moderate drinking of - in particular - red wine. The well-known health-protective 
properties of tea, especially of green tea, have repeatedly been shown to be caused by specific 
polyphenols.  
1.3.3.1 In vitro estrogenic activity 
The recurring suggestion that hops has a powerful estrogenic activity has been obvious 
from its traditional use in baths to treat gynaecological disorders29,30,31,32,33 and from reports of 
menstrual disturbances amongst female hop pickers. A number of journal articles29,34,35 and 
patents exist concerning the use of the estrogenic properties of hops. Koch and Heim reported 
in 1953 that hops contain ‘the equivalent of 20-300 g estradiol/g’.36 Chury published in 1961 
that the estrogenic activity for a saponified ethanol extract of hops was approximately 200-, 
150- and 50-times the activities observed for peas, red clover, and cabbage, respectively.37 
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However, even though the estrogenic properties of hops were well established, the hop 
fraction or the individual compounds responsible for the estrogenic activity remained 
unknown.  
In 1972, Nastainczyk reported the isolation of a compound named ‘hops pro-estrogen’, 
which is isomerized to a mixture called ‘hops estrogen’.25 In 1988, Hänsel and Schulz 
identified Nastainczyk’s ‘hops pro-estrogen’ as 3’-prenylnaringenin chalcone (now better 
known as DMX). Furthermore, they revealed that the ‘hops estrogen’ was a mixture of 8PN 
and 6PN. The researchers asserted, without experimental data, that 6PN was not estrogenic, 
but they did not state explicitly that 8PN is the active estrogen. However, they were the first 
to correctly report the chemical structure of the principal estrogenic component of hops. 
Following this report, contradictory literature reports on the estrogenically active fraction 
were published, probably due to the variable nature of the extracts and the variety of assays 
used. 
In 1997, De Keukeleire et al. examined the estrogenic activity of various hop fractions 
and individual compounds using a sensitive in vitro bioassay based on the ability of 
compounds with estrogenic activity to stimulate alkaline phosphatase activity in a human 
endometrial adenocarcinoma Ishikawa-Var I cell line.38 Estrogenic activity could only be 
found in the polyphenolic extracts and X, the compound until then believed to account for the 
potent estrogenic activity of hops, was shown to be inactive.  
The report in 1999 by the same research group in collaboration with Milligan et al. 
from King’s College (London) may be regarded as the beginning of the modern, unambiguous 
understanding of the in vitro estrogenic activity of hops.14 Milligan et al. identified the 
estrogenically active compound as 8PN by using 2 sensitive and specific in vitro bioassays 
(Ishikawa-Var I assay and an estrogen-inducible yeast screen from Saccharomyces cerevisiae) 
and proved that it was the most potent phytoestrogen known. The estrogenic activity of 8PN 
was completely blocked in Ishikawa cells by the anti-estrogen ICI 182,780, demonstrating 
that 8PN exerts its estrogenic effect by interaction with the estrogen receptor(s). 6PN 
displayed only very weak estrogenic activity (<1/100 of 8PN) and IX was weakly active in 
the Ishikawa Var I assay (1/100 of 8PN), but not active in the yeast cells. X was inactive in 
both assays. The relatively high estrogenic potency of 8PN was reflected in its ability to 
interact with the estrogen receptors in a competitive binding assay with rat uterine cytosol. IX 
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showed no activity in the receptor binding assay suggesting that its weak activity in the 
Ishikawa cell assay may have reflected metabolic conversion to 8PN.  
In 2000, again by the same group of investigators, the endocrine properties of various 
hop flavonoids, to which humans are exposed, were investigated.39 6PN, 6,8-
diprenylnaringenin, and 8-geranylnaringenin exhibited some estrogenic activity with a 
potency less than 1% compared to 8PN. The other compounds investigated (X, IX, 3’-
geranylchalconaringenin, 6-geranylnaringenin, 4’-O-methyl-3’-prenylchalconaringenin) 
showed no estrogenicity. 8PN competed strongly with 17-estradiol for binding to both ER 
and ER, whereas 8-geranylnaringenin showed only weak competition. None of the other 
compounds were able to displace [3H]-17-estradiol from either receptor. There was no 
evidence of either progestogenic or androgenic bioactivity in the polyphenolic hop extracts or 
for pure prenylflavonoids. However, Zierau et al. demonstrated in 2003 strong antiandrogen 
activities for 8PN using a yeast-based androgen receptor assay.40 8PN was able to inhibit the 
androgenic effects induced by 10-8M 5-dihydrotestosterone (DHT) at concentrations above 5 
x 10-6M. In an androgen receptor activity assay based on the analysis of prostate-specific 
antigen concentrations in the supernatants of treated PC3(AR)2 cells, 8PN had no detectable 
antiandrogenic effect. Zierau’s results could not provide evidence for an antiandrogenic effect 
of 8PN, but suggest the ability of this compound to act through the androgen receptor. 
The strong estrogenic properties of 8PN were confirmed by subsequent in vitro 
investigations.39,41,42,43,44,45,46 Kitaoka et al. demonstrated that a prenyl group at position 8 is 
important for binding to the ER.26 They also demonstrated that there were no significant 
differences in ER-binding potencies between the enantiomers of 8PN. However, Schaefer et 
al.47 found that the 2S-enantiomer shows a 2- to 3-fold higher affinity for both ERs compared 
to the 2R-enantiomer, in vitro and in vivo. They reported that 8PN is the first known ER-
selective phytoestrogen exhibiting >2-fold higher affinity for ER than ER measured by an 
in vitro competitive binding assay. Transactivational analysis revealed a >3.6-fold higher 
estrogenic activity of 8PN at ER than at ER, which is in strong contrast to the ER-
selective activation by coumestrol and genistein. It was proven that, on ER, 8PN is 10-fold 
more potent than coumestrol, 100-fold more potent than genistein, and only 70-times weaker 
than 17-estradiol. In vitro, 8PN acts as a pure agonist exhibiting an estrogenic activity profile 
comparable to estrone.  
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Bovee et al. tested the estrogenic potency of several phytoestrogens with ER and 
ER using a rapid yeast bioassay stably expressing human ER and ER.48 The ranking of the 
estrogenic potency with ER was: 17-estradiol >> 8PN > coumestrol > zearalenone >> 
genistein >> genistin > naringenin. The ranking with ER was: 17-estradiol >> coumestrol > 
genistein > zearalenone > 8PN >> naringenin > genistin. Effenberg et al. demonstrated that 
6PN, X, and IX, but not 8PN show ER-preference.49 In vitro evaluation of the estrogenic 
activity of hop extracts showed significant competitive binding to ER and ER, induction of 
alkaline phosphatase activity, upregulation of progesterone receptor mRNA in cultured 
endometrial cells, and upregulation of presenilin-2, another estrogen-inducible gene.50 
1.3.3.2 In vivo estrogenic activity 
The relative in vivo potency of the estrogenic 8PN was examined in an acute in vivo 
test using uterine vascular permeability as an endpoint.46 8PN and coumestrol were 
considerably less potent (<1%) in inducing a rapid increase in uterine vascular permeability 
within 4 h of administration compared to 17-estradiol. The dose-response relationship for 
8PN was similar to that of coumestrol and a large stimulatory effect was produced by 100 
nmoles 8PN. The amount of genistein to produce the same effect was at least 10-fold greater. 
The administration of 100 g ml-1 8PN to ovariectomized mice in their drinking water 
produced a significant estrogenic increase in vaginal mitosis after 72 h, which could be 
compared to the effect produced by the administration of 100 ng ml-1 17-estradiol. However, 
as opposed to 17-estradiol, 8PN had no effect on uterine mass and epithelial mitosis.  
Schaefer et al. assessed the in vivo estrogenic potency of 8PN for ER by classic 
uterine and vagina growth assays in juvenile rats and reported that 8PN has a affinity for ER, 
which is 20,000-fold less potent than that of 17-estradiol, while, in vitro, 8PN was found 
only 70-fold less potent than 17-estradiol in binding ER47. 
Diel et al. also investigated the in vivo estrogenic potency of 8PN by carrying out a 
three-day uterotrophic assay on ovariectomized young female rats.51 A single dose of 8PN (10 
mg/day/kg body mass) significantly stimulated uterine wet weight accompanied by a 
proliferative response, which was comparable to a single dose of 17-estradiol (0.03 
mg/day/kg body mass). The treatment resulted in a statistically significant increase of the 
uterine epithelial height as well as of the vaginal epithelial height. In response to treatment 
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with 8PN, the same change in gene expression pattern in the uterus and in the liver was 
observed as in reponse to treatment with 17-estradiol, but it wass less pronounced. 
Conversely, 8PN was found to be more potent than 17-estradiol in inducing expression of 
insulin-like growth factor binding protein 1 (IGFBP-1). This report again provides 
overwhelming evidence that 8PN has largely to be regarded as a pure estrogen agonist.  
Noteworthly is the work of Zierau et al., who compared the estrogenic effect of the 
phytoestrogens naringenin, 8PN, and 6-(1,1-dimethylallyl)naringenin in 2 mammalian in vitro 
systems and in fish as in vivo system.52 They observed strong differences. In the in vivo assay, 
no estrogenic effects of the naringenin-type flavonoids were observed, while the mammalian 
in vitro systems showed a similar and graded response to the test compounds.  
1.3.3.3 Effect on bone resorption and uterus growth 
Bone remodelling is a dynamic process, which is maintained by a balance between 
bone formation and bone resorption. It has long been recognized that the acute loss of 
estrogen at the onset of menopause is responsible for an accelerated bone loss in women, 
called Type I osteoporosis,53 which is characterized by an imbalance in bone remodelling and 
leads to an increased fracture risk. Hormone replacement therapy (HRT) is currently the most 
common therapy used for peri- and postmenopausal women to prevent bone loss. However, 
while HRT has a positive effect on bone, climacteric symptoms, and the cardiovascular 
system, there are also increased risks of breast and endometrial cancers after some period of 
application.53,54 Certain plant-derived compounds show selective estrogen-receptor modulator 
(SERM) activity. Such SERMs display the desirable estrogenic effects, but lack the 
undesirable side effects and may, therefore, be alternatives to conventional HRT. 
Tobe et al. made the interesting observation that bone resorption is inhibited by X in 
the pit formation assay.55 A dose-dependent inhibition was observed both for X (IC50 1–10 
μM). Miyamoto et al. examined the effect of 8PN in vivo on uterus and bone metabolism in 
ovariectomized rats as a model to mimic hormone-dependent osteoporosis in menopausal 
women.56 The rats were treated subcutaneously with 30 mg/kg/day for 2 weeks in comparison 
with 17-estradiol at 0.01 mg/kg/day. They found that 8PN and 17-estradiol completely 
protected from ovariectomy-induced bone loss and that 8PN showed a lower stimulation of 
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the uterus. However, the differences between both treatment groups were small and did not 
reach statistical significance.  
Hümpel et al. studied the effects of 2S-8PN and racemic 8PN in adult ovariectomized 
rats using a treatment of 28 days.57 They demonstrated that 8PN can completely protect from 
ovariectomy-induced bone loss, while exhibiting minimal trophic effects on uterus and 
endometrium. At equivalent bone-protective doses of 17-estradiol and 8PN, the 
phytoestrogen has a 10-fold lower stimulatory effect on uterus and endometrium. In addition, 
it was demonstrated that, in the in vivo situation, no differences in potency or quality of 
effects were noted between the 2S-enantiomer and racemic 8PN. Moreover, the bone tissue-
specific effect of 2S-8PN was confirmed in a transgenic reporter mouse model. 
Effenberger et al. demonstrated that 8PN, 6PN, X, and IX exert estrogen-like activities 
on bone metabolism by examining their effects to modulate markers of differentiation and 
gene expression in normal human fetal osteoblast cells (hFOB) and human osteosarcoma cells 
(U-2 OS) stably transfected with either ER or ER.49 The compounds exerted their dose-
dependent activity effect through ER stimulation.  
1.3.3.4 Anticancer activity 
Several hop-derived prenylflavonoids have been investigated for a specific activity or 
for a range of activities concerning cancer prevention. Each effect can be classified into three 
major cancer-development phases: initiation, promotion, and progression.  
A/ Initiation phase 
Many chemicals in the environment act as carcinogens following activation by 
cytochrome P450.58 Accordingly, compounds that inhibit P450-mediated reactions of pro-
carcinogens could be useful as cancer-chemopreventive agents at the initiation stage of 
carcinogenesis by blocking carcinogen activation. Other than inhibiting these phase I-
enzymes, compounds could exert carcinogen-protective effects by stimulating detoxification 
(stimulation of phase II-enzymes) of the carcinogens formed in phase I.  
Henderson et al. studied the in vitro effects of some hop-derived prenylflavonoids on 
cDNA-expressed human CYP enzymes.59 X almost completely inhibited the 7-
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ethoxyresorufin O-deethylase (EROD) activity of CYP1A1 and CYP1B1 at 10 M. The other 
prenylflavonoids (DMX, IX, 8PN, 6PN) decreased the EROD activity of the enzymes in 
varying inhibitory degrees at the same concentration. In general, prenylated flavanones were 
found to be more active than non-prenylated flavanones or isoflavones in inhibiting these two 
human P450 enzymes expressed in insect cells. In contrast, 8PN and IX proved to be the most 
potent inhibitors of CYP1A2 acetanilide 4-hydroxylase activity (> 90% inhibition at 
concentrations of 10 M) and of the CYP1A2 metabolism of aflatoxin B1 (AFB1) and both 
compounds decreased the covalent binding of radiolabelled AFB1 to microsomal protein in a 
concomitant manner. This proved that prenylflavanones are more inhibitory to human 
CYP1A2 than prenylchalcones. Furthermore, the number and the position of the prenyl 
group(s) on the flavanone structure seemed important regarding the inhibitory activity. 
However, no consistent structure-activity relationship was found in the inhibitory activity of 
the hop-derived prenylflavonoids towards different forms of human P450. X, IX, and 8PN 
were poor inhibitors of CYP2E1 and CYP3A4, thereby proving the important feature that the 
hop-derived prenylflavonoids not only inhibit some important CYP enzymes, but are also 
selective in their inhibition.  
Miranda et al. examined the chalcones X and DMX, and the flavanones IX, 6PN, and 
8PN for their ability to induce the phase II-enzyme, quinone reductase, in wild-type mouse 
Hepa 1c1c7 cells.60 All compounds were found to be potent inducers of the enzyme, X being 
most potent. None of the compounds were found to induce CYP1A1 nor to repress the 
expression of the enzyme. Furthermore, it was demonstrated that X, 8PN, and IX are potent 
inhibitors of the metabolic activation of the heterocyclic amine, 2-amino-3-
methylimidazo[4,5-f]quinoline (IQ). The compounds could potentially act as 
chemopreventive agents against cancer induced by heterocyclic amines activated by 
CYP1A2.61 
Gerhäuser et al. also examined the modulation of the activity of enzymes involved in 
carcinogen metabolism (phase I-enzyme CYP1A) and detoxification (phase II-enzyme 
quinone reductase, QR) and the antioxidant properties of X and IX.62 Both X and IX were 
identified as potent inhibitors of CYP1A activity in vitro, with IC50 values of 0.022 ± 0.002 
M and 0.30 ± 0.13 M, respectively. X was found to induce the specific activity of QR in a 
dose-dependent manner with a concentration-dependent value of 1.67 ± 0.23 M. Loss of the 
,-unsaturated keto by cyclization to the flavanone IX reduced the QR-inducing potential. X 
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and IX were identified as effective antioxidants with a capacity to scavenge physiologically 
relevant reactive oxygen species (ROS), including hydroxy and peroxy radicals for X and IX, 
and superoxide anion radicals for X. 
Dietz et al. studied the effect of a hop extract on QR and found that X was most 
effective at inducing QR with a concentration required to double the specific activity of QR of 
1.7 ± 0.7 M.63 They also investigated the reporter activity mediated by the androgen 
response element (ARE) in HepG2-ARE-8 cells after incubation with X for 24 h. X increased 
ARE-reporter activity in a dose-dependent manner. Moreover, it was shown that X alkylates 
human Keap1 protein most likely on a subset of the 27 cysteines of Keap1. This suggests that 
X induces QR by covalently modifying the Keap1 protein. Liu et al. developed a new 
screening method for the discovery of potential cancer chemoprevention agents based on 
mass spectrometric detection of alkylated Keap1 and they confirmed that X is a potent 
inducer of QR and that it reacts with Keap1.64  
B/ Promotion phase 
As potential antitumor-promoting mechanisms, X demonstrates antiinflammatory 
properties by inhibition of the constitutive form of cyclooxygenase Cox-1 and, more 
importantly, the inducible Cox-2 activity, which is linked to carcinogenesis with IC50 values 
of 16.6 ± 1.8 M and 41.5 M, respectively. IX was inactive with respect to both enzymes 
(IC50 > 100 M).62 
C/ Progression phase 
Miranda et al. investigated 6 hop-derived prenylflavonoids for their ability to inhibit 
the proliferation of human breast cancer (MCF-7) cells, colon cancer (HT-29) cells, and 
ovarian cancer (A2780) cells in vitro.65 A dose-dependent growth inhibition of the MCF-7 
cells was observed with X, IX, and dehydrocycloxanthohumol (DCX). The IC50 values were 
3.47, 6.87, and 4.69 μM, respectively, after 4 days of exposure. X and DCX were even more 
cytotoxic against ovarian cancer (A2780) cells with IC50 values of 0.52 and 5.00 μM, 
respectively, at 2 days of exposure. The viability of colon cancer (HT-29) cells was hardly 
decreased; X, IX, and 4 other prenylflavonoids showed a weak growth-inhibitory effect with 
IC50 values greater than 10 μM. X was the most cytotoxic prenylflavonoid in these studies, 
indicating that modification of its structure (cyclization of the prenyl function, demethylation, 
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and isomerization of the chalcone nucleus) leads to partial loss of cytotoxicity against the 3 
human cancer cells in vitro. None of the 6 prenylflavonoids was toxic to normal (rat 
hepatocyte) cells at 10 μM. These findings demonstrate that specific prenylflavonoids from 
hops have preferential growth-inhibitory effects on tumor cells, which cannot be explained by 
a general toxic effect. 
The effect of 8PN was investigated on aggregation, growth, and invasion in the human 
MCF-7 breast cancer cell line family.43,66 MCF7/6 cells showed a poor tendency to aggregate 
in slow aggregation assays. Treatment with 8PN at 10 M and 1 M had a beneficial effect 
on the aggregation, as was evident from the formation of larger and more compact aggregates. 
A significant growth-stimulatory effect was observed in cultures treated with varying 
concentrations of 8PN. 8PN had no effect on invasion in the embryonic chick heart assay. 
8PN had similar effects as 17-estradiol: it promotes cell-cell adhesion and growth without an 
effect on invasion. Xanthohumol was found to inhibit invasion of human breast cancer 
MCF7/6 and T47-D cells and to induce apoptosis of these cell lines67. 
Antiproliferative mechanisms of X to prevent carcinogenesis in the progression phase 
include inhibition of DNA synthesis (inhibition of DNA-polymerase- activity in vitro, as 
well as thymidine incorporation into newly synthesized DNA in vivo) and induction of cell 
cycle arrest in the S-phase and apoptosis in an ER-negative MDA-MB-435 mammary 
carcinoma cell line. Finally, X could induce terminal cell differentiation in transformed cells 
as a mechanism of prevention that is effective in late stages of carcinogenesis. These 
anticarcinogenic effects were verified in vivo demonstrating that X prevents carcinogen-
induced preneoplastic lesion in mouse mammary gland organ culture in the nanomolar range 
(IC50 value of 0.02 M).62  
DMX has been investigated for its antiproliferative and apoptotic activities. It was 
found to be antiproliferative and to induce apoptosis via the mitochondrial pathway in BJAB 
cells (Burkitt lymphoma cell line) and in primary lymphoblasts of childhood acute 
lymphoblastic leukaemia (ALL).68 Pepper et al. demonstrated that 8PN inhibits angiogenesis 
induced by basic fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF) 
or the synergistic effect of the two cytokines in combination, with an IC50-value of 3-10 pM 
using bovine microvascular endothelial cells derived from the adrenal cortex (BME cells) and 
from the thoracic aorta (BAE cells).69 The in vitro inhibitory effects of 8PN were comparable 
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to those found for genistein. Results from early chorioallantoic membrane (CAM) assays 
showed reductions in both vessel lengths and vein diameters, with a similar potency in the 
8PN and in the genistein groups.  
1.3.3.5 Effect on lipid metabolism 
Tabata et al. showed that a methanol extract of hop exerted an inhibitory activity 
against rat liver diacylglycerol acyltransferase (DGAT), an enzyme involved in lipid 
metabolism.70 Bioactivity-guided fractionation identified two active chalcones, X and XB 
(xanthohumol B), which inhibited DGAT with IC50 values of 50.3 M and 194 M, 
respectively, in rat liver microsomes.  
Miranda et al. examined the ability of hop-derived prenylflavonoids (X, DMX, IX, 
6PN, 8PN) to inhibit in vitro Cu2+-mediated oxidation of human low-density lipoprotein 
(LDL) by measuring the formation of conjugated dienes and thiobarbituric acid-reactive 
substances (TBARS) and the oxidation of tryptophan residues.71 It was found that especially 
the prenylated chalcones and, to a lesser extent, the prenylated flavanones displayed 
antioxidant activities and thus provide protection against oxidative modification of LDL. 
Moreover, it was shown that the presence of a prenyl group or a methoxy group enhanced the 
antioxidant activities of the chalcones. A prenyl group also appeared to be important in the 
antioxidant activities of flavanones at a high concentration (25 M). 
Rodriguez et al. studied the ability of hop-derived prenylflavonoids to inhibit lipid 
peroxidation by measuring the inhibition of metal-ion (iron)-dependent and independent (tert-
butyl hydroperoxide - TBH) lipid peroxidation in rat liver microsomes.72 Also, the ability of 
these compounds to protect isolated rat hepatocytes from injury caused by TBH was 
examined. Again, the antioxidant activity of these compounds was established and the 
importance of a prenyl group for the antioxidant activity of hop chalcones was confirmed. At 
25 M, prenylated chalcones such as X and DMX may have antioxidant activities comparable 
to the flavonol quercetin and better than those of the flavanone naringenin and the isoflavone 
genistein. Moreover, X was found to protect rat hepatocytes from TBH-induced injury.  
Stevens et al. demonstrated that X and some other chalcones and flavanones inhibit 
peroxynitrite-mediated oxidation of LDL at low micromolar concentrations.73 IX 
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unexpectedly showed a slight prooxidant effect instead of an inhibitory effect on LDL 
oxidation.  
1.3.3.6 Antimicrobial effects  
Mizobuchi and Sato investigated the antimicrobial activity of X, IX, 6PN, and 8PN. X 
and both flavanones were active against the fungi Trichophyton mentagrophytes and T. 
rubrum with minimum inhibitory concentrations in the range from 3.13 to 12.5 μg/ml.74 
Moreover, all compounds showed moderate activities against the fungus Mucor rouxianus 
and the bacterium Staphylococcus aureus. None of the flavonoids were active against the 
fungi Candida albicans and Fusarium oxysporum or against the bacteria Escherichia coli. 
Naringenin showed little activity against the above microorganisms. This indicates that 
introduction of a prenyl group is required for antifungal activity, probably because it renders 
the flavonoid skeleton sufficiently lipophilic to pass the cell membrane of the microbes or it 
could also be involved in more specific binding to microbial enzymes.  
1.3.3.7 Conclusions 
Due to the pure estrogen agonistic effect on the estrogen receptors and the consequent 
effect on bone metabolism, which is very comparable to that of 17-estradiol but without the 
strong uterus stimulation, 8PN is a very suitable candidate to compete with HRT in 
menopausal women. First clinical results from a phase Ia-study in menopausal women75 have 
demonstrated excellent tolerance and first signs of effectiveness after single oral doses. 
Heyerick et al. demonstrated in a prospective, randomized, double-blind, placebo-controlled 
study that the daily intake of a hop extract, standardized on 8-PN, exerted favorable effects on 
vasomotor symptoms and other menopausal discomforts and could, therefore, provide an 
attractive addition to the alternative treatments available for relief of hot flushes and other 
menopausal discomforts.76 Especially X has been shown to be a very potent cancer-
chemopreventive compound in vitro with an exceptional broad spectrum of inhibitory 
mechanisms at the initiation (by blocking the cytochrome P450-mediated activation of 
procarcinogens and by inducing the carcinogen-detoxifying enzymes such as quinone 
reductase), promotion (antiinflammatory properties), and progression (by inhibiting 
proliferation and angiogenesis) stages of carcinogenesis.  
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1.3.4 Metabolization of hop-derived prenylflavonoids 
Although flavonoids are abundantly present in the human diet and in animal feeds, 
little is known about their metabolism. The two major sites of flavonoid biotransformation are 
the liver and the colonic flora.77 Since the CYP superfamily is abundant in the liver and small 
intestine, a role in the metabolism of flavonoids is evident. Yilmazer et al. studied the in vitro 
biotransformation of X by rat liver microsomes from rats untreated or treated with various 
P450-inducing agents.78 Three major polar metabolites were produced from either untreated 
rats or phenobarbital-pretreated rats. Liver microsomes from isosafrole- and -
naphthoflavone-pretreated rats formed another major non-polar metabolite, which was 
identified as dehydrocycloxanthohumol (DX). The formation of these metabolites involved 
the role of CYP enzymes. Yilmazer suggested that modification of the prenyl substituent, 
induced by epoxidation of the double bond, constitutes a major metabolic pathway of 
prenylflavonoids.79 Miranda et al. demonstrated the antiproliferative activity of metabolite 
DX, which is also found in hops and beer, in human breast cancer MCF-7 cells at 
concentrations of 0.1 and 1.0 M.65 In addition two major glucuronides were found with 
either rat or human liver microsomes. Coldham et al. investigated the metabolic activation of 
IX to 8PN using hepatic microsomes and a sensitive yeast assay.80 They found that the 
estrogenic activity of IX remained unchanged after incubation with the microsomes and that 
evidence for metabolization of IX into 8PN is lacking. 
Nikolic et al. studied the metabolism of 8PN by human liver microsomes and 
identified a total of 12 metabolites.81 Biotransformations occurred on the prenyl group and the 
flavanone skeleton. The most abundant human liver microsomal metabolites were oxidation 
products of the prenyl group. Among these, hydroxylation of one of the terminal methyls of 
the prenyl group was more abundant than the epoxidation of the double bond. Yilmazer et al., 
however, did not observe oxidation of the prenyl methyl groups when investigating the 
metabolism of X in the rat.78 It was suggested that this pathway did not occur for the more 
rigid, open structure of X or that it was such a minor metabolite that is was undetectable. 
Nikolic et al. also observed that the oxidation of the prenyl methyl group was predominant at 
low concentrations and proportionally less dominant at higher substrate concentrations.81 
Yilmazer et al. used relatively high substrate concentrations (100 M), which could be 
another explanation why this pathway was not observed in the study of the metabolization of 
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X.78 Zierau et al. examined the estrogenic activity of the two most abundant metabolites of 
8PN.82 Using the yeast estrogen receptor assay, a dose-response analysis of the two 
metabolites was performed in comparison to 17-estradiol and 8PN. Both metabolites induced 
an estrogenic response with an EC50 value of approximately one order of magnitude less 
potent than 8PN. Using a bioluminescent estrogenic assay, both metabolites proved to induce 
luciferase activity in a dose-dependent manner, inducing a response comparable to the 
response induced by 10-8M 17-estradiol when applied in a concentration of 10-5M. Also, the 
metabolites were less active than the parental compound 8PN. Jang et al. reported that an 
isomeric metabolite of 8PN is a moderately potent, but a highly selective inhibitor of human 
cyclooxygenase-2.83  
Nikolic et al. investigated the metabolism of X and IX by human liver microsomes.84 
They found that hydroxylation of a prenyl methyl group was the primary route of oxidative 
metabolism forming either cis- or trans-hydroxylated metabolites of IX, but only the trans-
isomer of X. The double bond in the prenyl group of both compounds formed an epoxide, 
which was opened by an intramolecular reaction with the neighboring hydroxyl group. The 
potent phytoestrogen 8PN was detected as a demethylation product of IX. However, the 
analogous demethylation reaction was not observed for X. Since X can be converted to IX 
through acid-catalysed cyclization in the stomach, X might contribute to the in vivo levels of 
estrogenic 8PN.  
Possemiers et al. studied the bioavailabilities of X, IX, and 8PN, and the 
transformation potency of the intestinal microbial community.85 They found that, after 
incubation of IX with fecal samples, the estrogenic properties of some samples increased due 
to conversion of IX to 8PN. Eubacterium limosum was identified to be capable for this O-
demethylation of IX. These results show that, although there are great interindividual 
variabilities, the intestinal microbial community could more than 10-fold increase the 
exposure concentration of 8PN, if hop products containing IX (most abundant hop-derived 
prenylflavonoids in beer) are consumed. 
1.4 Hops legislation 
Humulus lupulus L. is listed, acording to the Royal Decree of the 29th of August 1997 
on the production and trade in food products composed of or containing plants or plant 
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preparations, in list 3. Article 4. §1 of this decree states that it is forbidden to produce or sell, 
in pre-dosed form, food products composed of or containing one or several of the plants 
mentioned in list 2 or list 3, if no prior notification has been filed with the Federal Agency of 
Medicine and Health Products in accordance with the clearly determined provisions.  
The foodstuffs specified in article 4, containing Humulus lupulus L., may only be 
marketed under the following condition: the absorption of the daily recommended amount 
indicated on the labelling or in advertising may not give rise to the quantity of 8PN ingested 
being greater than 400 g. By way of derogation to Article 4 (§1) (5), the results specified 
must be available for each batch of products. At this moment, there are no restrictions for the 
use of hops in non-predosed forms such as aromas, juices or teas (bulk or bags). 
1.5 Side effects and toxicity 
Humulus lupulus L. is believed to be non-toxic. However, as with all plants, it may 
cause allergic reactions in sensitive individuals. Humulus lupulus L. is known to cause a 
contact dermatitis in hop pickers. Additionally, contact dermatitis has been attributed to the 
rough hairs on the stem and secretions of the yellow glandular hairs on hops.86 No clinical 
cases of allergy or anaphylaxis resulting from therapeutic use of hops have been published. 
1.6 Contra-indications and drug-botanical interactions 
Hops should not be used in patients suffering from depression and, moreover, long-
lasting intake of hops may cause depressive moods. Limited evidence from one animal study 
suggests that hops may potentiate the effects of sedative drugs.87 Because of the estrogenic 
activity, hops is contra-indicated during pregnancy or in case of history or presence of 
hormonal-dependent diseases including breast and prostate cancer. However, the latter is a 
safety scenario, because it has not been argumented that phytoestrogens negatively influence 
these diseases. On the contrary, the evidence collected from the literature point out a variety 
of possible protective effects of phytoestrogens, but, indeed, more research, particular clinical 
studies, will have to be performed before final conclusions can be made.  
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2 Benign prostate hypertrophy and prostate cancer 
The prostate is a walnut-sized gland of 
the male reproductive system (Figure 2.1). It is 
located in front of the rectum just below the 
urinary bladder and is wrapped around the upper 
part of the urethra (Figure 2.2). The prostate 
gland contains three areas or zones (Figure 2.3). 
The central area of the prostate, which appears 
as 2 small pear-shaped lobes surrounding the 
proximal urethra (Figure 2.3, 2), is called the 
transition zone (Figure 2.3, 3). This zone makes 
up 5% of the total prostate volume. It is the area 
in which benign prostatic hypertrophy occurs and 15 to 
20% of the prostate cancers begin. The central zone 
(Figure 2.3, 1) is the second-largest element of the prostate 
(25% of the total gland volume), which surrounds the 
transition zone until the bladder base. The ejaculatory 
ducts (Figure 2.3, 8), where semen and sperm are 
combined before ejaculation, lay in the middle of this zone. 
About 5-10 % 
of prostate 
cancers originate in this area. The peripheral 
zone (Figure 2.3, 7) occupies about 70% of the 
prostate and it is the zone in which the majority 
of prostate cancers occur. It is also the most 
common site of chronic prostatitis. This area 
surrounds the two other zones from apex 
posterior to base. During a digital rectal exam, 
the peripheral zone is the only zone that can be 
felt. 
Figure 2.2 The prostate 
(http://health.allrefer.com/pictu
res-images/). 
Figure 2.3 Zones of the prostate. 
1, central zone; 2, 5, urethra; 3, transitional 
zone; 4, fibromuscular zone; 6, capsule; 7, 
peripheral zone; 8, ductus deferens 
(http://health.allrefer.com/pictures-images/). 
Figure 2.1 The male reproductive system 
(http://health.allrefer.com/pictures-
images/). 
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There are different types of tissues found in the prostate. The epithelial component is 
primarily glandular tissue. These small glands are surrounded by a layer of tissue called the 
stroma, which is comprised by smooth muscle and connective tissue. On the outside, the 
prostate gland is surrounded by a capsule of fibrous tissue called the prostatic capsule 
(Figure 2.3, 6). In the normal prostate, the relationship between the stromal and the epithelial 
component is approximately 2:1.88  
The primary function of the prostate gland is the secretion of the seminal fluid, which 
functions to nourish and to protect the sperm against the acid pH of the vagina, thereby 
increasing the chances that fertilization will occur. This seminal fluid is produced by the 
glandular cells from the prostate and the seminal vesicles, a pair of glands attached to the 
prostate. Sperm is produced in the testicles and carried through the vas deferens to the 
prostate, where sperm mixes with semen. During orgasm, this fluid is ejaculated first by a 
connection to the urethra called the ejaculatory ducts, which lay in the central zone of the 
prostate, and then through the urethra out of the body. The stroma contains approximately 
30% muscular tissue, which contracts during ejaculation to help move fluid into the urethra.89  
In the normal human prostate, the androgen receptor (AR) is almost equally 
distributed between stroma and epithelium, with an elective accumulation in the periurethral 
zone. The stromal AR is a primary target of androgen activity and its functionality appears to 
be particularly important during prostate development for maintaining the function of the 
normal prostate. It is needed for stromal-to-epithelial interactions that include various growth 
factor loops.90 The estrogen receptor  (ER) is expressed at low levels predominantly in the 
stroma of the normal human prostate.91 The estrogen receptor  (ER) predominantly 
localizes in the epithelium and to a lesser extent in the stroma. Although the reports vary in 
their assessment of the ER and ER status, it is generally accepted that there are higher 
levels of ER than ER in the normal human prostate.92 
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2.1 Benign prostatic hypertrophy 
There are a variety of prostate 
disorders that commonly afflict men of all 
ages. The most common prostate disease is 
benign prostatic hypertrophy or BPH (Figure 
2.4). BPH is the formation of a benign tumor 
in the prostate gland. Per definition is a 
tumor or neoplasm an abnormal mass of 
tissue that results from excessive cell 
division (mitotic activity). A benign tumor is 
a not-cancerous, not-malignant tumor, which 
is not potentially fatal and relatively 
harmless, because it does not invade nearby tissue or spread to other parts of the body.89 
The prostate gland resulting from BPH is generally composed of stromal elements. In 
patients with BPH, the stromal-to-epithelial ratio increases to 5:1 and the prostate gland can 
increase in size from 20 g, which is the average size of the prostate in younger men, to as 
large as 150 g.87 This stromal hyperplasia is considered due to the synergistic effects of both 
androgens and estrogens, receptors for both being present in the stromal compartment of the 
prostate. 
2.1.1 Incidence and prevalence 
Many studies have attempted to assess the prevalence of BPH and few have estimated 
the incidence. Assessing the occurrence of BPH is difficult due to the lack of a standardized 
case definition. Based on autopsy studies, the prevalence of histologically diagnosed BPH 
increases from 8% in men aged 31 to 40 years to up to 40-50% in men aged 51 to 60 years, 
and to more than 80% in men older than 80 years. Based on clinical criteria, 4 to 25% of men 
aged 40 years and older suffer from BPH. Although the observed prevalence of clinical BPH 
varies depending on the definition of BPH, all studies confirm that the prevalence of BPH 
strongly increases with age.93,94,95,96,97,98,99 
 
Figure 2.4 Normal prostate versus BPH 
(http://health.allrefer.com/pictures-images/). 
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2.1.2 Risk factors 
Age, normal androgenic function, and family history are known risk factors for BPH. 
Other potential risk factors include race, ethnicity, geographic location, and obesity.88,93 
2.1.3 Causes 
The aetiology of BPH has not yet been completely clarified despite its wide diffusion. 
Different factors are thought to be involved in the development of prostate hyperplasia: sexual 
hormones, stromal-epithelial interactions, stem cells, growth factors, insulin, and prolactin.100 
Among these, sexual hormones, in particular testicular androgens and estrogens, are 
recognized as playing the most important roles both in the physiological growth of the 
prostatic gland and in the development of BPH. It is believed that the condition is associated 
with very particular hormonal changes that occur as men age (see: 3.1).  
2.1.4 Signs and symptoms 
Patients with BPH often express urinary symptoms such as urge incontinence, 
dribbling, slow stream, and difficult voiding as a direct result of the pressure exerted by the 
enlarged prostate gland on the urethra thereby squizing it. These symptoms are called lower 
urinary tract symptoms (LUTS). LUTS, however, are not specific for BPH alone. Identical 
symptoms can also be caused by other urological conditions (e.g., urinary tract infections, 
detrusor instability) or other non-urological conditions such as heart failure and diabetes 
mellitus. The correlation between the severity of LUTS, prostate size, and the degree of 
obstruction is weak. Men with large prostates may be symptom-free, while those with small 
or normal-sized prostates may sometimes have symptoms that are more severe than in men 
with larger prostates.88,93,101 
LUTS are generally classified into voiding symptoms (hesitancy, poor urinary flow 
and need to strain, incomplete bladder emptying, terminal or postmicturition dribbling) and 
storage symptoms (frequency, urgency, nocturia, urge incontinence). To quantify the severity 
and the extent of the LUTS, men are generally asked to complete symptom 
questionnaires.88,93,94  
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2.1.5 Diagnosis 
The diagnosis of LUTS/BPH is made on the basis of medical history, physical 
examination including a digital rectal examination, urinalysis and uroflow measurements, 
and/or transrectal ultrasound (TRUS).93,101 
2.1.6 Current treatment methods 
The primary goals of treatment for BPH are to reduce the symptoms, to improve the 
urinary flow, and, to prevent progression. Not every patient with LUTS/BPH is treated and 
some patients are followed with the so-called watchful waiting strategy. Watchful waiting 
involves lifestyle changes such as avoiding alcohol, coffee, and certain drugs (e.g., diuretics, 
decongestants).88,93,101 The choice between watchful waiting and treatment depends on a 
number of factors such as the severity of the symptoms, the prostate size, and the urinary flow 
rates. Generally, watchful waiting is recommended in patients with mild symptoms. Patients 
with moderate or severe symptoms are pharmacologically treated or undergo prostate 
surgery. The decision to opt for a specific treatment regimen is based on LUTS symptom 
severity and the patient characteristics such as age and medical conditions.88,93 
The pharmacological treatments of obstructive and irritative symptoms associated with 
BPH include hormonal and non-hormonal therapies.100,102,103,104,105 Hormonal or endocrine 
therapy with androgens and estrogens used in the past may reduce symptomatology of BPH, 
but the serious side-effects related to this kind of therapy are unacceptable. Studies on the 
pathogenic mechanism of BPH highlighted that pharmacological agents including 
antiandrogens, antiestrogens, and inhibitors of 5-reductase and of aromatase may be 
effective in the therapy of BPH.105 Furthermore, it is very important to take into consideration 
that, for an effective treatment of BPH, a reduction of both the glandular and stromal elements 
must be achieved. Thus, both androgens and estrogens seem to be involved in the regulation 
of prostate (over)growth. Therefore, a combination of androgen and estrogen deprivation 
might be a more promising approach than any single treatment.106 Non-hormonal therapy 
includes treatment with 1-blockers that bind to 1-adrenoreceptors in the bladder neck and in 
the smooth muscle tissue of the prostate causing relaxation and thus improving urinary flow. 
Some of these drugs may also provoke apoptosis of the prostate epithelium.88,93,101 
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Recently, results from large randomized controlled trials have been published showing 
that treatment with 5-reductase inhibitors and, especially, the combination of 5-reductase 
inhibitors with an -blocker were not only beneficial in the relief of urinary symptoms, but 
were also able to prevent disease progression in terms of acute urinary retention, prostate 
surgery, and urinary tract infections.107,108 
In traditional medicine, various plant extracts are used in the treatment of urological 
disorders related to BPH. These extracts contain several active constituents that are endowed 
with antiandrogen and antiestrogen activity, inhibitory activity on prostaglandin synthesis, 
antiinflammatory and immunomodulatory effects, cholesterol-lowering activity, and 
interaction with sex hormone binding globulin (SHBG).109,110 The pharmacological effects 
exerted by extracts are not directly related to the activity of the single components, but, 
probably, to their additive and/or synergistic actions. The exact mechanism for most plant 
extracts remains unclear and their efficacy needs to be further investigated in well-designed, 
randomized, controlled trials.93,111 Positive monographs on Sabal fructus (Serenoa repens 
(Bartram) JK Small, fruit), Urticae radix (Urtica dioica L., U. urens L. and/or on their 
hybrids, root), and Cucurbita peponis (Cucurbita pepo L., seed) have been published by the 
Commission E for the Phytotherapeutic Substances of the German Federal Health Office. 
These extracts are reported to improve urological disturbances in patients with mild and 
moderate BPH, while the size of the prostate is, in most cases, not influenced by the 
phytotherapeutical agents. The extracts are reported to be well tolerated and to have minimal 
side-effects with a very good risk/benefit ratio.105 Next to these extracts, research into herbal 
products used for BPH has also focused on pygeum (African prune tree, Pygeum africanum 
Hook. f., Prunus Africana Hook. f.). Herbs such as Panax ginseng (also known as Korean 
ginseng or panax) have a history of traditional use as “male tonics” and are still used by 
herbalists to treat prostatic enlargement.112 In Italy, plant extracts are prescribed in almost 
50% of cases, whereas -blockers and hormonal therapies are both used around 5%.109 Plant 
extracts of the fruit of S. repens and from the bark of P. africanum Hook. f. constitute the 
active principles of pharmaceutical proprietary products currently used in the symptomatic 
treatment of BPH. 
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2.2 Prostate cancer 
Prostate cancer (PC) is the 
presence of a malignant tumor of mostly 
glandular origin in the prostate gland. A 
tumor or neoplasm is defined as an 
abnormal mass of tissue that results 
from excessive cell division. As cancer 
is always malignant, it signifies growth 
of a tumor with a tendency to invade 
and destroy nearby tissue and spread to 
other parts of the body through the 
bloodstream and lymphatic system, a 
process called metastasis. The word cancer originates from the Latin word for crab, because 
the swollen veins around a surface tumor appear like the legs of a crab. Cancer can be 
classified either by the cell type or by its primary site. Although there are several cell types in 
the prostate, over 95% of the prostate cancers originate in the glandular tissue and these types 
of cancer are referred to as adenocarcinomas. About 70% of these adenocarcinomas are 
derived from the glandular tissue of the peripheric zone. Prostate cancer often starts out 
localized in the prostate, but can then spread into adjacent tissue structures and lymph nodes if 
not detected early. The most common site of metastatic disease is the bone, but it can also 
spread to the lung, liver, and other organs. The most common cause of death from prostate 
cancer continues to be hormone-refractory metastatic disease.88   
2.2.1 Incidence and prevalence 
According to the American Cancer Society (ACS), prostate cancer is the most 
common malignancy, other than skin cancer, and the second leading cause of cancer death in 
men, second only to lung cancer, in the United States.113 In some Western countries, prostate 
cancer has become the leading cause of cancer deaths.  
As our population ages, the impact of prostate cancer increases and the development 
of new treatments is necessary to control the disease. No other cancer rises in incidence and 
mortality rate with increasing age as rapidly as does prostate cancer. However, much of the 
 
Figure 2.5 Normale prostate versus prostate cancer 
(http://health.allrefer.com/pictures-images/). 
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increased incidence has been related to public awareness and to the identification of a large 
number of prevalent, but previously undetected cases in the population through widespread 
screening using the prostate-specific antigen (PSA)-test.114 The overall prognosis for prostate 
cancer patients has dramatically improved compared with years ago. Over the past 20 years, 
the overall survival rates for all stages of prostate cancer combined have increased from 67% 
to 97%. This means that more men are living longer after diagnosis.  
Prostate cancer has a disproportional impact on certain segments of the human 
population. African-American men have the highest incidence of prostate cancer and are 
twice as likely to die from it than other Americans. Asian and native American men have the 
lowest incidence. It is observed that, as people migrate from Asia to the United States, the low 
rates observed in Asia begin to rise with time and with subsequent generations towards those 
observed commonly in the general population in the United States. Furthermore, as Asian 
countries adapt Western-style diets, the incidence of prostate cancer has started to 
rise.115,116,117,118 These observations suggest an environmental connection (e.g., high-fat diet, 
smoking).  
2.2.2 Risk factors 
The lifestyle risk factors accompanying prostate cancer include a lower risk associated 
with high intake of fruits, vegetables, fibre, and soy products. Alternatively, a higher risk is 
associated with increased intake of red meat, animal fats, dairy products, and steroid 
exposure, as well as body mass and birth weight. Other risk factors include age, race and 
nationality, exposure to sex steroids and genetic predisposition or family 
history.115,116,117,118,119 
2.2.3 Signs and symptoms 
In contrast with BPH, early prostate cancer usually does not cause any symptoms, 
because the cancerous gland is not necessarily enlarged. However, the tumor may spread from 
the prostate to surrounding areas and metastasize to nearby lymph nodes, bones or other 
organs. At first, the symptoms are often similar to those of BPH. However, while the cancer 
spreads, symptoms will get worse going from frequent urination (especially at night) with a 
weak or interrupted urinary flow to inability to urinate, blood in the urine or semen and the 
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presence of pain or stiffness in the back, hips, upper thighs or pelvis during ejaculation and 
urination (dysuria). All these signs should raise suspicion.89 
2.2.4 Diagnosis 
The diagnosis of early prostate cancer is done by a combination of PSA and digital 
rectal examination (DRE). Once a tumor is found a transrectal ultrasound (TRUS)-guided 
biopsy will be performed to determine if the tumor is benign or cancerous. Computer-assisted 
tomography scan (CAT scan or CT scan) and bone scans are carried out to visualize 
metastasis of the cancer. 
2.2.5 Current treatment methods 
The treatment strategy for prostate cancer depends on the stage of the disease and the 
patient's age and overall health. When cancer is confined to the prostate gland (local prostate 
cancer), the disease is usually curable. The urologist will choose between the watchful 
waiting strategy or surgery. In the case of advanced or metastatic prostate cancer, however, 
the disease can not be cured and a palliative therapy will be initiated. This includes endocrine 
treatment all or not in combination with chemotherapy.  
Endocrine therapy is a softer form of therapy supporting the patient for prolonged 
periods with minimal side-effects, hence, patients can live more comfortably than do many 
patients who are receiving chemotherapy.120 The main forms of endocrine therapy for prostate 
cancer interfere in some manner with the basic pathway of androgen stimulation of prostate 
cancer cells (Figure 2.6). Androgen deprivation can be achieved by bilateral orchiectomy 
(surgical castration), estrogens, LHRH agonists, antiandrogens or a combined androgen 
blockade.  
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Figure 2.6 Key physiologic pathways of endocrine therapy for advanced prostate cancer. Each form of 
therapy interferes in some way with the basic pathway of androgen stimulation of prostate cancer cells. 
LHRH, luteinizing hormone-releasing hormone; LH, luteinizing hormone; T, testosterone; DHT, 
dihydrotestosterone; 5R, 5-reductase; AR, androgen receptor; DNA, desoxyribonucleic acid 
(http://www.postgradmed.com/issues/1996/09_96/taub.htm). 
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PC patients and those with BPH are increasingly exploring the use of evidence-based 
CAM (Complementary Alternative Medicine) treatments,121 especially due to the risk of 
mortality and long-term morbidity associated with surgical procedures.122 Moreover, 
hormonal manipulation, -adrenergic blockers, and 5-reductase inhibitors may often have 
unpleasant and undesirable side-effects.123 These medications may also be ineffective due to 
the grade of tumor at presentation or hormone-insensitive profile of the tumor cell population. 
Several phytomedicines are used for prostatic disorders. Some herbals hold potential 
promises, although much research is still required to investigate the mechanism of action and 
the compounds that account for this activity. Promising plants to treat prostate cancer are 
Bidens pilosa L., which is better known as common black-jack, Hypoxis hemerocallidea Fish. 
and C.A. Mey. (syn. H. rooperi S. Moore), commonly known as the African potato, Prunus 
africanus (Hook. f.) Kalkm., also known as Pygeum africanum Hook. f., Serenoa serrulata 
Hook. f., commonly known as saw palmetto, Urtica dioica L. or stinging nettle, summer 
pumpkin (Cucurbita pepo L.), and rye grass pollen (Secale cereale). 
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3 Chemoprevention of prostate diseases 
Chemoprevention consists of the administration of drugs or other agents aimed at 
preventing the induction or inhibiting or delaying the progression of cancer. It is hypothesized 
that even a modest delay in the development of prostate cancer could substantially reduce the 
clinical impact of this very prevalent disease.124 With its long latency time, high incidence, 
significant morbidity, and mortality, well-documented risk factors, hormone dependency, the 
availability of a widely accepted ideal marker (prostate-specific antigen, PSA), and precursor 
lesions such as prostatic intraepithelial neoplasia (PIN), prostate cancer is a relevant target for 
chemoprevention.125 The development of chemopreventive strategies requires a proper 
knowledge of the pathogenesis of prostate diseases and identification of the agents that can 
interfere with the mechanisms involved in this pathogenesis.  
3.1 Pathogenesis of benign prostate hypertrophy and prostate cancer   
The prostate, a hormone-dependent gland, grows rapidly from adolescent to the early 
twenties,126 when the gland attains its maximal size and homeostasis is established. A growth 
regulatory balance is then achieved between the processes concerned with cell proliferation 
and those related with programmed cell death or apoptosis.127,128 This homeostasis, however, 
is not always established.  
Studies carried out by Coffey et al. indicate that microscopic benign prostate 
hypertrophy (BPH), hyperplasia of the epithelial cells, can be recognized in the prostates of 
men in the early twenties and the prevalence increases with age.127 This focal process that 
specifically develops periurethrally in the transition zone of the gland leads to nodular 
hyperplasia. The process would be seen as a consequence of an imbalance in the growth-
regulatory mechanisms with 5-dihydrotestosterone (DHT) having a pivotal role.115,127 The 
driving force for the development of this epithelial hyperplasia is, therefore, considered to be 
of androgenic nature. Bostwick et al. presume that microscopic BPH could lead to genetic 
instability and early cancer, possibly giving rise to transition-zone cancer, which constitutes 
approximately 15-20% of cancers of the prostate gland.129 However, it is generally believed 
that men diagnosed with BPH do not have an increased risk of prostate cancer and that there 
is no causal connection between both diseases, but both conditions can and do exist together. 
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Although preliminary stages in the development can be recognized many years earlier, 
BPH only becomes clinically manifest after 50 years of age. Aging is, therefore, a risk factor 
for both diseases. Since early castration prevents the development of clinical BPH as well as 
cancer125 and, since an enlarged prostate regresses following androgen withdrawal therapy, 
the pathogenesis of these diseases would seem to be mediated by androgens, either directly or 
passively. There is no doubt that androgenic steroids are important mitogenic factors within 
the prostate and a testicular source of testosterone (T) is a prerequisite to the pathogenesis of 
prostate disease.  
Paradoxically, testicular function and T concentration would generally decline with 
aging. This becomes evident from the age of 45-50 years on, as far as the concentration of 
total T is considered. There is an earlier and stronger decline in the free T-fraction compared 
to the total T-concentration, as a result of the increased binding capacity for T in the serum. 
The decline in androgen concentrations with aging is also partially attributable to impaired 
hypothalamic secretion of luteinizing hormone releasing hormone (LHRH) and decreased 
stimulation by luteinizing hormone (LH), but there is also evidence of a primary testicular 
deterioration. The concentration of the plasma estrogens is, however, sustained by increased 
peripheral aromatization due to increased adipose tissue in later years. The result is an 
enhanced ‘estrogenic status’ in older men, which is believed to be the trigger for the 
development of BPH.103,130,131 
T, the major circulating androgen hormone, diffuses across plasma membranes and is 
transformed into its active metabolite DHT within the prostatic gland by 5-reductase. DHT 
binds to cell androgen receptors at the level of the epithelial and stromal structures, thereby 
promoting the synthesis of nuclear mRNA and proteins, and cell growth. Even though the 
concentration of T in the plasma decreases, it is reported that the DHT concentration within 
the prostate gland increases with aging and this phenomenon could be involved in the 
development of BPH.103 This deposition and retention of DHT in the prostate could be 
explained by the abnormal enzyme activities present in BPH tissue compared to normal 
tissue: increased activity of 5-reductase, decreased activities of 3-hydroxysteroidreductase 
and 17-hydroxysteroidoxidase, enzymes which control the reduction of DHT to 
androstanediol and the conversion of DHT to androstanedione, respectively (Figure 3.1).105 
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BPH is primarily a stromal disease from a morphometric point of view.103,132 
Estrogens that are formed from T and androstenedione in men by the aromatase enzyme 
system may contribute to the proliferation of stroma cells. Interaction between the stromal and 
the epithelial compartment is also involved in the development of BPH. In particular, the 
proliferation of stroma cells induced by estrogens could stimulate androgen-dependent 
epithelial growth.100,104,133  
The observed estrogenic shift in aging men is also related to the increase in sex 
hormone binding globulin (SHBG), the synthesis of which is being induced especially by 
estrogens, but with a higher binding affinity for androgens than for estrogens. Consequently, 
the plasma concentration of free, biologically active T decreases and, therefore, the 
androgen/estrogen balance shifts further towards the estrogens.134 SHBG also has a direct 
effect by binding to the receptor sites on cell membranes of the human prostate. Therefore, it 
could play an important role as regulator of biochemical cell functions.135 Stromal growth 
factors seem to be involved in the prostate hyperplastic process. The basic fibroblast growth 
factor (b-FGF), which is present in higher amounts than normal in BPH tissue, is most 
important.100,105 
Prostate cancer (PC) is a complex, multi-stage process encompassing the 
premalignant hyperplastic lesions and cancer initiation, through promotion and progression to 
the invasive metastatic disease. Premalignancy, described as atypical hyperplasia, a diffuse or 
multifocal proliferation of ductal or epithelial tissue,136 is more prevalent in prostates 
associated with cancer. The clinically asymptomatic ‘latent carcinoma’ is a lesion that is 
originally recognized in approximately 30% of men aged over 50 years,137 men of all races 
from both East and West.138 It should be considered an early stage (a slowly growing lesion) 
in the development of the aggressive cancer phenotype and it would appear that a small 
proportion of these cancer foci progress to invasive disease in Western men, but less in their 
Eastern male counterparts. The recognition that prostate cancer progression is observed much 
less in the Asian male certainly deserves consideration and the important question is, 
therefore, whether dietary factors influence the development and progression of these early 
prostate cancer lesions.130 
In the pathogenesis of prostatic cancer, it is generally considered that androgens would 
play at least a permissive role and there is a discussion on whether early prostate cancer is 
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specifically DHT-dependent139 such that a 5-reductase inhibitor would restrain the 
progression of the cancer. Androgen insensitivity is implicated in prostate cancer progression 
to the so-called ‘androgen-independent’ state. Androgen sensitivity may be greater than had 
hitherto been suspected and greater sensitivity may be conferred on cancer cells. Since the 
expression of the androgen receptor (AR) is maintained in most androgen-resistant prostate 
cancers, the presence of AR may offer a growth advantage, even in the presence of extreme 
low concentrations of androgens.130  
In the prostate gland, androgens in particular, but also estrogens and glucocorticoids, 
modulate the production and the biological activities of the various growth regulating factors, 
the intrinsic factors. Steroid hormones should, therefore, be considered the extrinsic factors. 
These growth factors directly stimulate cell proliferation. The intercellular signalling systems, 
whereby a growth factor made by one type of cell is released to influence another cell type 
(paracrine effect), or, alternatively, affects the type of cell from which it is produced 
(autocrine effect), is orchestrated by the steroid hormones. The concept is that DHT is formed 
in the stromal compartment and then promotes the production of the keratinocyte growth 
factor (KGF) by the fibroblasts, which, through a paracrine effect, induces epithelial cell 
proliferation. As part of the homeostatic status, a growth-inhibitory factor, the transforming 
growth factor- (TGF-), inhibits proliferation and promotes apoptosis or cell death. The 
binding of the growth factors to cell membrane receptors induces, by way of the tyrosine-
specific protein kinase (TK) enzyme, the intracellular signal transduction processes that 
activate genes such as the Fos and Jun proto-oncogenes, growth-related genes that encode for 
the Fos and Jun proteins, respectively. The Fos and Jun proteins as tissue factors (TFs) 
interact with their own specific (AP-1) recognition sites on the genome. The TFs are depicted 
in juxta-position to the DHT-AR complex on the genome, the Fos-Jun proteins associating as 
heterodimers on their recognition sites. As such, the modulating influence exercized by the 
DHT-AR complex on the growth factor activity relates to the capacity of the complex to alter 
the spatial orientation of DNA such that the change facilitates easier access of the TFs to their 
recognition sites. This interrelationship between the signalling pathways that is promoted by 
androgens and the other pathways mediated by peptide growth factors is referred to as ‘cross-
talk’ and is probably pivotal to the growth-regulatory control and the concept of steroid 
sensitivity.  
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The presence of a relative high concentration of the estrogen receptor  (ER) in the 
smooth muscle cells of the stroma of the prostate suggests an important physiological role for 
estrogens in prostate development, as well as in prostate cancer pathogenesis. It is accepted 
that 17-estradiol helps to sustain AR levels within the prostate and it has been suggested that 
estrogens may be essential for the androgen-mediated promotion of epithelial proliferation 
and, like DHT, may also inhibit apoptosis.140 17-Estradiol probably promotes stromal 
hyperplasia by inducing the production of fibroblast growth factor-II (FGF-II). The cross-talk 
between estrogens and signalling pathways of growth factors, and the synergistic functional 
interaction between ERs and co-activators and co-repressors in juxta-position of the genome 
are probably different for both ERs. The ER-mediated signalling pathways seem more 
complex and could have a role in sustaining prostate cancer progression.130  
3.2 Chemopreventive agents and targets for BPH and PC 
Chemopreventive agents have the potential to influence one or more of the targets in 
the pathogenesis of prostate diseases. A significant proportion of the promising 
chemopreventive agents are phytonutrients from food, whose potential has been demonstrated 
in chemopreventive trials. The marked differences in the incidence of certain types of cancers 
between various countries or regions of the world suggest that particular dietary factors can 
influence the biological processes related to carcinogenesis. In the past decade, data have been 
accumulated supporting the role for such dietary factors and, although often contradictory, a 
pattern is recognisable, which directs attention to the potential benefits for healthcare of 
preventive studies related to the intake of these factors.141 Geographical differences in cancer 
incidence attributed to the diet are supported by changes observed in the incidence rates in 
migrants, who move from areas of low risk for particular cancers to countries where the risk 
is higher.118 Such changes are illustrated by data from the migration of Japanese and Chinese 
men and women to Hawaii and to mainland USA, whose risk of developing prostate or breast 
cancer (previously being low) increases to match that of the indigenous population within a 
few generations.142,143,144 
Cancers of the prostate and breast, cardiovascular disease, and osteoporosis feature 
prominently as ‘Western-type diseases’. The Western-style diet is characterized by high-meat 
and high-fat, and low-fruit and low-fibre intakes, which contrasts with the diet of the Asian 
communities that are low in animal fat and rich in starches, legumes, fruit and vegetables, all 
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of which have a high fibre content. Predictably, therefore, animal fat is considered a causative 
factor. More recently, however, it has been recognized that certain constituents of the Asian 
diet and that of the Mediterranean region protect against the development of these diseases 
and the lack of these constituents in the Western diet is the most important factor.130,141  
The health-beneficial effects of these factors regarding prostate diseases indicate the 
ability to interfere with one or more targets of the pathogenesis process. Many of these health-
protective constituents belong to the phytoestrogens that could potentially exert an influence 
on hormone-dependent diseases such as BPH and PC. Phytoestrogens are non-steroidal plant-
derived compounds that structurally or functionally mimic mammalian estrogens and, 
therefore, are considered to play an important role in the prevention of cancers, heart disease, 
menopausal symptoms, and osteoporosis. Their structures relate closely to the structure of the 
endogenous estrogen 17-estradiol in that they usually possess at least two phenolic groups 
adequately positioned. Phytoestrogens constitute a diverse group of compounds with regard to 
their chemical structures as well as their biological activities. In general, four main groups are 
distinguished, namely isoflavonoids, flavonoids, coumestans, and lignans.145,146 Many plants 
contain phytoestrogens, although the amounts and the combinations of the various compounds 
vary significantly. For isoflavones, the main dietary source for humans is soybean, while 
flavonoids are more widely distributed in the plant kingdom, as they are found in several 
vegetables, fruits, berries, herbs, and also in green tea. For coumestrol, the only significant 
sources are sprouts of alfalfa and various beans. Lignans are present in fibre-rich foods such 
as flaxseed, unrefined grain products, rye, and some berries. However, their active forms 
(enterodiol and enterolacton) are only formed after metabolisation by the gut 
microflora.147,148,149,150,151 
Clinical evidence points to the beneficial role of soya in inhibiting the growth of 
prostate cancer in Japanese men.152,153 The advantages of a soya-based diet have been 
attributed to isoflavonoids.154 There is an inverse relationship between the consumption of 
soya and the incidence of clinically significant prostate cancer,155 furthermore between 
coumestrol and daidzein and prostate cancer risk.156  
Although there are considerable experimental data regarding the antitumoral effects of 
several soya-derived products, large-scale epidemiological studies are sparse. A recently 
published work aimed to identify variables for prostate cancer mortality from data collected in 
LIES DELMULLE 155x240 - 148 blz - INDESIGN.indd   54 05-11-2007   15:54:50
 43 
59 countries.157 Prostate cancer was inversely associated with estimated consumption of 
cereals, nuts, oil seeds, fish, and, in particular, soya products. While dietary phytoestrogens 
have been implicated in prostate cancer prevention, they are now under investigation as a 
possible treatment for prostate cancer, in view of their multiple mechanisms of action that 
may or may not be related to their hormonal activity.  
3.2.1 Interaction with hormonal regulation 
Hormonal regulation is controlled by the hypothalamus and the anterior pituitary 
gland, which influence both the testicular activity and the adrenal activity (Figure 3.1). The 
two principal functions of the male hypothalamic-pituitary-gonadal axis are production of 
regulated quantities of physiologically relevant sex steroid hormones and production of 
healthy male gametes under diverse environmental conditions. The two corresponding 
activities of the testes are segregated anatomically. Androgen biosynthesis occurs in Leydig 
cells and spermatogenesis is accomplished in the seminiferous tubules. The hypothalamus and 
the anterior pituitary gland participate integrally in the regulation of these functions via 
respective secretion of gonadotropin-releasing hormone (GnRH) (formerly called luteinizing 
hormone-releasing hormone or LHRH) by specific brain stem neurons and subsequent 
stimulation of the release of the two gonadotropins, luteinizing hormone (LH) and follicle-
stimulating hormone (FSH) by specific adenohypophyseal cells. The amounts of the released 
hormones are dependent on the age and the hormonal status of the individual both before and 
after birth. 
Circulating androgens exert a direct negative feedback on the pituitary gland and an 
indirect negative feedback on the hypothalamus after conversion into estrogens by the 
aromatase enzyme. Circulating estrogens exert direct negative feedbacks on the 
hypothalamus, pituitary gland, and on their own production from cholesterol in the Leydig 
cells. This decreases the frequency of the GnRH pulse generator and, consequently, the 
quantity and the quality of bioactivity of released LH molecules, thereby decreasing the 
production of steroids. 
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Figure 3.1 Hormonal regulation in men. 
E2: 17-Estradiol, T: Testosterone, 5R: 5-Reductase, DHT: 5-Dihydrotestosterone, LHRH: 
Luteinizing hormone-releasing hormone, LH: Luteinizing hormone, FSH: Follicle-stimulating hormone, 
(+): stimulation, (-): inhibition. 
The protective effect of phytoestrogens could be related to the reduction in androgen 
production via the hypothalamic-pituitary-gonadal axis leading to a reduced gonadal T 
production, however, so far there is no evidence of this effect.158 
3.2.2 Interaction with the steroid metabolism 
About 95% of the total amount of T is produced in the testes by the Leydig cells. The 
remaining 5% is secreted by the adrenal glands, which are situated on top of the kidneys. 
Circulating T is bound by proteins in the plasma and the small unbound fraction passively 
diffuses into prostate cells, where it is converted to DHT by 5-reductase located on the 
nuclear membrane. DHT, on its turn, binds to the androgen receptor in the cytoplasm and the 
DHT-AR complex is then transported to the nucleus to directly modulate gene expression and 
stimulate cell division.130,159 
Estrogens are primarily produced from T by the aromatase enzyme. About 30-40% of 
the estrogens in plasma is synthesized and secreted by the Leydig cells in the testes, the 
remainder being derived from the peripheral aromatization of adrenal androgens by adipose 
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and muscular tissue. Because this adipose tissue is a major source of aromatase, the sensitive 
ratio of estrogens to androgens can be altered by the body mass and the degree of fat within 
the body.160 Figure 3.2 demonstrates the hormonal conversions and the relevant enzymes in 
men.  
3.2.2.1 Inhibition of the human 5-reductase enzyme 
The conversion of T to its potent derivative DHT through the 5-reductase enzyme 
activity represents a crucial step for androgen-mediated activity on the prostate gland. 
Compounds that inhibit or influence this conversion could indirectly diminish the androgenic 
stimulatory influence on the prostate.  
3.2.2.2 Inhibition of the 17-hydroxysteroid-dehydrogenase 
17-Hydroxysteroid-dehydrogenase regulates the reversible interconversion between 
testosterone and androstenedione, on the one hand, and, estrone and 17-estradiol, on the 
other hand.161 Compounds that affect this conversion could influence the steroid metabolism, 
thereby altering the hormonal influence on the prostate gland.  
3.2.2.3 Inhibition of the human aromatase-enzyme system 
The human aromatase-enzyme system regulates the production of estrogens from the 
C19-androgen precursors such as T and androstenedione. The system is an enzyme complex 
consisting of two components, a flavoprotein NADPH-cytochrome P-450 reductase, which 
transfers electrons from NADPH to the terminal enzyme, and a specific form of cytochrome 
P-450 known as aromatase cytochrome P-450.162 Aromatization occurs in specific tissues. 
About 30% of the plasma estrogens is synthesized and excreted in the testes, where 
aromatization constitutes the last and one of the most important steps in the biosynthetic 
progression from cholesterol to estrogens. Aromatization also occurs in adipose tissue and, 
therefore, increases in aging men resulting in a change in hormonal balance and a increased 
risk to develop BPH. Therefore, specific inhibitors of the aromatase-enzyme system could be 
useful in controlling pathologic conditions associated with estrogens, especially BPH and 
maybe also PC. 
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Figure 3.2 Steroid metabolism in men. 
DHEA: Dehydroepiandrosterone, 5-DHT: 5-Dihydrotestosterone, 3HSD: 3-Hydroxysteroid-
dehydrogenase, 3HSD 1 and 2: 3-Hydroxysteroid-dehydrogenase 1 and 2, 17HSD 1-5: 17-
Hydroxysteroid-dehydrogenase 1-5. 
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Numerous in vitro studies have shown that phytoestrogens such as the lignane 
enterolactone and the soya-derived isoflavone genistein inhibit several of the key enzymes in 
estrogen and androgen biosynthesis including 17-hydroxysteroid-oxidoreductases, 
aromatase, and 5-reductase.160,163,164,165 None of these actions have been confirmed in vivo. 
However, it was demonstrated that the levels of the indicators for the activities of 5-
reductase, namely 3,17-androstanediol and androsterone glucuronide, were much lower in 
young Japanese men compared to young men in the United States.166 This suggests that 
phytoestrogens may modulate the production and the bioavailability of endogenous steroidal 
estrogens and androgens, hence, they could alter the exposure to these hormones resulting in 
hormone- or antihormone-like activity.  
3.2.3 Interaction with the steroid receptors 
Even though the mechanism of action is not fully understood, there is no doubt that the 
presence of steroid hormones, more specifically androgens and estrogens, are predominant in 
the development and evolution of BPH and PC. Compounds that can interfere with the 
hormonal activities could alter the hormonal influence on the prostate and, thereby, also the 
pathogenesis of BPH and PC. 
Several in vitro studies have indicated that phytoestrogens act similarly to steroidal 
estrogens. They bind to estrogen receptors, induce estrogen-responsive genes, stimulate the 
growth of estrogen-sensitive cancer cells, and their activities can be blocked by pure 
antiestrogens.167,168,169 However, phytoestrogens are generally weaker than the endogenous 
steroidal estrogens and it has been suggested that they could act as antiestrogens or partial 
agonists by competing with the more potent endogenous estrogens for binding to the ERs. 
With regard to their sensitive activities, phytoestrogens could be classified as selective 
estrogen receptor modulators (SERMs) that may function as agonists or antagonists 
depending on the tissue, ERs, and concentrations of circulating endogenous estrogens. Pure 
antiestrogenic activity has not been demonstrated for isoflavones or coumestrol and only few 
phytoestrogens with very weak intrinsic estrogenic activity including naringenin can be 
classified as such.170 
Kuiper et al. have screened the binding affinities of several phytoestrogens to the ERs 
and showed that some phytoestrogens such as genistein and coumestrol are efficient ligands 
LIES DELMULLE 155x240 - 148 blz - INDESIGN.indd   59 05-11-2007   15:54:53
 48 
for ERs, while other isoflavones or flavonoids bind with much less affinity.171 Intriguingly, 
phytoestrogens prefer ER for binding, while most endogenous steroidal estrogens show no 
such difference.169 This could allow unique, tissue- or organ-specific actions, different from 
those of endogenous hormones. Phytoestrogens stimulate the transcriptional activity of both 
ER subtypes at nanomolar concentrations. When phytoestrogens bind to the ERs, heat shock 
proteins dissociate, a change in conformation and homodimerisation occurs enabling 
subsequent binding to the estrogen response element (ERE), which functions to enhance the 
transcriptional potential of a gene. The EREs are typically located in the promoters of 
estrogen-responsive genes and upstream from the transcriptional start site. The ligand-
activated, DNA-bound receptor then recruits co-activators, which serve as a bridge between 
the receptor and the general transcription machinery (Figure 3.3). The relative binding 
affinities of phytoestrogens for the ERs differ between studies, each displaying different 
agonist and antagonist activities. Moreover, the relative binding affinities of the 
phytoestrogens do not necessarily correlate with the affinities of the receptors for the ERE and 
the transcriptional activities of the receptor-ERE complex.172,173,174,175  
 
Figure 3.3 General estrogen receptor mechanism. On ligand binding (hormone), the estrogen receptor 
(ER) homodimerises, interacts with the estrogen response element (ERE) located in the promoter region 
of estrogen-activated genes and recruits co-regulator proteins, which serve as a physical bridge between 
the receptor and the general transcription machinery (www.andrology.be/life98/technical.php). 
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The potential of phytoestrogens to target the pathogenesis of PBH and PC could be 
expected from their preferential binding to the ER in the prostate epithelium, which is the 
predominant ER in the prostate, and is related to antiproliferative activities, but so far there is 
no evidence for this effect of phytoestrogens. The difference in binding affinity and activity of 
phytoestrogens for both ER types compared to endogenic estrogens could result in different 
cross-talk and different stromal-epithelial interactions at the prostate level that may change 
the overall hormonal influence of both androgens and estrogens on the prostate gland. 
3.2.4 Non-hormonal interactions 
3.2.4.1 Stimulation of the production of sex hormone-binding globulin 
Of the total T in the plasma, only 2% is free, enters the prostate, and is biologically 
active. The stimulation of the production of sex hormone-binding globulin (SHBG) results in 
a decrease in the free fraction of T and an altered hormonal influence on the prostate. This 
phenomenon was demonstrated in vegetarian176 and Japanese and Chinese men,177 who had 
high levels of isoflavonoids in urine and plasma. However, if the concentration of free T 
drops under a critical level, the expression of the C-met oncogene is stimulated in the prostate 
cancer cells, which is associated with an increased invasive character.178 This U-shaped 
connection between T levels and cancer invasiveness is a very critical balance, which should 
be taken into account when targeting androgen activities on the prostate. Phytoestrogens have 
been demonstrated to stimulate the production of SHBG in vitro.179 
3.2.4.2 Interaction with tyrosine-specific protein kinases 
Tyrosine-specific protein kinases are a part of the receptor proteins that are localized 
in the cell membrane. These receptors are necessary for signal transduction activated by 
several growth factors such as the epidermal growth factor (EGF), the platelet-derived growth 
factor, and the insuline growth factor (IGF).180,181 Fosforylation of tyrosine plays an important 
role in cell proliferation and cell transformation. It was demonstrated that genistein is a 
tyrosine-kinase-specific inhibitor and, therefore, a compound which can influence the 
processes of cell proliferation and transformation.182 
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3.2.4.3 Influence on angiogenesis 
Angiogenesis or neovascularization is concerned with the formation of new 
capillaries, a process involving proliferation and migration of endothelial cells. Normally, the 
process is restricted to wound healing, but is enhanced in association with tumor growth. 
Folkman reported that new capillary blood vesssels are necessary for a cancer to expand 
beyond 2 mm in size, having been involved in 27 doublings prior to that phase.130 
Angiogenesis, therefore, exercises an important role in cancer progression and is essentially 
seen as the growth of capillary sprouts of endothelial cells from pre-existing capillaries 
towards cancer foci, a process probably promoted by the production of growth factors. The 
fibroblast growth factor (FGF–II) and the vascular endothelial growth factor (VEGF), which 
is produced by neuroendocrine cells in the prostate, are potent angiogenic agents.130 Genistein 
has been demonstrated to inhibit angiogenesis and endothelial cell proliferation, possibly 
through its capacity to influence the tyrosine-specific protein kinase of the growth factor 
receptor (VEGF-R) and other enzymes promoting cell growth such as topoisomerases I and 
II.183  
3.2.4.4 Influence on DNA topoisomerases 
DNA topoisomerases are enzymes that alter the conformation of DNA and are crucial 
to the process of cell division. By strand cleavage, strand passage, and religation, these 
enzymes untangle supercoiled DNA which simplifies the replication.184 Topoisomerases are a 
well-researched target in the development of new anticancer drugs.130 It has been shown that 
genistein inhibits the activity of DNA topoisomerase, which could induce apoptosis.185,186,187  
 
 
 
 
 
LIES DELMULLE 155x240 - 148 blz - INDESIGN.indd   62 05-11-2007   15:54:54
 51 
REFERENCES 
                                                
 
 
1 Greuter W, Mcneill J, Barrie FR, Burdet HM, Demoulin V, Filgueiras TS, Nicolson DH, Silva PC, Skog JE, 
Trehane P, Turland NJ, Hawksworth DL. Regnum Vegetabile, 2000, vol 138. International Code of Botanical 
Nomenclature (St. Louis Code) Adopted by the 16th International Botanical Congress St. Louis, MO, USA, July-
August 1999. Koeltz Scientific Books, Königstein, Germany. 
2 Burgess A. Hops: Botany, Cultivation and Utilization, 1964. Leonard Hill, London, UK.  
3 Neve RA. Hops. 1991. Chapman & Hall, New York, USA. 
4 Verhelst G. Groot Handboek Geneeskrachtige Planten, Mannavita, Wevelgem, België, 2004, pp. 263-266. 
5 Blumenthal M. The Complete German Commission E Monograph: Therapeutic Guide to Herbal Medicines. 
Ed. M Blumenthal, USA, American Botanical Council, Austin, Texas, 1998, p. 147. 
6 Fussel A, Wolf A, Brattstrom A. Effect of a fixed valerian-hop extract combination (Ze 91019) on sleep 
polygraphy in patients with non-organic insomnia: a pilot study. Eur J Med Res, 2000, 5: 385-390. 
7 Schmitz M, Jackel M. Comparative study for assessing quality of life of patients with exogenous sleep 
disorders (temporary sleep onset and sleep interruption disorders) treated with a hops valerian preparation and a 
benzodiazepine drug. Wien Med Wochenschr, 1998, 148: 291-298. 
8 Chadwick LR, Pauli GF, Farnsworth NR. The pharmacognosy of Humulus lupulus L. (hops) with an emphasis 
on estrogenic properties. Phytomedicine, 2006, 13: 119–131. 
9 Sikorski H, Rusiecki W. The sedative action of various constituents of hops. Bull Int Acad Polon Sci Classe 
Med, 1938: 73–83. 
10 Wohlfart R, Hänsel R, Schmidt H. Nachweis sedativ-hypnotischer Wirkstoffe im Hopfen. Planta Med, 1982, 
45: 224–228. 
11 De Keukeleire D, De Cooman L, Rong H, Heyerick A, Kalita J, Milligan SR. Functional Properties of Hop 
Polyphenols. Plant Polyphenols 2: Chemistry, Biology, Pharmacology, Ecology. Ed. Gross GG, Hemingway 
RW, Yoshida T, Branham SJ. Kluwer Academic/Plenum Publishers, New York, USA, 1999, pp. 739-760. 
12 Hänsel R, Wohlfart R. Narcotic action of 2-methyl-3-butene-2-ol contained in the hops essential oil. Z 
Naturforsch Ser C, 1980, 35C: 1096–1097. 
13 Lorenzetti B, Souza G, Sarti S, Filho D, Ferreira S. Myrcene mimics the peripheral analgesic activity of 
lemongrass tea. J Ethnopharmacol, 1991, 34: 43–48. 
14 Milligan SR, Kalita JC, Heyerick A, Rong H, De Cooman L, De Keukeleire D. Identification of a potent 
phytestrogen in hops (Humulus lupulus L.) and beer. J Clin Endocrinol Metab, 1999, 83: 2249-2252. 
15 Eri S, Khoo BK, Lech J, Hartman TG. Direct thermal desorption-gas chromatography and gas 
chromatography-mass spectrometry profiling of hop (Humulus lupulus L.) essential oils in support of varietal 
characterization. J Agric Food Chem, 2000, 48: 1140-1149.  
16 Verzele M, De Keukeleire D. Chemistry and Analysis of Hop and Beer Bitter Acids. Elsevier, Amsterdam, 
The Netherlands, 1991. 
17 De Cooman L, Everaert E, De Keukeleire D. Quantitative analysis of hop acids, essential oils and flavonoids 
as a clue to the identification of hop varieties. Phytochem Anal, 1998, 9: 145-150. 
18 Mizobuchi S, Sato Y. A new flavanone with antifungal activity isolated from hops. Agric Biol Chem, 1994, 
48: 2771-2775. 
19 Stevens JF, Ivancic M, Hsu V, Deinzer ML. Prenylflavonoids from Humulus lupulus. Phytochemistry, 1997, 
44: 1575-1585. 
20 Stevens JF, Taylor AW, Clawson JE, Deinzer ML. Fate of xanthohumol and related prenylflavonoids from 
hops to beer. J Agric Food Chem, 1999, 47: 2421-2428. 
21 Stevens JF, Taylor AW, Deinzer ML. Quantitative analysis of xanthohumol and related prenylflavonoids in 
hops and beer by liquid chromatography-tandem mass spectrometry. J Chromatogr A, 1999, 832: 97-107. 
22 Stevens JF, Taylor AW, Nickerson GB, Ivancic M, Henning J, Haunold A, Deinzer ML. Prenylflavonoid 
variation in Humulus lupulus: distribution and taxonomic significance of xanthogalenol and 4’-O-
methylxanthohumol. Phytochemistry, 2000, 53: 759-775. 
23 Zuurbier KW, Leser J, Berger T, Hofte AJ, Schroder G, Verpoorte R, Schroder J. 4-Hydroxy-2-pyrone 
formation by chalcone and stilbene synthase with non-physiological substrates. Phytochemistry, 1998, 49: 1945-
1951. 
LIES DELMULLE 155x240 - 148 blz - INDESIGN.indd   63 05-11-2007   15:54:54
 52 
                                                                                                                                                   
 
 
24 Hänsel RV, Schulz J. Desmethylxanthohumol: Isolierung aus Hopfen und Cyclizierung zu Flavanonen. Arch 
Pharm Weinheim, 1988, 321: 37-40. 
25 Nastainczyk W. Untersuchung über die östrogene Wirkung des Hopfens und des Bieres. Ph.D. Dissertation, 
1972, Universität Saarbrücken, Germany. 
26 Kitaoka M, Kadokawa H, Sugano M, Ichikawa K, Taki M, Takaishi S, Iijima Y, Tsusumi S, Boriboon M, 
Akiyama T. Prenylflavonoids: a new class of non-steroidal phytestrogens (Part 1). Isolation of 8-
isopentenylnaringenin and an initial study on its structure-activity relationship. Planta Med, 1998, 64: 511-515. 
27 De Keukeleire D, Milligan SR, Kalita JC, Pocock V, De Cooman L, Heyerick A, Rong H, Roelens F. 
Prenylflavonoids are key agents in relation to health-beneficial properties of beer. Proceedings of the 28th 
International Congress of the European Brewery Convention, 2001, Budapest, Hungary. 
28 Middleton M, Kandaswami C. The Impact of Plant Flavonoids on Mammalian Biology: Implications for 
Immunity, Inflammation and Cancer. In: The Flavonoids. Advances in Research since 1986. Ed. JB Harborne, 
Chapman and Hall, London, UK, 1994, pp. 619-652. 
29 Fenselau C, Talalay P. Is estrogenic activity present in hops? Food Cosmet Toxicol, 1973, 11: 597-603. 
30 Donsback KW. Herbs Book No. 1. Institute for Natural Health Sciences, 1977, Huntington Beach, CA, USA. 
31 Zagari A. Medicinal Plants. Tehran University Publications, Tehran, Iran, 1992. 
32 Racz G, Fazakas B, Racz-Kotilla E. Trichomonazide und anthelmintische Wirkung in der rumanischen 
Volksmedizin verwendeten Pflanzen. Planta Med, 1980, 39: 257. 
33 Goetz P. Traitment des bouffées de chaleur par insuffisance ovarienne par l’extrait de houblon (Humulus 
lupulus). Rev Phytother Prat, 1990, 4: 13-15. 
34 Bednar IJ, Zenisek A. Identification of the estrogenic activity of hops. Brauwissenschaft, 1961, 14: 4-7.  
35 Zenisek A., Bednar IJ. Contribution to the identification of the estrogen activity of hops. Am Perf Arom, 1960, 
75: 61-62. 
36 Koch W, Heim G. Östrogene Hormone in Hopfen und Bier. Muench Med Wochenschr, 1953, 95: 845. 
37 Chury J. Experimental contribution to the chromatographic separation of sexually active substances in plant 
extracts. Sb Vys Sk Zemedel Brne Rada, 1961, B 9: 411-419 (Chem Abstr 55, 55060). 
38 De Keukeleire D, Milligan SR, De Cooman L, Heyerick A. The estrogenic activity of hops (Humulus lupulus 
L.) revisited. Pharm Pharmacol Lett, 1997, 7(2/3): 83-86. 
39 Milligan SR, Kalita JC, Pocock V, Van de Kauter V, Stevens JF, Deinzer ML, Rong H, De Keukeleire D. The 
endocrine activities of 8-prenylnaringenin and related hop (Humulus lupulus L.) flavonoids. J Clin Endocrinol 
Metab, 2000, 85: 4912-4915. 
40 Zierau O, Morrissey C, Watson RW, Schwab P, Kolba S, Metz P, Vollmer G. Antiandrogenic activity of the 
phytoestrogens naringenin, 6-(1,1-dimethylallyl)naringenin and 8-prenylnaringenin. Planta Med, 2003, 69: 856–
858. 
41 Zierau O, Gester S, Schwab P, Metz P, Kolba S, Wulf M, Vollmer G. Estrogenic activity of the 
phytoestrogens naringenin, 6-(1,1-dimethylallyl)naringenin and 8-prenylnaringenin. Planta Med, 2002, 68: 449-
451. 
42 Coldham NG, Sauer MJ. Identification, quantitation and biological activity of phytoestrogens in a dietary 
supplement for breast enhancement. Food Chem Toxicol, 2001, 39: 1211-1224. 
43 Rong H, Boterberg T, Maubach J, Stove C, Depypere H, Van Slambrouck S, Serreyn R, De Keukeleire D, 
Mareel M, Bracke M. 8-Prenylnaringenin, the phytoestrogen in hops and beer, upregulates the function of the E-
cadherin/catenin complex in human mammary carcinoma cells. Eur J Cell Biol, 2001, 80: 580-585. 
44 Takamura-Enya T, Ishihara J, Tahara S, Goto S, Totsuka Y, Sugimura T, Wakabayashi K. Analysis of 
estrogenic activity of foodstuffs and cigarette smoke condensates using a yeast estrogen screening method. Food 
Chem Toxicol, 2003, 41: 543-550. 
45 Matsamura A, Ghosh A, Pope GS, Darbre PD. Comparative study of estrogenic properties of eight 
phytestrogens in MCF7 human breast cancer cells. J Steroid Biochem Mol Biol, 2005, 94: 431-443. 
46 Milligan SR, Kalita JC, Pocock V, Heyerick A, De Cooman L, Rong H, De Keukeleire D. Estrogenic activity 
of the hop phyto-estrogen 8-prenylnaringenin. Reproduction, 2002, 123: 235-242. 
47 Schaefer O, Humpel M, Fritzemeier KH, Bohlmann R, Schleuning WD. 8-Prenylnaringenin is a potent 
ERalpha selective phytoestrogen present in hops and beer. J Steroid Biochem Mol Biol, 2003, 84: 359-360. 
48 Bovee TFH, Helsdingen RJR, Rietjens IMCM, Keijer J, Hoogenboom RLAP. Rapid yeast estrogen bioassay 
stably expressing human estrogen receptors alpha and beta, and green fluorescent protein: a comparison of 
different compounds with both receptor types. J Steroid Biochem Mol Biol, 2004, 91: 99-109. 
49 Effenberger KE, Johnsen SA, Monroe DG, Spelsberg TC, Westendorff JJ. Regulation of osteoblastic 
phenotype and gene expression by hop-derived phytoestrogens. J Steroid Biochem Mol Biol, 2005, 96: 387-399. 
LIES DELMULLE 155x240 - 148 blz - INDESIGN.indd   64 05-11-2007   15:54:55
 53 
                                                                                                                                                   
 
 
50 Liu J, Burdette JE, Xu H, Gu CG, van Breemen RB, Bhat KPL, Booth N, Constantinou AI, Pezzuto JM, Fong 
HHS, Farnsworth NR, Bolton JL. Evaluation of estrogenic activity of plant extracts for the potential treatment of 
menopausal symptoms. J Agric Food Chem, 2001, 49: 2472-2479. 
51 Diel P, Thomae RB, Caldarelli A, Zierau O, Kolba S, Schmidt S, Schwab P, Metz P, Vollmer G. Regulation of 
gene expression by 8-prenylnaringenin in uterus and liver of Wistar rats. Planta Med, 2004, 70: 39-44. 
52 Zierau O, Hamann J, Tischer S, Schwab P, Metz P, Vollmer G, Gutzeit HO, Scholz S. Naringenin-type 
flavonoids show different estrogenic effects in mammalian and teleost test systems. Biochem Biophys Res 
Commun, 2005, 326: 909-916. 
53 Rizzoli R, Bonjour JP. Hormones and bones. Lancet, 1997, 349(Suppl 1): s120-s123. 
54 Gustafsson JA, Warner M. Estrogen receptor beta in the breast: role in estrogen responsiveness and 
development of breast cancer. J Steroid Biochem Mol Biol, 2000, 74: 245-248. 
55 Tobe H, Muraki Y, Kitamura K, Komiyama O, Sato Y, Sugioka T, Maruyama HB, Matsuda E, Nagai M. Bone 
resorption inhibitors from hop extract. Biosci Biotech Biochem, 1997, 61: 158-159. 
56 Miyamoto M, Matsushita Y, Kiyokawa A, Fukuda C, Iijima Y, Sugano M, Akiyama T. Prenylflavonoids: a 
new class of non-steroidal phytoestrogen (part 2). Estrogenic effects of 8-isopentenylnaringenin on bone 
metabolism. Planta Med, 1998, 64: 516-519. 
57 Hümpel M, Isaksson P, Schaefer O, Kaufmann U, Ciana P, Maggi A, Schleuning WD. Tissue specificity of 8-
prenylnaringenin: Protection from ovariectomy induced bone loss with minimal trophic effects on uterus. J 
Steroid Biochem Mol Biol, 2005, 97: 299-305. 
58 Gonzalez FJ and Gelboin HV. Role of human cytochromes P450 in the metabolic activation of chemical 
carcinogens and toxins. Drug Metab Rev, 1994, 26: 165-183.  
59 Henderson MC, Miranda CL, Stevens JF, Deinzer ML, Buhler DR. In vitro inhibition of human P450 enzymes 
by prenylflavonoids from hop, Humulus lupulus. Xenobiotica, 2000, 30: 235-251. 
60 Miranda CL, Aponso GL, Stevens JF, Deinzer ML, Buhler DR. Prenylated chalcones and flavanones as 
inducers of quinone reductase in mouse hepa 1c1c7 cells. Cancer Lett, 2000, 149: 21-29. 
61 Miranda CL, Yang YH, Henderson MC, Stevens JF, Santana-Rios G, Deinzer ML, Buhler DR. 
Prenylflavonoids from hops inhibit the metabolic activation of the carcinogenic heterocyclic 2-amino-3-
methylimidazo[4,5-f]quinoline, mediated by cDNA-expressed human Cyp1A2. Drug Metab Dispos, 2000, 28: 
1297-1302. 
62 Gerhäuser C, Alt A, Heiss E, Gamal-Eldeen A, Klimo K, Knauft J, Neumann I, Scherf HR, Frank N, Bartsch 
H, Becker H. Cancer chemopreventive activity of xanthohumol, a natural product derived from hop. Molec 
Cancer Therap, 2002, 1: 959-969. 
63 Dietz BM, Kang YH, Liu GW, Eggler AL, Yao P, Chadwick LR, Pauli GF, Farnsworth NR, Mesecar AD, 
Van Breemen RB, Bolton JL. Xanthohumol isolated from Humulus lupulus inhibits menadione-induced DNA 
damage through induction of quinone reductase. Chem Res Toxicol, 2005, 18: 1296-1305.  
64 Liu GW, Eggler AL, Dietz BM, Mesecar AD, Bolton JL, Pezzuto JM, Van Breemen RB. Screening method 
for the discovery of potential cancer chemoprevention agents based on mass spectrometric detection of alkylated 
Keap1. Anal Chem, 2005, 77: 6407-6414. 
65 Miranda CL, Stevens JF, Helmrich A, Henderson MC, Rodriguez RJ, Yang YH, Deinzer ML, Barnes DW, 
Buhler DR. Antiproliferative and cytotoxic effects of prenylflavonoids from hops (Humulus lupulus) in human 
cancer cell lines. Food Chem Toxicol, 1999, 37: 271-285.  
66 Depypere H, Rong H, Boterberg T, Serryn R, Stove C, van Slambrouck S, De Keukeleire D, Mareel M, 
Bracke M. 8-Prenylnaringenin, the phytoestrogen in hops and beer, may influence the incidence of breast cancer. 
Eur J Cancer, 2002, 38(suppl. 6): S87-S95. 
67 Vanhoecke B, Derycke L, Van Marck V, Depypere H, De Keukeleire D, Bracke M. Antiinvasive effect of 
xanthohumol, a prenylated chalcone present in hops (Humulus lupulus L.) and beer. Int J Cancer, 2005, 117, 
889-895. 
68 Diller RA, Riepl HM, Rose O, Frias C, Henze G, Prokop A. Synthesis of desmethylxanthohumol, a new potent 
apoptosis-inducing agent from hops. Chem Biodiv, 2005, 2: 1331-1337. 
69 Pepper MS, Hazel SJ, Hümpel M, Schleuning WD. 8-Prenylnaringenin, a novel phytoestrogen, inhibits 
angiogenisis in vitro and in vivo. J Cell Phys, 2004, 199: 98-107. 
70 Tabata N, Ito M, Tomoda H, Omura S. Xanthohumols, diacylglycerol acyltransferase inhibitors, from 
Humulus lupulus. Phytochemistry, 1997, 46: 683-687. 
71 Miranda CL, Stevens JF, Ivanov V, McCall M, Frei B, Deinzer ML, Buhler DR. Antioxidant and prooxidant 
actions of prenylated and nonprenylated chalcones and flavanones in vitro. J Agric Food Chem, 2000, 48: 3876-
3884. 
LIES DELMULLE 155x240 - 148 blz - INDESIGN.indd   65 05-11-2007   15:54:55
 54 
                                                                                                                                                   
 
 
72 Rodriguez RJ, Miranda CL, Stevens JF, Deinzer ML, Buhler DR. Influence of prenylated and non-
prenylflavonoids on liver microsomal lipid peroxidation and oxidative injury in rat hepatocytes. Food Chem 
Toxicol, 2001, 39: 437-445.  
73 Stevens JF, Miranda CL, Frei B, Buhler DR. Inhibition of peroxynitrite-mediated oxidation by 
prenylflavonoids: the alpha, beta-unsaturated keto functionality of 2’-hydroxychalcones as a novel antioxidant 
pharmacophore. Chem Res Toxicol, 2003, 16: 1277-1286. 
74 Mizobuchi S, Sato Y. A new flavanone with antifungal activity isolated from hops. Agric Biol Chem, 1984, 
48: 2771-2775. 
75 Rad M, Hümpel M, Schaefer O, Schoemaker RC, Schleuning WD, Cohen AF, Burggraaf J. Pharmacokinetics 
and systemic endocrine effects of the phytoestrogen 8-prenylnaringenin after single oral doses to 
postmenopausal women. Br J Clin Pharmacol, 2006, 62: 288-296. 
76 Heyerick A, Vervarcke S, Depypere H, Bracke M, De Keukeleire D. A first prospective, randomized, double-
blind, placebo-controlled study on the use of a standardized hop extract to alleviate menopausal discomforts. 
Maturitas, 2006, 54: 164-175. 
77 Hollman PC, Katan MB. Bioavailability and health effects of dietary flavonols in man. Arch Toxicol Suppl, 
1998, 20: 237-248. 
78 Yilmazer M, Stevens JF, Deinzer ML, Buhler DR. In vitro biotransformation of xanthohumol, a flavonoid 
from hops (Humulus lupulus), by rat liver microsomes. Drug Metab Dispos, 2001, 29:223-231. 
79 Yilmazer M, Stevens J F, Buhler DR. In vitro glucuronidation of xanthohumol, a flavonoid in hop and beer, by 
rat and human liver microsomes. FEBS Lett, 2001, 491: 252-256. 
80 Coldham NG, Horton R, Byford MF, Sauer MJ. A binary screening assay for pro-estrogens in food: metabolic 
activation using hepatic microsomes and detection with estrogen sensitive recombinant yeast cells. Food Addit 
Contam, 2002, 19: 1138-1147. 
81 Nikolic D, Li Y, Chadwick LR, Grubjesic S, Schwab P, Metz P, van Breemen RB. Metabolism of 8-
prenylnaringenin, a potent phytoestrogen from hops (Humulus lupulus), by human liver microsomes. Am Soc 
Pharmacol Exp Ther, 2004, 32: 272-279. 
82 Zierau O, Hauswald S, Schwab P, Metz P, Vollmer G. Two major metabolites of 8-prenylnaringenin are 
estrogenic in vitro. J Steroid Biochem Mol Biol, 2004, 92: 107-110. 
83 Jang DS, Cuendet M, Hawthorne ME, Kardono LBS, Kawanishi K, Fong HHS, Mehta RG, Pezzuto JM, 
Kinghorn AD. Prenylflavonoids of the leaves of Macaranga conifera with inhibitory activity against 
cyclooxygenase-2. Phytochemistry, 2002, 61: 867-872. 
84 Nikolic D, Li YM, Chadwick LR, Pauli GF, van Breemen RB. Metabolism of xanthohumol and 
isoxanthohumol, prenylflavonoids from hops (Humulus lupulus L.), by human liver microsomes. J Mass 
Spectrom, 2005, 40: 289-299. 
85 Possemiers S, Heyerick A, Robbens V, De Keukeleire D, Verstraete W. Activation of proestrogens from hops 
(Humulus lupulus L.) by intestinal microbiota; Conversion of isoxanthohumol into 8-prenylnaringenin. J Agric 
Food Chem, 2005, 53: 6281-6288. 
86 Estrada JL, Gozalo F, Cecchini C, Casquete E. Contact urticaria from hops (Humulus lupulus) in a patient with 
previous urticaria-angioedema from peanut, chestnut, and banana. Contact Dermatitis, 2002, 46: 127. 
87 Lee KM, Jung JS, Song DK, Kräuter M, Kim YH. Effects of Humulus lupulus extract on the central nervous 
system in mice. Planta Med, 1993, 59: A691. 
88 Cabelin MA, Te AE, Kaplan SA. Benign prostatic hyperplasia: challenges for the new millennium. Curr Opin 
Urol, 2000, 10: 301-306. 
89 Cornell University Wmc. BPH general information. www.cornellurology.com (date of consultation: Oktober 
2003). 
90 Culig Z, Hobish A, Bartsch G, Klocker H. Androgen receptor – an update of mechanisms of action in prostate 
cancer. Urol Res, 2000, 28: 211-219. 
91 Leav I, Lau KM, Adams JY, McNeal JE, Taplin ME, Wang J, Singh H, Ho SM. Comparative studies of the 
estrogen receptors beta and alpha and the androgen receptor in normal human prostate glands, dysplasia, and in 
primary and metastatic carcinoma. Am J Pathol, 2001, 159: 79-92. 
92 Morrissey C, Watson RWG. Phytoestrogens and prostate cancer. Curr Drug Targets, 2003, 4: 231-241. 
93 Thorpe A, Neal D. Benign prostatic hyperplasia. Lancet, 2003, 361: 1359-1367. 
94 Bhargava S, Canda AE, Chapple CR. A rational approach to benign prostatic hyperplasia evolution: recent 
advances. Curr Opin Urol, 2004, 14: 1-6. 
LIES DELMULLE 155x240 - 148 blz - INDESIGN.indd   66 05-11-2007   15:54:56
 55 
                                                                                                                                                   
 
 
95 Emberton M, Andriole GL, de la Rosette J, Djavan B, Hoefner K, Navarrete RV, Nordling J, Roehrborn C, 
Schulman C, Teillac P, Tubaro A, Nickel JC. Benign prostatic hyperplasia: a progressive disease of aging men. 
Urology, 2003, 61: 267-273. 
96 Artibani W. Introduction. Eur Urol, 2001, 40(suppl 4): 1-4. 
97 Chapple CR. Urology. Introduction. Urology, 2003, 62(3 suppl 1): 1-5. 
98 Bosch JL, Hop WC, Kirkels WJ, Schroder FH. Natural history of benign prostatic hyperplasia: appropriate 
case definition and estimation of its prevalence in the community. Urology, 1995, 46(3 Suppl A): 34-40. 
99 Garraway WM, Collins GN, Lee RJ. High prevalence of benign prostatic hypertrophy in the community. 
Lancet, 1991, 338: 469-471. 
100 Meikle AW, Stephenson RA, Lewis CM, Middleton RG. Effects of age and sex hormones on transition and 
peripheral zone volumes of prostate and benign prostatic hyperplasia in twins. J Clin Endocrinol Metabol, 1997, 
82: 571-575. 
101 Abrams P. Managing lower urinary tract symptoms in older men. Br Med J, 1995, 310: 1113-1117. 
102 Geller J. Pathogenesis and medical treatment of benign prostatic hyperplasia. Prostate Suppl, 1989, 2: 95-104. 
103 Dreikorn K, Richter R, Schönhöfer PS. Konservative, nicht-hormonelle Behandlung der benignen 
Prostatahyperlasie. Urologe, 1990, 29: 8. 
104 Henderson D, Habenicht UF, Nishino Y, Kerb U, El Etreby MF. Aromatase inhibitors and benign prostatic 
hyperplasia. J Steroid Biochem, 1986, 25: 867-876. 
105 Marandola P, Jallous H, Bombardelli E, Morazzoni P. Main phytoderivatives in the management of benign 
prostatic hyperplasia. Fitoterapia, 1997, 68: 195-204. 
106 Habenicht UF, Tunn UW, Senge T, Schröder FH, Schweikert HU, Bartsch G, El Etreby MF. Management of 
benign prostatic hyperplasia with particular emphasis on aromatase inhibitors. J Steroid Biochem Molec Biol, 
1993, 44: 557-563. 
107 McConnell JD, Bruskewitz R, Walsh P, Andriole G, Lieber M,Holtgrewe HL. The effect of finasteride on the 
risk of acute urinary retention and the need of surgical treatment among men with benign prostatic hyperplasia. 
Finasteride Long-Term Efficacy and Safety Study Group. N Engl J Med, 1998, 338: 557-563. 
108 McConnellJD, Roehrborn CG, Bautista OM, Andriole GL, Jr., Dixon CM, Kusek JW. The long-term effect of 
doxazosin, finasteride and combination therapy on the clinical progression of benign prostatic hyperplasia. N 
Engl J Med, 2003, 349: 2387-2398. 
109 Di Silverio F, Flammia GP, Sciarra A, Caponera M, Mauro M, Buscarini M, Tavani M, D’Eramo G. Plant 
extracts in BPH. Minerva Urol Nefrol, 1993, 45: 143-149. 
110 Wagner H, Willer F, Samtleben R, Boos G. Search for the antiprostatic principle of stinging nettle (Urtica 
dioica) roots. Phytomedicine, 1994, 1: 213-214. 
111 Barry M, Roehrborn C, Webber R. Benign prostatic hyperplasia. Clin Evid, 2004, 11: 1119-1138. 
112 Mills S, Bone K. Principles and Practice of Phytotherapy. Churchill Livingstone, Edinburgh, UK, 2000. 
113 Landis SH, Murray T, Bolden S, Wingo PA. Cancer Statistics, 1999. CA Cancer J Clin, 1999, 49: 8-31. 
114 Carter HB, Coffey DS. The prostate: an increasing medical problem. Prostate, 1990, 16: 39-48. 
115 Griffiths K, Morton MS, Denis LJ. Diet and Prostate Disease. Eds. HB Carter, DS Coffey. International 
Prostate Health Council, Oxford, UK, 1998. 
116 Lopez-Otin C, Diamandis EP. Breast and prostate cancer: an analysis of common epidemiological, common 
genetic, common and biochemical features. Endocrinol Rev, 1998, 19: 365-396. 
117 Prentice RL, Sheppard L. Dietary fat and cancer: consistency of the epidemiological data, and disease 
prevention that may follow from a practical reduction in fat consumption. Cancer Causes Control, 1990, 1: 81-
97. 
118 Shimizu H, Ross RK, Bernstein L, Yatani R, Henderson BE, Mack TM. Cancer of the prostate and breast 
among Japanese and white immigrants in Los Angeles County. Br J Cancer, 1991, 63: 963-966. 
119 Willets WC. Specific fatty acids and risks of breast and prostate cancer: dietary intake. Am J Clin Nutr, 1997, 
66: 15575-15635. 
120 Herr HW, Kornblith AB, Ofman U. A comparison of the quality of life of patients with metastatic prostate 
cancer who received or did not receive hormonal therapy. Cancer, 1993, 71:1143-50. 
121 Jacobson JS,  Chetty AP. Complementary and alternative medicine in prostate cancer. Curr Oncol Rep, 2001, 
3: 448-452. 
122 Chapple CR. Medical therapy and quality of life. Eur Urol, 1998, 34:10-17. 
123 Buck AC. Phytotherapy for the prostate. Br J Urol, 1996, 78: 325-336. 
124 Gupta S. Prostate cancer chemoprevention: Models, limitations and potential. Int J Oncol, 2004, 25: 1133-
1148. 
LIES DELMULLE 155x240 - 148 blz - INDESIGN.indd   67 05-11-2007   15:54:57
 56 
                                                                                                                                                   
 
 
125 Crawford ED. Epidemiology of prostate cancer. Urology, 2003, 62: 3-12. 
126 Isaacs JT, Coffey DS. Etiology and disease process of benign prostatic hyperplasia. Prostate, 1989, 2 (suppl): 
33-50. 
127 Coffey D, Griffiths K, Cockett A, di Sant’ Agnese A, Ichikawa T, Krieg M, Lee C, McKeehan W, Schalken J, 
Sciarra F, Steiner G, Sugimura Y, Yamanaka H. The Regulation of Prostatic Growth. In: The 3rd International 
Consultation on Benign Prostatic Hyperplasia. Eds. ATK Cockett, S Khoury, Y Aso, C Chatelain, L Denis, K 
Griffiths, G Murphy, S.C.I., Paris, France, 1996, pp. 73-115. 
128 Coffey D, Griffiths K, Cockett A, di Sant’ Agnese A, Ichikawa T, Krieg M, Lee C, McKeehan W, Schalken J, 
Sciarra F, Steiner G, Sugimura Y, Yamanaka H. The Regulation of Prostatic Growth. In: The 3rd International 
Consultation on Benign Prostatic Hyperplasia. Eds. ATK Cockett, S Khoury, Y Aso, C Chatelain, L Denis, K 
Griffiths, G Murphy, S.C.I., Paris, France, 1998, pp. 83-128. 
129 Bostwick DG, Sole Balcells F, Cooner WH, Denis LJ, Fang-Liu G, Jones GW, Khoury S, Kotake T, De 
Matteis A, Pagano F, Scardino F, Scardino P, Murphy GP. Benign Prostatic Hyperplasia (BPH) and cancer of 
the prostate. In: Proceedings of the International Consultation on Benign Prostatic Hyperplasia (BPH). Eds. ATK 
Cockett, Y Aso, C Chatelain, L Denis, K Griffiths, S Khoury , G Murphy, S.C.I., Paris, France, 1991, pp. 139-
159. 
130 Denis L, Griffiths K, Turkes A. The concept of prevention as a public health strategy for prostate cancer 
control. Arch Med Sci, 2005, 1: 23-33. 
131 Thomas JA, Keenan EJ. Effects of estrogens on the prostate. J Androl, 1994, 15: 97-99. 
132 Bartsch G, Daxenbichler G, Rohr HP. Steroid pathophysiology of BPH. Correlative morphological and 
biochemical investigations on the stromal tissue of the human prostate. J Steroid Biochem, 1983, 19: 174-154. 
133 McNeal JE. Origin and evolution of benign prostatic enlargement. Invest Urol, 1978, 15:340-345. 
134 Comhaire FH. Andropause: hormone replacement therapy in the ageing male. Eur Urol, 2000, 38: 655-662. 
135 Rosner W, Hryb DJ, Khan MS, Nakhala AM, Romas NA. Sex hormone-binding globulin. Binding to cell 
membranes and generation of a second messenger. J Androl, 1992, 13:101-106. 
136 Bostwick DG, Brawer MK. Prostatic intraepithelial neoplasia and early invasion in prostatic cancer. Cancer, 
1987, 59: 788-794. 
137 Baba S. Epidemiology of Cancer of the Prostate: Analysis of Countries of High and Low Incidence. In: 
Prostate Cancer. International Perspectives in Urology 3. Eds.: GH Jacobi, R Hohenfellner, Williams & Wilkins, 
Baltimore, MD, USA, 1982, pp. 11-28. 
138 Yatani R, Chigusa I, Akazaki K, Stemmerman GN, Welsh RA, Correa P. Geographic pathology of latent 
prostate cancer. Int J Cancer, 1982, 29: 611-616. 
139 Schroeder FH. 5-reductase inhibitors and prostatic disease. Clin Endocrinol, 1994, 41: 139-147. 
140 Coffey D, Berry SJ, Ewing LL. An Overview of Current Concepts in the Study of Benign Prostatic 
Hyperplasia. In: Benign Prostatic Hyperplasia II. Eds. CH Rodgers, DS Coffey, GR Cunha, JT Grayhack, F 
Hinman, R Horton, NIH Publ., No 87-2881, U.S. Dept. Health, Human Serv., NIH, Bethesda, MD, USA, 1987, 
pp. 1-13. 
141 Denis L, Morton MS, Griffiths K. Diet and its preventive role in prostatic disease. Eur Urol, 1999, 35: 377-
87. 
142 Skrabanek P. Invited viewpoints. Eur J Cancer, 1994, 30A: 220-221. 
143 McMichael AJ. Invited viewpoints. Eur J Cancer, 1994, 30A: 221-223. 
144 Anon. Diet and breast cancer. Nature, 1992, 359: 760. 
145 Cos P, De Bruyne T, Apers S, Vanden Berghe D, Pieters L, Vlietinck AJ. Phytoestrogens: Recent 
developments. Planta Med, 2003, 69: 589-599. 
146 Ososki AL, Kennelly EJ. Phytoestrogens: A review of the present state of research. Phytother Res, 2003, 17: 
845-869. 
147 Lindner HR. Occurrence of anabolic agents in plants and their importance. Environ Qual Saf Suppl, 1976, 5: 
151-158. 
148 Dwyer JT, Goldin BR, Saul N, Gualtieri L, Barakat S, Adlercreutz H. Tofu and soy drinks contain 
phytoestrogens. J Am Diet Assoc, 1994, 94: 739-743. 
149 Gehm BD, McAndrews JM, Chien PY, Jameson JL. Reservatrol, a polyphenolic compound found in grapes 
and wine, is an agonist for the estrogen receptor. Proc Natl Acad Sci USA, 1997, 94: 14138-14143. 
150 Mazur WM, Uehara M, Wahala K, Adlercreutz H. Phyto-oestrogen content of berries, and plasma 
concentrations and urinary excretion of enterolactone after a single strawberry-meal in human subjects. Br J 
Nutr, 2000, 83: 381-387. 
LIES DELMULLE 155x240 - 148 blz - INDESIGN.indd   68 05-11-2007   15:54:57
 57 
                                                                                                                                                   
 
 
151 Risbridger GP, Wang H, Frydenberg M, Husband A. The in vivo effect of red clover diet on ventral prostate 
growth in adult male mice. Reprod Fertil Dev, 2001, 13: 325-329. 
152 Adlercreutz H, Markkanen H, Watanabe S. Plasma concentrations of phytoestrogens in Japanese men. 
Lancet, 1993, 342: 1209-1210. 
153 Pumford SL, Morton MM, Turkes A, Griffiths K. Determination of the isoflavonoids genistein and daidzein 
in biological samples by gas chromatography-mass spectrometry. Ann Clin Biochem, 2002, 39: 281-292. 
154 Lu LJ, Grady JJ, Marshall MV, Ramanujam VM, Anderson KE. Altered time course of urinary daidzein and 
genistein excretion during chronic soya diet in healthy male subjects. Nutr Cancer, 1995, 24: 311-323. 
155 Severson RK, Nomura AM, Grove JS, Stemmermann GN. A prospective study of demographics, diet, and 
prostate cancer among men of Japanese ancestry in Hawaii. Cancer Res, 1989, 49: 1857-1860. 
156 Strom SS, Yamamura Y, Duphorne CM, Spitz MR, BabaianRJ, Pillow PC, Hursting SD. Phytoestrogen 
intake and prostate cancer: a case-control study using a new database. Nutr Cancer, 1999, 33: 20-25. 
157 Hebert JR, Hurley TG, Olendzki BC, Teas J, Ma Y, Hampl JS. Nutritional and socioeconomic factors in 
relation to prostate cancer mortality: a cross-national study. J Natl Cancer Inst, 1998; 90: 1637–1647. 
158 Sharpe RM, Skakkebaek NE. Are estrogens involved in falling sperm counts and disorders of the male 
reproductive tract? Lancet, 1993, 341: 1392-1395. 
159 Taub M, Begas A, Love N. Advanced prostate cancer. Endocrine therapies and palliative measures. Postgrad 
Med, 1996, 100: 139-152. 
160 Coffey DS. Similarities of prostate and breast cancer: evolution, diet, and estrogens. Urology, 2001, 57: 31-
38. 
161 Evans BAJ, Griffiths K, Morton M. Inhibition of 5-reductase and 17-hydroxysteroid dehydrogenase in 
genital skin fibroblasts by dietary lignans and isoflavonoids. J Endocrinol, 1995, 147: 295-302. 
162 Simpson ER, Davis SR. Minireview: aromatase and the regulation of estrogen biosynthesis - some new 
perspectives. Endocrinology, 2001, 142: 4589-4594. 
163 Kao YC, Zhou C, Sherman M, Laughton CA, Chen S. Molecular basis of the inhibition of human aromatase 
(estrogen synthetase) by flavone and isoflavone phytestrogens: A site-directed mutagenesis study. Environ 
Health Perspect, 1998, 106: 85–92. 
164 Mäkelä S, Poutanen M, Lehtimaki J, Kostian ML, Santti R, Vihko R. Inhibition of 17-hydroxysteroid 
oxidoreductase by flavonoids in breast and prostate cancer cells. Proc Soc Exp Biol Med, 1998, 217: 310–316. 
165 Krazeisen A, Breitling R, Möller G, Adamski J. Phytoestrogens inhibit human 17-hydroxysteroid 
dehydrogenase type 5. Mol Cel Endocrinol, 2001, 171: 151-162. 
166 Ross RK, Bernstein L, Lobo RA, Shimizu H, Stanczyk FZ, Pike MC, Henderson BE. 5-Reductase activity 
and risk of prostate cancer among Japanese and United States white and black males. Lancet, 1992, 339: 887-
889. 
167 Mäkelä S, Davis VL, Tally WC, Korkman J, Salo L, Vihko R, Santti R, Korach KS. Dietary estrogens act 
through estrogen receptor mediated processes and show no antiestrogenicity in cultured breast cancer cells. 
Environ Health Perspect, 1994, 102: 572–578. 
168 Miksicek RJ. Estrogenic flavonoids: Structural requirements for biological activity. Proc Soc Exp Biol Med, 
1995, 30: 212–217. 
169 Kuiper GG, Carlsson B, Grandien K, Enmark E, Haggblad J, Nilsson S, Gustafsson JA. Comparison of the 
ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta. Endocrinology, 
1997, 138:  863–870. 
170 Ruh MF, Zacharewski T, Connor K, Howell J, Chen I, Safe S. Naringenin: A weakly estrogenic bioflavonoid 
that exhibits antiestrogenic activity. Biochem Pharmacol, 1995, 50: 1485–1493. 
171 Kuiper GG, Enmark E, Pelto-Huikko M, Nilsson S, Gustafsson JÅ. Cloning a novel estrogen receptor 
expressed in rat prostate and ovary. Proc Natl Acad Sci USA, 1996, 93: 5925–5930. 
172 Morito K, Aomori T, Hirose T, Kinjo J, Hasegawa J, Ogawa S, Inoue S, Muramatsu M, Masamune Y. 
Interactions of phytoestrogens with estrogen receptors  and . Biol Pharm Bull, 2002, 25: 48-52. 
173 Kuiper GG, Lemmen JG, Carlsson B, Corton JC, Safe SH, Van der Saag PT, Van der Burg B, Gustafsson JA. 
Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor beta. Endocrinology, 1998, 139: 
4252-4263. 
174 Nikov GN, Hopkins NE, Boue S, Alworth WL. Interactions of dietary estrogens with human estrogen 
receptors and the effect on estrogen receptor-estrogen response element complex formation. Environ Health 
Perspect, 2000, 108: 867-872. 
LIES DELMULLE 155x240 - 148 blz - INDESIGN.indd   69 05-11-2007   15:54:58
 58 
                                                                                                                                                   
 
 
175 Bowers JL, Tyulmenkov VV, Jernigan SC, Klinge CM. Resveratrol acts as a mixed agonist/antagonist for 
estrogen receptors  and ß. Endocrinology, 2000, 141: 3657-3667. 
176 Belanger A, Locong A, Noel C, Cusan L, Dupont A, Prevost J, Caron S, Sevigny J. Influence of diet on 
plasma steroids and sex plasma-binding globulin levels in adult men. J Steroid Biochem, 1989, 32: 829-833. 
177 Vermeulen A. Metabolic effects of obesity in men. Verh Koninkl Acad Geneesk België, 1993, 55: 393-397. 
178 Comhaire FH. Andropause: Hormone replacement therapy in the ageing male. Eur Urol, 2000, 38: 655-662. 
179 Adlercreutz H, Hockerstedt K, Bannwart C, Bloigu S, Hamalainen E, Fotsis T, Ollus A. Effect of dietary 
components, including lignans and phytoestrogens, on enterohepatic circulation and liver metabolism of 
estrogens and on sex hormone binding globulin (SHBG). J Steroid Biochem, 1987, 27: 1135–1144. 
180 Aaronson S. Growth factors and cancer. Science, 1991, 254: 1146-1153. 
181 Griffiths K.The Regulation of Prostatic Growth. In: The 3rd International Consultation on Benign Prostatic 
Hyperplasia. Eds. Cockett, A.T.K., SCI, Paris, France, 1995, pp. 71-115. 
182 Akiyama T, Ishida J, Nakagawa S et al. Genistein, a specific inhibitor of tyrosine-specific protein kinases. J 
Biol Chem, 1987, 262: 5592–5595. 
183 Fotsis T, Pepper M, Adlercreutz H, Fleischmann G, Hase T, Montesano R, Schweigerer L. Genistein, a 
dietary derived inhibitor of in vitro angiogenesis. Proc Natl Acad Sci USA, 1993, 90: 2690–2694. 
184 Cummings J, Smyth JF. DNA topoisomerase I and II as targets for rational design of new anticancer drugs. 
Ann Oncol, 1993, 4: 533-543. 
185 Bylund A, Zhang JX, Bergh A, Damber JE, Widmark A, Johansson A, Adlercreutz H, Åman P, Shepherd MJ, 
Hallmans G. Rye bran and soy protein delay growth and increase apoptosis of human LNCaP prostate 
adenocarcinoma in nude mice. Prostate, 2000, 42: 304–314. 
186 McCabe MJJr, Orrenius S. Genistein induces apoptosis in immature human thymocytes by inhibiting 
topoisomerase-II. Biochem Biophys Res Commun, 1993, 194: 944-950. 
187 Messina MJ, Persky VL, Setchell KDR, Barnes S.  Soy intake and cancer risk: a review of the in vitro and in 
vivo data. Nutr Cancer, 1994, 21: 113-131. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
====================================================== 
LIES DELMULLE 155x240 - 148 blz - INDESIGN.indd   70 05-11-2007   15:54:58
  
59 
 
4. Isolation, purification and stability of hop-derived 
prenylflavonoids                                                
4.1. Isolation and purification of xanthohumol and desmethyl-
xanthohumol 
Xanthohumol (X) and desmethylxanthohumol (DMX) (Figure 4.1) were isolated from 
spent hops, a residue obtained after supercritical carbon dioxide extraction of the hop variety 
Nugget (NATECO2, Wolnzach, Germany).  
 
O 
O H O H 
OMe 
C H 3 C H 3 
O H 
 
 
           Xanthohumol (X) 
 
O 
O H O H 
O H 
C H 3 C H 3 
O H 
  
 
Desmethylxanthohumol (DMX) 
Figure 4.1: Structures of the chalcones xanthohumol (X) and desmethylxanthohumol (DMX). 
Spent hops (100 g) were extracted with MeOH (3 x 1 L) at ambient temperature. After 
filtration, the volume was reduced to about 500 ml (Büchi rotavapor R-200, 35°C), diluted 
with H2O (1:1, v/v), and extracted with n-hexane (3 x 1 L). The upper layer was rejected and 
the remaining volume was reduced to about 500 ml, diluted with H2O (1:1, v/v), and extracted 
with EtOAc (2 x 1 L). The organic layer was separated and evaporation of EtOAc afforded a 
residue (ca. 5 g) containing approximately 12% X and 1.2% DMX, as determined by HPLC. 
HPLC separations (Waters Alliance 2695 Separation Module, Milford, MA, USA) were 
achieved using a Varian Omnisphere C18 column (4.6 mm x 250 mm, 5 m) at a flow rate of 
0.9 ml.min
-1
 using a linear gradient from 45% MeOH to 95% MeOH in H2O containing 
0.05% formic acid over a time span of 29 min (conditions, see: Table 4.1). UV detection of X 
and DMX was done at 370 nm. The retention times of X and DMX were 26.9 min and 23.9 
min, respectively.  
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The linear gradient was applied for semi-preparative isolation of X and DMX (residue 
dissolved in MeOH containing 0.05% formic acid [100 mg/ml]) using an Alltech Econosil 
C18 column (22 mm x 250 mm, 10 m) at a flow rate of 10 ml.min-1 (conditions, see: Table 
4.2). Fractions containing X and DMX were collected separately, the solvent was evaporated 
(Büchi rotavapor R-200, 35°C), and the residue was freeze-dried (Heto Lyolab 3000, 
connected to a Pfeiffer vacuum pump). Freeze-dried residues were dissolved in MeOH (50 
mg/mL). 
Final purification (Alltech Econosil C18, 22 mm x 250 mm, 10 m) was achieved 
using isocratic elution (60% MeCN in H2O containing 0.05% formic acid for X and 55% 
MeCN in H2O containing 0.05% formic acid for DMX) (conditions, see: Table 4.2).  
The identity of the pure compounds was confirmed by analytical HPLC (tR and UV 
spectra) and 
1
H-NMR (Varian 300 MHz). 
1
H-NMR and UV spectra of the compounds were in 
accordance with those described in the literature
1,2
.  
Table 4.1: Conditions for analytical HPLC 
HPLC apparatus Waters Alliance 2695 Separation Module 
Sample ± 0.05 mg/mL MeOH, 0.22-m filter 
Column Varian Omnisphere C18; dp: 5 m; i.d.: 4.6 mm; length: 250 mm 
Eluens Solvent A: 0.05 % HCOOH in H2O 
Solvent B: 0.05 % HCOOH in MeOH 
Gradient range 45 % B in A to 95 % B in A 
Gradient course 0-3 min: isocratic 45 % B in A 
3-32 min: 45 % B in A to 95 % B in A 
32-37 min: isocratic 95 % B in A 
37-45 min: 95 % B in A to 45 % B in A 
45-47 min: isocratic 45 % B in A 
Flow rate  0.9 mL/min 
Injection volume 20 L 
Detector Photodiode Array Detector Waters 996 
Detection wavelength X, DMX: 370 nm 
IX, 8PN, 6PN: 295 nm 
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4.2. Semi-synthesis and purification of isoxanthohumol 
IX was prepared by refluxing xanthohumol (1 g) in alkaline (KOH, 0.18 M) MeOH 
(100 ml) for 1 h at 85°C (Figure 4.2). Acidification with HCl (0.18 M), removal of the 
solvent, addition of H2O (150 ml), extraction with EtOAc (1 x 150 ml), evaporation of 
EtOAc, and lyophilization (Heto Lyolab 3000 with a Pfeiffer vacuum pump) furnished a 
residue, which was dissolved in MeOH at a concentration of 100 mg/ml and separated by 
semi-preparative HPLC (Alltech Econosil C18, 22 mm x 250 mm, 10 m) using isocratic 
elution (40% MeCN in H2O containing 0.05% formic acid) (conditions, see: Table 4.2). The 
purity (> 99%) was confirmed by analytical HPLC (Varian Omnisphere C18, 4.6 mm x 250 
mm, 5 m) (conditions, see: Table 4.1) and 1H-NMR (Varian 300 MHz). The retention time 
of IX was 19.5 min. Comparison of the 
1
H -NMR and UV spectra with literature data led to 
correct identification.
1,2
 
 
Figure 4.2: Isomerization of the chalcone xanthohumol (X) into the flavanone isoxanthohumol (IX). 
 
4.3. Synthesis and purification of 8-prenylnaringenin and 6-
prenylnaringenin 
The flavanones 8-prenylnaringenin (8PN) and 6-prenylnaringenin (6PN) were 
synthesized according to a previously published method (Figure 4.3).
3
  
Final purification of the mixture obtained after synthesis (Alltech Econosil C18, 22 
mm x 250 mm, 10 m) was achieved using isocratic elution (50% MeCN in H2O containing 
0.05% formic acid for 8PN and 6PN) (conditions, see: Table 4.2). The identity of the pure 
compounds and the purity (> 99%) were confirmed by analytical HPLC (Varian Omnisphere 
C18, 4.6 mm x 250 mm, 5 m) and 1H-NMR (Varian 300 MHz). The retention time of 8PN 
OH
O
OH OH
OMe  
 
Xanthohumol (X) 
O
OH O
OH
OMe   
 
Isoxanthohumol (IX) 
Isomerization 
 (T, alkali) 
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and 6PN were 21.5 min and 25.4 min, respectively. Comparison of the 
1
H -NMR and UV 
spectra with literature data led to correct identification.
1,2
 
OOH
OH O
OH
1
2
6
8
 
8-Prenylnaringenin (8PN) 
OOH
OH
OH
O
 
6-Prenylnaringenin (6PN) 
Figure 4.3: Structures of the flavanones 8-prenylnaringenin (8PN) and 6-prenylnaringenin (6PN). 
 
 
Table 4.2: Conditions for semi-preparative HPLC  
Prepurification  
HPLC apparatus Gilson 322 
Sample 100 mg/mL MeOH, 0.22-m filter 
Column Alltech Econosil C18; dp: 10 m; i.d.: 22 mm; lengte: 250 mm 
Eluens Solvent A: 0.05 % HCOOH in H2O 
Solvent B: 0.05 % HCOOH in MeOH 
Gradient range 45 % B in A to 95 % B in A 
Gradient course 0-2 min: isocratic 45 % B in A 
2-32 min: 45 % B in A tot 95 % B in A 
32-38 min: isocratic 95 % B in A 
38-45 min: 95 % B in A tot 45 % B in A 
45-47 min: isocratic 45 % B in A 
Flow rate  10 mL/min 
Injection volume 0.5-1 mL 
Detector Gilson dual wavelength UV detector (UV/VIS-156) 
Detection wavelength X, DMX: 370 nm 
IX, 8PN, 6PN: 295 nm 
Fraction collector Gilson 206 
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Final purification  
HPLC apparatus Gilson 322 
Sample 50 mg/mL MeOH, 0.22-m filter 
Column Alltech Econosil C18; dp: 10 m; i.d.: 22 mm; lengte: 250 mm 
Eluens Solvent A: 0.05 % HCOOH in H2O 
Solvent B: 0.05 % HCOOH in MeCN 
Isocratic system X: 60 % B in A 
DMX: 55 % B in A 
IX: 40 % B in A 
8PN: 50 % B in A 
6PN: 50 % B in A 
Flow rate  10 mL/min 
Injection volume 0.5-1 mL 
Detector Gilson dual wavelength UV detector (UV/VIS-156) 
Detection wavelength X, DMX: 370 nm 
IX, 8PN, 6PN: 295 nm 
Fraction collector Gilson 206 
4.4. Stability of the purified hop-derived prenylflavonoids 
The pure hop-derived prenylflavonoids, X, DMX, IX, 8PN, and 6PN were tested for 
their stability in dry, solid form or dissolved in EtOH (200 mM) by storage at different 
temperatures (–20°C, 4°C and room temperature) during 1 year.  
At regular time intervals, small fractions of the stored samples were analysed by 
HPLC (Waters Alliance 2695 Separation Module, Milford, MA, USA) using a Varian 
Omnisphere C18 column (4.6 mm x 250 mm, 5 m) at a flow rate of 0.9 ml.min-1 under 
isocratic conditions previously established for the semi-preperative purification of the 
compounds (conditions, see: Table 4.2). 
In view of the use of prenylflavonoids in appropriate bio-assays, it was necessary to 
determine the stability of the pure hop-derived prenylflavonoids for long term-incubations at 
37°C. Therefore, stock solutions of individual compounds were prepared in EtOH (200 mM), 
diluted with water (1:1000) and incubated at 37°C during 2 days. At the start of incubation 
and after every 24 h, fractions of the incubated samples were analysed by HPLC (Waters 
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Alliance 2695 Separation Module, Milford, MA, USA) using a Varian Omnisphere C18 
column (4.6 mm x 250 mm, 5 m) at a flow rate of 0.9 ml.min-1 in the isocratic conditions 
previously established for the semi-preparative purification of the compounds (conditions, 
see: Table 4.2).  
The results demonstrate that the optimum storage conditions in dry, solid form are at a 
temperature of –20°C. Storage in solution promotes isomerization and especially DMX shows 
a time-dependent conversion at each temperature tested.  Furthermore, even after storage in 
dry, solid form, the chalcone DMX proved to be instable. Thus, DMX must be purified just 
prior to use. The addition of a small quantity of acid (0.05 % HCOOH) improved the stability 
of this chalcone remarkably and the acidic conditions were routinely applied during storage of 
all prenylflavonoids. X, IX, 8PN and 6PN, were shown to be stable, as well in dry, solid form, 
as in solution.  
Figure 4.4 shows the time-dependent conversion of DMX to the isomeric 8PN and 
6PN following incubation at 37°C. After 48 h (mean incubation time of the bioassays), nearly 
50% of DMX was converted into a mixture of 35% 6PN and 15% 8PN. This feature must be 
taken into account when interpreting the results of the bio-assays. 
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Figure 4.4: Stability of desmethylxanthohumol (DMX) and isomerization into 8-prenylnaringenin (8PN) 
and 6-prenylnaringenin (6PN) after incubation at 37°C during 48 h. 
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5. Antiproliferative, cytotoxic, antiangiogenic, and estrogenic 
properties of hop-derived prenylflavonoids 
Development of cancer-chemopreventive and chemotherapeutic agents requires testing 
in in vitro cell culture systems prior to in vivo studies by appropriate animal model(s) that 
may be validated in final clinical trials. Models that emulate any or all of the key features of 
prostate cancer development and progression may prove to be valuable in understanding the 
mechanisms involved in carcinogenesis and in identifying useful chemopreventive agents.
4
 
The need for representative in vitro models of prostate cancer chemoprevention and 
development has led to numerous attempts to establish cell lines from human prostate 
carcinoma and approximately 30 cell lines have been used for research purposes.
5
 Molecular 
characterization and karyotype analysis of most commonly used cells have been described in 
recent studies.
6
 
The LNCaP cells are unique human prostate carcinoma cells that have retained 
functional differentiation of prostatic epithelial cells.
7
 LNCaP cells were derived from a 
supraclavicular lymph node of a prostate cancer patient. LNCaP cells are androgen-sensitive 
and they secrete prostate specific antigen (PSA) and prostatic acid phosphatase, and express 
the androgen receptor.
8
 They have been widely used as an androgen-sensitive model for 
prostate cancer in both basic research and chemopreventive studies. 
Other frequently applied cell lines are DU145 and PC-3 cells. DU145 cells are derived 
from brain metastases of an untreated prostate cancer patient, whereas PC-3 cells are derived 
from bone metastases of a patient with androgen-independent prostate cancer.
9,10
 Both these 
cell lines are androgen-insensitive and they do not express PSA nor the androgen receptor.
11
 
These cell lines represent excellent models for the study of advanced prostate cancer and of 
the androgen-repressed phenotype of late events during prostate cancer progression. To study 
the chemopreventive or therapeutic potential of the hop-derived prenylflavonoids in prostate 
cancer (PC), a series of in vitro experiments was set up using the well-established human 
prostate cancer cell lines LNCaP.FGC, PC-3, and DU145. We aimed to get insights in how 
the hop-derived prenylflavonoids xanthohumol (X), desmethylxanthohumol (DMX), 
isoxanthohumol (IX), 8-prenylnaringenin (8PN) and 6-prenylnaringenin (6PN) influence the 
pathogenesis of PC, and in how the underlying mechanisms operate. These investigations 
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were performed in laboratories that possessed the expertise necessary for the purpose of each 
set of experiments.  
The antiproliferative, cytotoxic, antiangiogenic, and estrogenic properties were studied 
at the laboratory of Prof. Dr. Em. F. Comhaire, Ghent University Hospital, Department of 
Endocrinology, Ghent, Belgium, and the laboratory of Prof. Dr. V. Castronovo, Metastasis 
Research Laboratory, University of Liège, Liège, Belgium. 
5.1. Purpose 
We aimed to determine the relative potencies of the individual hop-derived 
prenylflavonoids in inhibiting the growth of human cancer cells and to assess the sensitivities 
of the different cell lines to these compounds using the proliferation assays WST1 and SRB. 
Proliferation assays using human cancer cell lines are commonly recognized procedures to 
examine compounds of varying sources and diverse nature for their potential anticarcinogenic 
properties.  
More specifically, we aimed at getting detailed insights into the effects of the 
chalcones X and DMX, and the flavanones IX, 8PN, and 6PN on the proliferation of different 
types of prostate carcinoma cells (PC-3, DU145, LNCaP.FGC). Each of these cell lines 
represents a different stage of the disease and has a different hormonal status and response. 
Therefore, the hormonal status of the cell lines, more specifically the presence of the estrogen 
recptor alpha (ER) and beta (ER) mRNA transcripts, was evaluated using RT-PCR.  
As the inhibitory effects of the prenylflavonoids on cancer cells may be mediated 
through hormonal - in particular estrogenic - mechanisms, we additionally assessed the 
estrogenic activity by a growth-stimulatory experiment and an estrogen-inducible yeast 
screening assay (yeast estrogen screen; YES) and we submitted the breast cancer cell lines 
MCF-7/6 and MDA-MB-231 in parallel to all experiments to serve as an estrogen-responsive 
reference control model. 
Angiogenesis is an important process correlated to tumor growth and cancer 
development. Agents with potential antiangiogenic properties could be promising anticancer 
drugs. Therefore, we investigated hop-derived prenylflavonoids in vitro for their 
antiangiogenic activities on a human bone marrow endothelial cell line (HBME).  
66
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5.2. Introduction 
Cancer in various forms is one of the leading causes of death in the human population 
and it has been well established that cancer incidence rates differ strikingly. Hormone-related 
cancers of breast and prostate have been reported to vary by as much as 5- to 20-fold between 
populations and migrant studies indicate that differences are largely attributed to 
environmental factors rather than genetics.
12,13
  
Diet is probably one of the most important environmental factors influencing cancer 
risk and mortality, and intense research is being carried out to estimate the effects of the diet 
on human health. There are numerous natural products of plant origin (phytochemicals) that 
are of potential value as chemopreventive or therapeutic agents.  
Hop (Humulus lupulus L.), an essential raw material for beer brewing, is a rich source 
of phenolic and polyphenolic compounds. Phenolic acids, catechins, proanthocyanidins, and 
flavonols represent the major classes and their relative proportions vary widely depending on 
the hop variety and the growing conditions.
14
 Total concentrations of polyphenols in dried 
hop cones amount to few percentages. Xanthohumol (X), the most abundant prenylchalcone 
present in hops (concentrations up to 1%, w/w), is accompanied by its homolog, 
desmethylxanthohumol (DMX), albeit in lower concentrations.
1
 Both chalcones are readily 
isomerized (intramolecular Michael-type addition reaction) to the corresponding flavanones, 
X giving rise to isoxanthohumol (IX) and DMX being converted into a mixture of 8-
prenylnaringenin (8PN) and 6-prenylnaringenin (6PN). IX is the main prenylflavonoid in 
beer, since X is largely isomerized during particular stages in the course of brewing that occur 
at elevated temperatures.
15
  
X, DMX, and IX, as well as some minor hop-derived prenylflavonoids, have been 
investigated for their ability to inhibit the proliferation of various human cancer cell lines in 
vitro.
16
 A dose- and cell-type-dependent growth inhibition was observed for X and IX with 
IC50 values in the micromolar range for breast and ovarian cancer cells.  
Recently, cancer-chemopreventive properties of X were demonstrated by cell- and 
enzyme-based in vitro bioassays using markers relevant for the inhibition of carcinogenesis 
during initiation, promotion, and progression.
17
 Despite intensive studies on X and 8PN,
3
 no 
data are available about their effects on prostate cancer cells.  
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In this study, X, DMX, IX, 8PN, and 6PN have been investigated using PC-3, DU145 
and LNCaP.FGC prostate cancer cell lines. Because of the hormone-dependent nature of 
prostate cancer, we also aimed at correlating the observed antiproliferative effects with the 
estrogenic activity of the prenylflavonoids and with the effects observed with the reference 
breast cancer cell lines MCF7/6 and MDA-MB-231. For an adequate interpretation of the 
results, it was important to assess the hormonal status of all cell lines used. We investigated 
the presence of the ER and ER mRNA transcripts in the human prostate (PC-3, DU145, 
LNCaP.FGC) and breast cancer (MCF7/6, MDA-MB-231) cell lines by means of RT-PCR. 
Despite the well-known estrogenic activity of hops, mainly due to the presence of 
8PN,
3
 not all hop-derived prenylflavonoids investigated in this study have been comparatively 
examined for their estrogenic activity. Therefore, we additionally evaluated the estrogenic 
activities of these compounds using a growth-stimulatory experiment and an estrogen-
inducible yeast screening assay (yeast estrogen screen; YES).
18
 The correlation between 
antiproliferative effects, estrogenic activity, hormonal status, and hormone responsiveness of 
the different types of cell lines presents a matter of discussion. 
Angiogenesis or neovascularization concerns the formation of new capillaries, a 
process involving proliferation and migration of endothelial cells. The normal process is 
restricted to wound healing, but is enhanced in association with tumor growth. Folkman 
reported that new capillary blood vessels are necessary for a cancer to expand beyond 2 mm 
in size having been involved in 27 doublings prior to that phase.
19
 Angiogenesis, therefore, 
exercises an important role in cancer progression and is essentially seen as the growth towards 
foci of cancer of capillary sprouts of endothelial cells from pre-existing capillaries, a process 
that is probably promoted by cancerous production of growth factors. The fibroblast growth 
factor II (FGF-II) and the vascular endothelial growth factor (VEGF) (produced by 
neuroendocrine cells in the prostate) are potent angiogenic agents.
19
 
Pepper et al. demonstrated that 8PN inhibits angiogenesis induced by basic fibroblast 
growth factor (bFGF), vascular endothelial growth factor (VEGF) or by the two cytokines in 
combination, with an IC50 of between 3 and 10 M using bovine microvascular endothelial 
cells derived from the adrenal cortex (BME cells) and from the thoracic aorta (BAE cells).
20
 
CAM (chorioallantoic membrane) assay results showed reductions in both vessel lengths and 
vein diameters. 
68
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Because of the observations for 8PN, we embarked on a first screening of 
antiangiogenic effects of the hop-derived prenylflavonoids by measuring antiproliferative and 
cytotoxic activities using a human bone marrow endothelial cell line (HBME). 
5.3. Materials 
5.3.1. Hop-derived prenylflavonoids 
The hop-derived prenylflavonoids X, DMX, IX, 8PN, and 6PN were isolated and 
purified from spent hops as described in chapter 4. 
5.3.2. Chemicals 
17-Estradiol (E2; > 98% purity) and HEPES (N-(2-Hydroxyethyl)piperazine-N-(2-
ethanesulfonic acid) were purchased from Sigma-Aldrich (Bornem, Belgium). Solvents 
(HPLC grade) were from Biosolve (Valkenswaard, The Netherlands). Cell culture media, L-
glutamine, non-essential amino acids (NEAA), penicillin (10,000 IU/ml), streptomycin 
(10,000 g/ml), foetal bovine serum (FBS), and sodium pyruvate were obtained from 
Invitrogen (Merelbeke, Belgium).  
The RNeasy Mini Kit and the developed sets of primers were purchased from Qiagen 
(Leusden, The Netherlands). DNase-stock and DNase-buffer were from Fermentas (Sint-
Leon-Rot, Germany). Agarose powder was purchased from Biozym Resource TM Line 
Agaroses (Landgraaf, The Netherlands). All PCR-materials (MulVRTase, Taq DNA-
polymerase, dNTP mix, PCR-buffer, MgCl2, ribonuclease inhibitor, TBE buffer, ethidium 
bromide, loading buffer Orange G, low range DNA-ladder from 100 to 1000 bp) were 
obtained from Fermentas (Sint-Leon-Rot, Germany). The 50 bp DNA-ladder was purchased 
from Invitrogen (Merelbeke, Belgium). 
5.3.3. Product specifications 
The enzyme MulVRTase (Murine Leukemia Virus Reverse Transcriptase) is a RNA-
dependent DNA-polymerase. The Taq DNA-polymerase is a recombinant 94 kDa DNA-
polymerase originally isolated from Thermus aquaticus and expressed in Escherichia coli. 
The dNTP mixture is a mixture of dATP, dCTP, dGTP, and dTTP. The PCR-buffer contained 
LIES DELMULLE 155x240 - 148 blz - INDESIGN.indd   81 05-11-2007   15:55:02
  
70 
 
500 mM KCl and 100 mM Tris-HCl. The concentration of the MgCl2-solution was 25 mM. 
The ribonuclease inhibitor was purified from human placenta. 
5.3.4. Cells and culture media 
The mammary adenocarcinoma cell lines were obtained as follows: MCF-7/6 from Dr. 
H. Rochefort (Unité d’Endocrinologie Cellulaire et Moléculaire, Montpellier, France) and 
MDA-MB-231 from the American Type Culture Collection (ATCC, Rockville, Maryland, 
USA). The established human prostate cancer cell lines (LNCaP.FGC, PC-3, DU145) and a 
human bone marrow endothelial cell line (HBME) were obtained from the American Type 
Culture Collection (ATCC, Rockville, Maryland, USA). Cells were maintained in cell 
specific media at 37°C in a humidified atmosphere of 5% carbon dioxide. The cells were 
passed at 70% confluency (i.e., two or three times a week). To reduce potential variations of 
cell characteristics, cells were used within 10 passages for all experiments. 
The LNCaP.FGC, PC-3 and DU145 cells were cultured in Dulbecco’s Modified 
Eagle’s Medium DMEM/F12 (Ham) 1:1 (Dubecco’s Mem Nut Mix F–12 (HAM)) with L–
glutamine (365,00 mg/L) and 15 mM HEPES. The MCF-7/6 cells were cultured in Minimum 
Essential Medium (MEM) supplemented with 2 mM L-glutamine, 0.1 mM non-essential 
amino acids (NEAA). The MDA-MB-231 and HBME cells were cultured in high-glucose 
(4500 mg/L) Dulbecco’s Modified Eagle Medium (DMEM). HBME cells needed 
supplementation of 1 mM sodium pyruvate. All media were supplemented with 10% foetal 
bovine serum (FBS) and antibiotic agents (penicillin 10,000 IU/ml and streptomycin 10,000 
g/ml).  
Experimental media differed from the maintenance media. Experiments with MCF-
7/6, MDA-MB-231, DU145 and HBME cells were performed in high-glucose (4,500 mg/L) 
DMEM without phenol red; experiments with LNCaP.FGC and PC-3 cells were performed in 
phenol red-free RPMI 1640. Both media were supplemented with 10% steroid-free, dextran-
coated, charcoal-treated FBS and 1% antibiotic agents (penicillin 10,000 IU/mL and 
streptomycin 10,000 g/mL). In addition, 2 mM L-glutamine, 0.1 mM NEAA, and 1 mM 
sodium pyruvate were added to the DMEM medium and 1 mM sodium pyruvate and 10 mM 
HEPES were added to the RPMI 1640 medium.  
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5.3.5. Dextran-coated charcoal-stripped foetal bovine serum (DCC-FBS) 
Charcoal was coated with dextran by stirring equal volumes (50 ml) of a 10% charcoal 
suspension in water and a 1% solution of dextran in water for 30 min, followed by 
centrifugation at 4200 x g for 10 min at 4°C. The supernatant was removed and the pellet was 
resuspended with FBS (same volume as the supernatant) and rotated overnight at 4°C. After 
centrifugation at 4200 x g for 15 min, the mixture was rotated again with a freshly prepared 
pellet of dextran-coated charcoal for 6 h at 4°C. This mixture was centrifuged at 4200 x g for 
15 min at 4°C, the supernatant was centrifuged again at 550000 x g for 30 min, and the 
resulting solution was immediately sterilized by passage through a cellulose acetate filter with 
0.22 m pore size (Schleicher & Schuell, Dassel, Germany) and stored at -20°C. 
5.4. Methods 
5.4.1. Cell proliferation assays 
5.4.1.1. WST1 tetrazolium assay 
Mosmann developed a colorimetric method for the determination of proliferation and 
viability of cells.
21
 This method assays proliferation by analysing the number of viable cells 
and is based on the cleavage of tetrazolium salts added to the culture medium. In recent years, 
various tetrazolium salts have been described. All salts are cleaved to their formazan 
products, a process catalyzed by the succinate dehydrogenase complex II of the inner 
mitochondrial membrane, an enzyme belonging to the respiratory chain of the mitochondria 
and involved in oxidative phosphorylation. However, other mechanisms could be involved as 
well. According to Slater et al., this system is active only in viable cells.
22
 An increasing 
number of viable cells results in an increasing number of mitochondria and an increase in the 
overall activity of mitochondrial dehydrogenases. Thus, these assays reflect both the number 
of cells and the activity status of the mitochondria.  
MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is a yellow 
water-soluble tetrazolium salt. Metabolically active cells are able to convert the dye to its 
water-insoluble dark blue formazan poduct by reductive cleavage of the tetrazolium ring.
21,22
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The cellular reactions involved in this reduction are not completely understood. The 
involvement of active mitochondria, namely the mitochondrial succinate dehyrogenase 
system has been discussed.
21,23,24,25 
It has been shown that cells with inactivated mitochondria 
are also able to produce the same amount of formazan product compared to cells with 
operative mitochondria.
26
 Many non-mitochondrial dehydrogenases and flavin oxidases are 
able to reduce MTT.
27,28
 Little attention has been given to the ability of extracellular factors to 
reduce MTT to its formazan product.
29
 
 Compared to MTT, WST1 is a more recently used tetrazolium salt (4-[3-(4-
iodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-1,3-benzene disulphonate) which is cleaved to 
its formazan product (Figure 5.1). WST1 yields water-soluble cleavage products, thereby 
avoiding dissolution before colorimetric measurement.
21,23,30
 The maximum absorbance for 
the formed formazan product is found between 420 and 480 nm. 
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Figure 5.1. Reduction of WST1 to its formazan product. 
Bruggisser et al. showed that the MTT tetrazolium assay may lead to false positive 
results when investigating natural compounds with an intrinsic reductive potential.
31
 When 
testing the effects of kaempferol on breast cancer cell numbers (crystal violet staining) and 
viability (MTT tetrazolium assay), conflicting results were obtained. The cell number 
decreased but formazan product formation increased suggesting a direct interaction of 
kaempferol with MTT. This was highlighted in a cell-free system for kaempferol and 
resveratrol. Formazan product formation was immediately noticeable in the absence of cells. 
Additionally, antioxidants such as ascorbic acid, vitamin E, and N-acetylcysteine interfered 
with the MTT tetrazolium assay. When MCF7 and HS578 cells treated with kaempferol were 
washed before addition of MTT tetrazolium, direct reduction of the dye was significantly 
inhibited. These results indicate that the MTT tetrazolium assay may lead to false positive 
results when testing natural compounds with intrinsic reductive potential. Therefore, 
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application of tetrazolium assays in a screening system to detect the influence of natural 
products on the cell viability should be done with great care. 
The cells were seeded into flat-bottomed 96-well tissue culture plates (Falcon, 
Beckton Dickinson, France) at a density of 2,000 cells/well for MCF-7/6, 3,000 cells/well for 
DU145, 6,000 cells/well for PC-3 and HBME, 10,000 cells/well for MDA-MB-231, and 
17,000 cells/well for LNCaP.FGC, in 100 l experimental growth medium (see: 5.4.3.1 and 
5.6.3.1).  
After 24 h (or 48 h for LNCaP.FGC), the cells (20-30% confluent) were exposed for 
48 h to culture media containing a serial dilution of the prenylflavonoids prepared in ethanol 
from a 200 mM stock solution to a final ethanol concentration of 0.1 % in each well. All 
experiments included a solvent control. Initial concentrations ranged from 10 nM to 200 M, 
thereafter suitable concentrations were used to determine the IC50 values for each compound. 
All experiments were repeated three times with six replicas per condition. After two days, cell 
viability was measured using the 4-[3-(4-iodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-1,3-
benzene (WST1) assay (Roche Diagnostics, Vilvoorde, Belgium) according to the 
manufacturer’s instructions. At each well containing 100 L incubation medium, 10 L of the 
WST1 reagent was added and the plate was incubated for another 3 h (determined 
experimentally) at 37°C. After 3 h, absorbances were measured at 450 nm using a microplate-
spectrophotometer (Multiscan RC, Thermo Labsystems, Genesis Lite Software, Helsinki, 
Finland). 
 The average absorbance of the treated wells was compared with the average 
absorbance of the control wells to give a percentage of the control proliferation 
([value/control]x100). IC50 values were calculated using Sigmaplot 8.0 (SPSS, Chicago, 
Illinois, USA) in a four-parameter logistic regression model. The experimental absorbances of 
X and DMX were corrected for their inherent absorption at 450 nm. 
Possible interactions of the flavonoids with WST1 were investigated by incubation of 
WST1 with 100 M of the prenylflavonoids in a cell-free environment under identical 
incubation conditions as described for the cell proliferation assay. More specifically, wells of 
a flat-bottomed 96-well tissue culture plates (Falcon, Beckton Dickinson, France) were filled 
with 100 L experimental medium containing the test compounds at a concentration of 100 
M and 10 L of WST1. Plates were incubated at 37°C for 3 h and formation of formazan 
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salt was monitored at varying time intervals by measuring the absorbance at 450 nm using a 
microplate-spectrophotometer (Multiscan RC, Thermo Labsystems, Genesis Lite Software, 
Helsinki, Finland). 
To be able to correct for interferences of inherent absorptions, ‘correction’ wells were 
used in each experiment containing cells, experimental medium, and X or DMX at various 
concentrations in the absence of WST1. More specifically, wells of flat-bottomed 96-well 
tissue culture plates (Falcon, Beckton Dickinson, France) were filled with 100 L 
experimental medium containing the test compounds at the same concentrations used for the 
WST1 proliferation assay. After incubation for 48 h at 37°C, the absorbances were measured 
at 450 nm using a microplate-spectrophotometer (Multiscan RC, Thermo Labsystems, 
Genesis Lite Software, Helsinki, Finland). The experimental values for X and DMX obtained 
by the WST1 tetrazolium assay were appropriately corrected for inherent absorbances. 
5.4.1.2. SRB assay 
The Sulforhodamine B (SRB) assay provides a sensitive method for measuring drug 
cytotoxicity in culture. SRB (Figure 5.2) is a bright pink aminoxanthene dye with two 
sulfonic groups. Under mildly acidic conditions, SRB binds to basic amino acid residues in 
trichloroacetic acid (TCA)-fixed cells to provide a sensitive index of the cellular protein 
content that is linear over a cell density range of at least 2 orders of magnitude. The cellular 
protein content is directly correlated to the number of cells in culture thereby indicating a 
growth-stimulatory or growth-inhibitory effect of the compound tested in the assay.  
 
Figure 5.2. Structure of sulforhodamine B (SRB) 
The SRB method appears to offer several advantages over the MTT assay for very 
large-scale drug screening. The SRB assay is simpler, faster, and more sensitive, provides a 
better linearity with the cell number, permits the use of saturating dye concentrations, is less 
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sensitive to environmental fluctuations, is independent of intermediary metabolism, and 
provides a fixed endpoint that does not require a time-sensitive measurement of the initial 
reaction velocity.
32
   
The cells were seeded into flat-bottomed 96-well tissue culture plates (Falcon, 
Beckton Dickinson, France) at a density of 2,000 cells/well for MCF-7/6, 3,000 cells/well for 
DU145, 6,000 cells/well for PC-3 and HBME, 10,000 cells/well for MDA-MB-231, and 
17,000 cells/well for LNCaP.FGC, in 100 l experimental growth medium (see: 5.4.3.1 and 
5.6.3.1).  
After 24 h (or 48 h for LNCaP.FGC), the cells (20-30% confluent) were exposed for 
48 h to culture media containing a serial dilution of the prenylflavonoids prepared in ethanol 
from a 200 mM stock solution to a final ethanol concentration of 0.1 % in each well. All 
experiments included a solvent control. Initial concentrations ranged from 10 nM to 200 M, 
thereafter suitable concentrations were used to determine the IC50 values for each compound. 
All experiments were repeated three times with six replicas per condition. After two days, cell 
viability was measured using the SRB assay. At each well, containing 100 L incubation 
medium, 25 μL 50 % TCA was added to fix the cells and the plates were stored during 1 h at 
4°C. After 1 h, the plates were washed 5 times with water and dried on the air overnight. To 
the dry wells, 50 μL SRB dye solution (0,4 % in 1 % acetic acid) was added and plates were 
incubated for 30 min. After 30 min, the plates were gently washed with 1% acetic acid (± 500 
ml/plate depending on the intensity of color formation) until all the unbound color was 
washed off. Washed plates were dried on the air overnight. To dissolve the fixed dye, 200 L 
Trisbuffer (2-Amino-2-(hydroxymethyl)-1,3-propanediol, 10 mM, pH 10.5) was added to 
each well and the absorbances were measured at 540 nm and 620 nm using a microplate-
spectrophotometer (Multiscan RC, Thermo Labsystems, Genesis Lite Software, Helsinki, 
Finland). In each experiment, ‘blank’ wells (n=3) containing only incubation medium (no 
cells) were added to test for non-specific binding of SRB.  
 The average absorbance of the treated wells at 540 nm was corrected for the 
background absorbance at 620 nm and for the corrected ‘blank’ average absorption value. 
([Expvalue540nm-Expvalue620nm]-[Blankvalue540nm-Blankvalue620nm]). These corrected average 
absorption values were compared with the average absorbance of the control wells to give a 
percentage of the control proliferation ([value/control]x100). IC50 values were calculated 
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using Sigmaplot 8.0 (SPSS, Chicago, Illinois, USA) in a four-parameter logistic regression 
model. 
5.4.2. Estrogenicity assay 
Many compounds of plant origin with the ability to bind to estrogen receptors have 
been identified. There is evidence that the consumption of some of these phytoestrogens may 
have beneficial effects, but it also seems possible that others may act as endocrine disrupters. 
For this reason, there is a need to characterize the estrogenic potency of these substances. In 
vitro test systems offer the possibility to screen compounds very efficiently. Routinely in use 
and widespread for the determination of estrogenicity are: (I) receptor binding assays, test 
systems where the binding affinity of a compound to the estrogen receptor is determined; (II) 
cell-proliferation assays (E-screens), (III) reporter gene assays, and (IV) analysis of the 
regulation of endogenous estrogen-sensitive genes in cell lines. All these test systems rely on 
the molecular mechanisms that are involved in the ‘classical’ estrogen action.
33
 
5.4.2.1. Growth-stimulatory assay 
The cell proliferation assay or E-screen is a widely used assay to determine the 
estrogenic potency of natural and environmental compounds. In these in vitro test systems, 
the ability of a substance to stimulate the growth of estrogen-dependent cell lines is measured. 
Most commonly, estrogen-dependent human breast cancer cell lines like MCF-7 or T47-D are 
used. To measure the proliferation of a cell population, either the synthesis of new DNA or 
changes in the metabolic activity of viable cells is determined. This method suffers from the 
fact that a considerable number of substances give positive results in the E-screen without 
exerting estrogenic activity.  
Only the growth of hormone-dependent cancer cells is detected, although the growth 
of cancer cells can be stimulated in a similar way by cytokines, growth factors, mitogens, and 
nutrients. For this reason, the culture conditions of the cells may have a big influence on the 
results. In addition, it has been demonstrated that different MCF-7 stocks may possess wide 
variations with regard to their sensitivity to 17-estradiol.33 
The MCF-7/6 cells were seeded into flat-bottomed 96-well tissue culture plates 
(Falcon, Beckton Dickinson, Meylan, France) at a density of 5,000 cells/well for the 
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experiment using culture medium supplemented with 2% dextran-coated charcoal-stripped 
foetal bovine serum (DCC-FBS), and 10,000 cells/well for the experiment using culture 
medium which was not supplemented with DCC-FBS in 100 l experimental growth medium. 
The experimental medium was supplemented once with 2% and once without DCC-FBS (see: 
5.4.3.2 and 5.6.3.2). 
After 24 h, the cells (20-30% confluent) were exposed for 72 h to culture media 
containing a serial dilution of 8PN (1 fM to 200 μM) (for the experiment using culture 
medium supplemented with 2% DCC-FBS) or of 17-estradiol (1 fM to 1 μM) (for the 
experiment using culture medium which was not supplemented with DCC-FBS) from 200 
mM and 1 mM stock solutions, respectively, to a final ethanol concentration of 0.1 % in each 
well. All experiments included a solvent control and they were repeated three times with six 
replicas per condition. After three days, cell viability was measured using the WST1 assay 
and the SRB assay (see: 5.4.1.1 and 5.4.1.2, respectively).  
To investigate the effect of X on the growth stimulatory concentrations of 8PN (1, 10 
and 100 nM) (see: 5.6.2.1), MCF-7/6 cells were seeded into flat-bottomed 96-well tissue 
culture plates (Falcon, Beckton Dickinson, Meylan, France) at a density of 5,000 cells/well in 
100 l experimental growth medium. The experimental medium was supplemented with 2% 
DCC-FBS (see: 5.4.3.2 and 5.6.3.2). 
After 24 h, the cells (20-30% confluent) were exposed for 72 h to culture media 
containing a mixture of a specific concentration of 8PN (1, 10 or 100 nM) with any of the 
concentrations from a serial dilution of X (100 nM tot 200 nM) from a 200 mM stock 
solution. The final ethanol concentration in each well was 0.2 %. All experiments included a 
solvent control and they were repeated three times with six replicas per condition. After three 
days, cell viability was measured using the WST1 assay and the SRB assay (see: 5.4.1.1 and 
5.4.1.2, respectively). 
5.4.2.2. Recombinant yeast estrogen screen (YES) 
In a reporter gene assay, the ability of a substance to activate the transcription of an 
estrogen-sensitive promotor is analyzed. Eukaryotic cells, either mammalian or yeast cells, 
are transfected with an expression vector encoding the human estrogen receptor and a reporter 
gene vector. The reporter gene vector is composed of an estrogen-sensitive promoter, which is 
LIES DELMULLE 155x240 - 148 blz - INDESIGN.indd   89 05-11-2007   15:55:05
  
78 
 
linked to a reporter gene. The reporter gene encodes for a protein with metabolic activity 
which can be easily quantified. The principle mechanism of the reporter gene assay is shown 
in figure 5.3. 
 
Figure 5.3. The functional principle of a reporter gene assay. R, estrogen receptor; ERE, estrogen 
response element. 
The yeast estrogen screen (YES) is based on the stimulation of the transcriptional 
activity of the human estrogen receptors (ER and ER) in recombinant yeast cells. An 
estrogen-inducible expression system was developed in yeast (Saccharomyces cerevisiae) in 
the Genetics Department of Glaxo Wellcome, Beckenham, Kent, to determine the estrogenic 
activity of compounds that interact with the human ER (Figure 5.4). Because yeast does not 
contain nuclear receptors, the DNA sequence of the human ER was integrated into the 
chromosome to effect expression of the receptor. Besides binding to an estrogen-active 
compound, the ligand-receptor complex is able to bind to the estrogen response element 
(ERE), which is situated on the integrated expression plasmides that carry the Lac-Z-gene. 
The Lac-Z gene measures the activity of the receptor by encoding to the enzyme -
galactosidase. Once excreted in the medium, this enzyme converts the yellow substrate, 
chlorophenol-red--D-galactopyranoside (CPRG), present in the medium, to the red reaction 
product, chlorophenol-red, which is measured spectrophotometrically at 540 nm. This 
reaction is very selective for compounds that bind to the ERs and, therefore, the absorbance is 
directly in accordance with the activity of the receptor.   
78
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Figure 5.4. Estrogen-inducible expression system in yeast (adapted from Routledge et al., 1996). 
ER, estrogen receptor; ERE, estrogen response element. 
 
The yeast system possesses several advantages compared to mammalian cells. Yeasts 
are easy to culture and, in contrast to mammalian cells, it is possible to incubate yeasts with 
non-purified naturally occurring extracts from plants or from the environment. Since there are 
no naturally occurring ERs in this species, yeast systems are very useful to analyse molecular 
mechanisms of initiation of transcription. However, analysis of the ER-induced 
transactivation in yeasts is a highly artificial test system as are all transactivition systems 
including those that are performed in mammalian cells.
34
 The results show a wide variation 
depending on the reporter gene, promoter, and cell line used. Nevertheless, reporter gene 
assays are very useful and powerful tools to identify substances that are able to activate 
estrogen-dependent transcription and to determine their estrogenic potencies. Furthermore, 
they are suitable to characterize the agonistic and antagonistic properties of a substance. 
These assays give the possibility to analyse a high number of substances in a short period of 
time.
33
  
A yeast assay to assess estrogenic activity was kindly provided by Prof. Dr. J. Sumpter 
(Brunel University, UK). Details of the YES have been previously described.
18
 In brief, yeast 
cells, carrying the genetic code for the human estrogen receptor alpha together with 
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expression plasmids coding for secretory -galactosidase under control of estrogen response 
elements (ERE) were incubated in media containing serial dilutions of the test compounds 
prepared in ethanol from a 2 g/L stock solution and chlorophenol red--D-galactopyranoside 
(CPRG). The estrogenic activity was determined from enzymatic hydrolysis of CPRG into 
chlorophenol by monitoring the absorbance at 540 nm. Because of the low activity of some of 
the compounds, the test was incubated for a longer period (5-6 days) than the usual three 
days.  
Dose-response curves for -galactosidase activity were obtained using corrected 
absorbance (A) units (CAU): CAU = A(540nm) compound  – [ A(620nm) compound – mean 
A(620nm) blank]. Curve analysis was performed using Sigmaplot 8.0 (SPSS, Chicago, Illinois, 
USA) in a four-parameter logistic regression model. The relative potency (RP) of a test 
compound is the ratio of that concentration of 17-estradiol that caused the same CAU as the 
compound at its half-maximal response and the compound's EC50. The relative induction 
efficiency (RIE) is the ratio between the (max-min) absorbance achieved with the test 
compound and that of 17-estradiol (x 100). The detection limit is defined as the 
concentration of 17-estradiol corresponding to an effect equal to the mean of the corrected 
absorbances of the blank rows plus three times the standard deviation. A compound was 
considered to exhibit estrogenic activity when, in at least two separate experiments, it caused 
dose-dependent (two consecutive concentrations) color formation above the detection limit. 
5.4.3. Determination of the cell seeding density 
5.4.3.1. Cell proliferation assay 
The seeding density was determined experimentally by preparing ‘blank’ curves for 
each cell line separately. Therefore, a serial dilution of the suspended cells (MCF7/6, MDA-
MB-231, PC-3, DU145 and HBME: from 1,000 cells/well to 10,000 cells/well; LNCaP.FGC: 
from 20,000 cells/well to 200,000 cells/well) were seeded into flat-bottomed 96-well tissue 
culture plates (Falcon, Beckton Dickinson, Meylan, France) in 100 l experimental growth 
medium and incubated under the same conditions as for the proposed cell proliferation assays 
(same experimental media, same incubation times) (see: 5.4.1), but without the stimulation of 
compounds. After 24 h (or 48 h for LNCaP.FGC), the cells were exposed for 48 h to fresh 
culture medium in the same way as fresh medium was provided to the cells during stimulation 
with the test agents. All experiments were repeated three times with six replicas per condition. 
80
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After two days, cell viability or protein content was measured using the WST1 assay or SRB 
assay, respectively (see: 5.4.1.1 and 5.4.1.2, respectively). 
5.4.3.2. Growth-stimulatory assay 
The seeding density was determined experimentally by preparing ‘blank’ curves for 
the breast cancer cell line MCF7/6. Therefore, a serial diluation of the suspended cells (from 
500 cells/well to 10,000 cells/well) were seeded into flat-bottomed 96-well tissue culture 
plates (Falcon, Beckton Dickinson, Meylan, France) in 100 l experimental growth medium 
and incubated under the same conditions as for the proposed growth stimulatory assay (same 
experimental medium, same incubation times) (see: 5.4.2.1), but without the stimulation of 
compounds. The experimental medium was supplemented with varying concentrations of 
steroid-free, dextran-coated charcoal treated FBS (0 %, 2 % or 5 %). After 24 h, the cells were 
exposed for 72 h to fresh culture medium in the same way as fresh medium was provided to 
the cells during stimulation with the test agents. All experiments were repeated three times 
with six replicas per condition. After two days, the protein content was measured using the 
SRB assay (see: 5.4.1.2).  
5.4.4. Determination of the presence of ER and ER mRNA transcripts by RT-PCR 
The presence of the ER and ER mRNA transcripts in the human prostate (PC-3, 
DU145, LNCaP.FGC) and breast (MCF7/6, MDA-MB-231) cancer cell lines was determined 
by the reverse transcriptase polymerase chain reaction (RT-PCR). Therefore, mRNA was 
extracted from the cell cultures and, after conversion to its complementary doublestranded 
copy DNA (cDNA) by means of the reverse transcriptase enzyme MulVRTase, it was 
selectively amplified by the Taq DNA polymerase enzyme. The resulting copies of identical 
DNA-fragments were separated by gel electrophoresis, detected by staining with ethidium 
bromide, and identified by comparing with a standard.  
5.4.4.1. RNA extraction 
The specific mRNA-sequence that will serve as the template for RT-PCR (after 
conversion to cDNA) was isolated from the cell content by RNA extraction using the RNeasy 
procedure. Total RNA was extracted from the cell content of the cell cultures MCF7/6, MDA-
MB-231, PC-3, DU145, and LNCaP.FGC using the RNeasy Mini Kit (Qiagen, Leusden, The 
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Netherlands). An optimized number of detached cells (5,000,000 cells) were centrifuged (10 
min at 40 x g), the medium was gently removed, and the cell pellet was resuspended in 200 
L ice-cold PBS. After centrifugation (1 min at 2400 x g) and removal of PBS, 350 L lysis 
buffer (10 μL -mercaptoethanol in 1 mL RLT–buffer; ex-tempore preparation) was added to 
the loosened cell pellet and mixed well (incomplete loosening of the cell pellet may lead to 
inefficient lysis and reduced yields). The lysate was then homogenized by passing it 10-times 
through a 20-gauge needle (0,9 mm diameter) fitted to a RNase-free syringe. Then, 350 μL 
ethanol (70 %) was added to the homogenized lysate and mixed well by pipetting. 
A maximum of 700 L of the sample was applied to an RNeasy mini column and 
centrifuged for 15 s at 8000 x g. The column was washed a first time by application of 700 L 
wash buffer RW1 and centrifugation for 15 s at 8000 x g, and a second time by application of 
500 L wash buffer RPE and centrifugation for 15 s at 8000 x g. Another 500 L wash buffer 
RPE was applied to the column and the column was dried by centrifugation for 2 min at 8000 
x g and for 1 min at 11200 x g. 
To elute the RNA from the column, 100 L of RNase-free water was pipetted directly 
onto the column and centrifuged for 1 min at 8000 x g. This first eluate was applied again 
onto the column followed by centrifugation for 1 min at 8000 x g thereby affording a second 
eluate, which was again applied onto the column and centrifuged for 1 min at 8000 x g.  
If DNase needed to be used during the extraction protocol, the column was washed a 
first time by application of 350 L wash buffer RW1 and centrifugated for 15 s at 8000 x g 
after application of a maximum of 700 L of the sample to a RNeasy mini column and 
centrifugation for 15 s at 8000 x g. The dry column was completely covered with 80 L of 
DNase solution (prepared by gently mixing 27.3 U DNase-stock with 52.7 L DNase-buffer) 
and incubated for 15 min at room temperature. After incubation, the column was washed and 
the RNA was eluted from the column as described above.  
The RNA concentration in the eluate was determined by measurement of the 
absorbances at 260 nm and 280 nm using a Beckman DU-600 UV-Vis Diode Array 
Spectrometer (DNA oligo quant-method) (Hainburg, Germany).  
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5.4.4.2. Development of selective oligonucleotide  primers 
The oligonucleotide primers provide a very selective targetted starting point for the 
reverse transcriptase and DNA-polymerase enzymes. The sequence of these primers can be 
found in the literature or can be developed using appropriate software such as the program 
“Primer 3”
35
 or “clonewin” (a kind gift from Dr. Wim Vanden Berghe, Ghent University, 
Faculty of Sciences, Department of Molecular Biology, Laboratory for Eucaryotic Gene 
Expression and Signal Transduction). They are developed starting from the cDNA sequence 
from the human ER and ER (see: the National Centre for Biotechnological Information 
site
36
 or the ‘Ensembl’ site
37
). The sequences of human ER and ER found at both sites have 
to be compared and only the overlapping part is used to develop the primers in order to bind 
to this part of the cDNA sequence. The optimum length of the primers is about 20 bp and the 
optimum length of the amplicon (part in-between the primers that will have to be synthesized 
by the enzyme) is 200 to 400 bp. 
The primers should be developed such that they should be selective and provide a 
difference between the mRNA template and the (possibly present) genomic DNA. Selective 
primers are primers that have no affinity for other genes than the target genes. Thus, only the 
desired part of the target mRNA is reversed to cDNA and further amplified in the PCR 
reaction. The selectivity of the primers can be tested on the National Centre for 
Biotechnological Information (NCBI) site using the Basic Logical Alignment Search Tool 
(BLAST).  
The developed primers should also be able to make a difference between mRNA and 
genomic DNA. Therefore, it is necessary that either both primers of a set of primers bind at 
the level of two different exons or either one or both primers from a set of primers bind at the 
overlap of two neighbouring exons. In the first case, the amplicon produced from the genomic 
DNA is much larger (or is too large to be produced) than the amplicon derived from mRNA, 
because of the presence of one or more introns between the exons that result in two different 
signals after separation by gel electrophoresis and staining with ethidium bromide. In the 
second case, there is no amplification of the genomic DNA, since the primers cannot bind at 
the overlap of two exons because of one or more intron(s) that lie in-between.  
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5.4.4.3. The RT-PCR reaction 
The RT-PCR reaction was performed in 96 multi-eppendorf plates (Fermentas, Sint-
Leon-Rot, Germany). Each eppendorf was filled with 20 L RT-PCR reaction mixture 
resulting from addition of the non-enzyme and non-primer materials (PCR buffer, MgCl2, 
dNTP, RNase-free water) to a recipient in a certain volume while mixing well by vortexing. 
This mixture was kept on ice during manipulation. Next, the enzymes (RNase–inhibitor, 
MulVRTase, Taq DNA-polymerase), the RNA extract of a cell culture, and the primers 
(‘forward’ and ‘reverse’ primers) were added in a certain volume and mixed well by 
vortexing. The amount of RNA necessary in one reaction mixture of 20 L was 
experimentally determined to be 0.1 g. The necessary volume of RNA extract to be added to 
the reaction mixture giving a concentration of 0.1 g/20 L RNA was determined by 
measurement of the RNA concentration for each extract separately.  
An example of a reaction mixture is given in figure 5.5. The amounts of each reagent 
can vary depending on the concentration of the stock solution. The total volume was kept at 
20 L by adapting the amount of RNase-free water. 
To control for the possible presence of genomic DNA, MulVRTase was removed from 
the reaction mix. To control for a positive RT-PCR reaction, the transcription of -actin was 
examined in each reaction.  
Product Stock Final Dilution Volume (L)
PCR-buffer 10 X 1 X 10 2
MgCl2 25 mM 2.5 mM 10 2
dNTP 10 mM 300 M 33.33 0.6
RNase inhibitor 20 U/L 0.04 U/L 500 0.04
FP 25 M 200 nM 125 0.16
RP 25 M 200 nM 125 0.16
MulVRTase 20 U/L 0.06 U/L 416.67 0.05
Taq DNA-polymerase 5 U/L 0.05 U/L 100 0.2
RNase-free water  -  -  - X
mRNA template (extract)  -  -  - Y (= 0.1 g RNA)
Final Volume 20
 
Figure 5.5: Example of a RT-PCR reaction mixture. MulVRTase: Murine Leukemia Virus Reverse 
Transcriptase, FP: Forward Primer, RP: Reversed Primer.  
Product specifications, see: 5.3.3. 
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A/ Thermogradient method 
 For every new set of primers, a thermogradient method was performed to determine 
the optimum annealing temperature at which a certain selective primer binds to its 
complement on mRNA or cDNA with the least possible chance of aspecific binding. Practice 
learned that the proposed annealing temperatures were not always the most optimum ones.   
The following multistep optimized RT-PCR reaction program was used for the 
thermogradient method: 
1. 30 min at 48˚C, the optimum temperature for the activity of the reverse 
transcriptase enzyme MulVRTase, which reversely transcribes mRNA into its 
cDNA complement.  
2. 10 min at 91˚C, the temperature at which the denaturation process occurs and 
the doublestranded cDNA is separated. At this temperature, the Taq DNA-
polymerase is activated. 
3. 45 s at 91˚C, the denaturation step starting from the second cycle 
4. 45˚C to 65˚C in 45 s, the thermogradient to determine the optimum annealing 
temperature for a specific set of primers (column 1: 45.0°C, column 2: 45.5°C, 
column 3: 46.5°C, column 4: 48.2°C, column 5: 50.5°C, column 6: 53.4°C, 
column 7: 56.7°C, column 8: 59.6°C, column 9: 61.8°C, column 10: 63.4°C, 
column 11: 64.6°C, column 12: 65.0°C). 
5. 1 min at 72˚C, the extension step at which the nucleotides (dNTP mixture) are 
stringed together by Taq DNA-polymerase to build the complementary DNA 
strand on the template. 
6. End of cycle 1 (step 3 to step 5) and starting again with step 3 for the second 
cyle. This is repeated 39 times to a grand total of 40 cycles. 
7. 10 min at 75˚C, the final extension step at which loosely bonded DNA 
segments that are not fully complementary are broken. 
8. 10˚C for indefinite time, which is the maximum temperature at which the 
reaction mixture remains stable overnight.  
To determine the annealing temperature for one set of primers, the reaction mixture 
was tested at 12 different temperatures. Therefore, 12 x 20 L (total of 240 L) of reaction 
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mixture was necessary for one set of primers and one RNA extract of a certain type of cell 
culture.  
B/ Fixed-temperature method 
Once the optimum annealing temperature for a specific set of primers has been 
determined using the thermogradient method, this set of primers can be applied for further 
RT-PCR reactions using a simplified program. The steps are identical to the thermogradient 
program, except for step 4, which was set at the determined optimum annealing temperature 
for that particular primer set. The duration of this step was 45 s. Using this program, only one 
RT-PCR reaction mixture of 20 L was necessary for one set of primers and one RNA extract 
of a certain type of cell culture.  
5.4.4.4. Gel electrophoresis 
An agarose gel of 2% was used to separate the amplicons present in the reaction 
mixture resulting from the RT-PCR reaction. Therefore, 2.8 g agarose powder was dissolved 
in 140 mL TBE-buffer 1x (tris boric acid EDTA) by stepwise heating in a microwave oven 
and gently stirring in-between the heating steps until a clear liquid solution was formed at the 
boiling temperature. Next, the solution was cooled to about 60˚C and poured into a casting 
tray containing a sample comb, and allowed to solidify at room temperature or in a 
refrigerator and form a gel. After solidifying, the comb was carefully removed.  
The gel in its plastic tray was inserted horizontally into the electrophoresis chamber 
and covered with a minimum of TBE-buffer (0.5 x). This buffer needed to be replaced after 
about 7 electrophoresis runs. The samples to be loaded on the gels were prepared by adding 4 
L loading buffer Orange G to each eppendorf of the 96-multi-eppendorf plate in which the 
RT-PCR reaction occurred. The samples were then pipetted into the sample wells of the 
agarose gel. The outer sample wells of the gel were filled with 7.5 L of a low range DNA-
ladder from 100 to 1000 bp (Fermentas, Sint-Leon–Rot, Germany) or with 1 L of a 50 bp 
DNA-ladder in 5 L Orange G (Invitrogen, Belgium) (Figure 5.6). Gel electrophoresis was 
performed at 200 V for about 60 min. The gel was removed at the point where the loading 
buffer was at 2 cm from the edge of the gel at the kathode site.  
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Figure 5.6: Illustration of the DNA-ladders separated by gel electrophoresis and visualized after ethidium 
bromide staining.  
Ladder A: low range DNA–ladder. Ladder B: 50 bp DNA-ladder (signal every 50 bp). 
After gel electrophoresis, the gel was removed and soaked in a solution of 50 L 
ethidium bromide (10 mg/mL) in TBE-buffer (1 L) during 20 min. To visualize the DNA 
fragments, the gel was placed on an ultraviolet transilluminator and pictures were taken using 
a DC forte DC120 digital camera (Eastman Kodak, New York, USA). The intensity of 
fluorescence is proportional to the amount of DNA from the sample. This method does not 
allow quantification and it was, therefore, only used for a qualitative study of the presence of 
a certain mRNA fragment in the cellular extracts of different cell lines.  
5.5. Statistical analysis 
All additional statistics were performed using SPSS 10.0 (SPSS, Chicago, Illinois, 
USA). 
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5.6. Results 
5.6.1. Cell proliferation assays 
The cell proliferation reagent WST-1 (4-[3-(4-iodophenyl)-2-(4-nitrophenyl)-2H-5-
tetrazolio]-1,3-benzene) and the SRB (sulforhodamine B) cytotoxicity test were applied for 
the quantification of cell proliferation rates and cytotoxicity. More specifically, these tests 
were used to determine the relative potencies of the individual compounds in inhibiting the 
growth of cancer cells and in assaying the sensitivities of the different cell lines to these 
compounds.  
The WST1 colorimetric assay is based on the cellular reduction of WST1 to a 
formazan product by the mitochondrial dehydrogenases of viable cells and, thus, is used for 
the quantitation of cell viability and cell proliferation. This assay is very sensitive and gives 
results that directly correlate to the number of metabolically active cells in culture. The SRB 
assay uses an anionogenic aminoxanthene dye with two sulfonic groups, which binds to the 
proteins of fixed cells in culture.  The results of this assay correlate directly to the number of 
cells in culture thereby providing an indication of the growth-stimulatory or growth-inhibitory 
effect of the compounds tested. 
The antiproliferative effects of the chalcones, X and DMX, and the flavanones, IX, 
8PN, and 6PN, were assessed using the human prostate cancer cell lines LNCaP.FGC, PC-3, 
and DU145. The human breast cancer cell lines MCF-7/6 and MDA-MB-231 served as a 
estrogen-responsive reference control model. All compounds caused, for all cell lines, a dose-
dependent growth inhibition after two days of exposure. No significant differences between 
the results obtained with the WST1 assay and those obtained with the SRB assay were noted 
initially, hence, the WST1 assay was pursued further. The only small difference observed 
between both assays was the value of the absorbances at the highest concentrations of test 
agents. At these concentrations, the WST1 assay measures no activity, while the SRB assay 
measures a small absorbance due to the remaining cell debris from dead cells on the bottom of 
the wells in the 96-well tissue culture plates. The results of the WST1 assay are illustrated in 
figure 5.7 and figure 5.8.  
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Figure 5.7: Dose-response relationships for hop-derived prenylflavonoids on the growth of human breast 
cancer cells (A: MCF-7/6, B: MDA-MB-231). Data are means ± SD (n=3). Materials and Methods, see: 5.3 
and 5.4.1, respectively.  
X: xanthohumol, DMX: desmethylxanthohumol, IX: Isoxanthohumol, 8PN: 8-prenylnaringenin, 6PN: 6-
prenylnaringenin. 
 
Chalcone X proved to be the most potent compound in inhibiting the growth of all cell 
lines (except for LNCaP.FGC), DU145 being the most sensitive (IC50 of 12.3 ± 1.1 M), 
followed by MCF-7/6, PC-3, and MDA-MB-231 (IC50 of 12.4 ± 1.1 M, 13.2 ± 1.1 M, and 
36.3 ± 1.1 M, respectively). Flavanone 6PN appeared as the second most active compound 
(except for LNCaP.FGC) with a marked growth-inhibitory effect on PC-3 (IC50 of 18.4 ± 1.2 
M), followed by DU145, MCF-7/6, and MDA-MB-231 (IC50 of 29.1 ± 1.1 M, 32.6 ± 1.0 
M, and 65.1 ± 1.0 M, respectively). Flavanone 8PN showed its most pronounced 
antiproliferative effects on PC-3, LNCaP.FGC, and DU145 (IC50 of 33.5 ± 1.0, 42.8 ± 1.2, 
and IC50 of 43.1 ± 1.2 M, respectively), while IX was more effective on the breast cancer 
cells MCF-7/6 (IC50 of 32.9 ± 1.1), but showing activities on prostate cancer cells comparable 
to those of 8PN (IC50 of 45.2 ± 1.1 M on PC-3 and 47.4 ± 1.1 M on DU145). However, IX 
proved to be the most potent inhibitor of LNCaP.FGC with an IC50 of 34.4 ± 1.0 M. DMX 
was the least active compound in all cell lines (data are missing for LNCaP.FGC). 
The calculated IC50 values (the dose resulting in a 50% inhibition of cell growth) are 
presented in figure 5.9. 
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Figure 5.8. Dose-response relationships for hop-derived prenylflavonoids on the growth of human prostate 
cancer cells (C: PC-3, D: DU145, E: LNCaP.FGC) after 2 days of exposure. Data are means ± SD (n=3). 
Materials and Methods, see: 5.3 and 5.4.1, respectively.  
X: xanthohumol, DMX: desmethylxanthohumol, IX: Isoxanthohumol, 8PN: 8-prenylnaringenin, 6PN: 6-
prenylnaringenin. 
On LNCaP.FGC prostate cancer cells, X and 6PN showed a biphasic dose-response 
behavior stimulating growth at low concentrations and inhibiting growth at higher 
concentrations. IX and 8PN, which are the most potent inhibitors for the growth of this cell 
line, inhibited growth at the same concentrations for which stimulation by X and 6PN was 
noted. DMX shows a similar trend as observed for X and 6PN. The highest concentrations 
tested for this compound on LNCaP.FGC are growth-stimulatory compared to the lower 
concentrations. The calculated EC50 values for growth stimulation of X and 6PN are 12.8 ± 
1.1 and 29.6 ± 1.3, respectively. These compounds exhibit a very strong growth stimulation of 
about 300% compared to the control. 
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Figure 5.9: IC50 values of hop-derived prenylflavonoids in the WST1 proliferation assay for human breast 
cancer cells (MCF7/6, MDA-MB-231) and human prostate cancer cells (PC-3, DU145, LNCaP.FGC). Data 
are means ± SD (n=3). Materials and Methods, see: 5.3 and 5.4.1, respectively. 
Biphasic dose-response behavior was noted for all compounds on MCF-7/6 breast 
cancer cells, whereby growth was stimulated at lower concentrations and inhibited at higher 
concentrations (Figure 5.7, A). The most potent growth stimulation was observed for X with 
a maximum effect at 5 M. The other compounds were less active compared to X; 6PN gave 
the highest maximum growth stimulation at 20 M, followed by DMX (30 M), IX (15 M), 
and 8PN (10 M).   
To determine the antiangiogenic potencies of the hop-derived prenylflavonoids, the 
antiproliferative effects of the chalcones X and DMX and the flavanones IX, 8PN, and 6PN  
were assessed using a human bone marrow endothelial (HBME) cell line. X proved to be a 
very potent inhibitor of the growth of HBME endothelial cells with an IC50 value of 3.2 ± 1.2 
M. IX and 6PN were the second most active growth inhibitors with IC50 values of 29.4 ± 1.1 
M and 39.8 ± 1.0 M, respectively. 8PN and DMX were the least active growth inhibitors 
with IC50 values of 77.1 ± 1.0 M and 72.7 ± 1.0 M, respectively. Furthermore, compared to 
the breast and prostate cancer cell lines, where X also proved to be the strongest growth 
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inhibitor (except for LNCaP.FGC prostate cancer cells), the growth-inhibitory activity on 
endothelial cancer cell lines was much stronger. The results of the WST1 assay are illustrated 
in figure 5.10. 
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Figure 5.10: Dose-response relationships for hop-derived prenylflavonoids on the growth of human 
endothelial cancer cells (HBME). Data are means ± SD (n=3). Materials and Methods, see: 5.3 and 5.4.1, 
respectively.  
X: xanthohumol, DMX: desmethylxanthohumol, IX: Isoxanthohumol, 8PN: 8-prenylnaringenin, 6PN: 6-
prenylnaringenin. 
The MTT assay as first described by Mosmann
21
 was critically analyzed in a screening 
system.
31
 Compounds with an intrinsic reductive potential reduce the MTT irrespective of any 
cellular mechanism and, therefore, may give false-positive results, unless the potentially 
interfering agents are removed by adequate washing. Bruggisser et al. concluded that the 
application of tetrazolium assays in a screening system to detect the influence on the cell 
viability demands precautions.
31
 It is recommended to perform a pre-screening in cell-free 
systems to examine potential reductive activity before any cell culture experiment should be 
performed. When reduction occurs, washing procedures have to be implemented and results 
have to be interpreted carefully to avoid wrong interpretations. None of the hop-derived 
prenylflavonoids under study showed chemical interactions with the WST1 reagent. 
Therefore, possible false-positive results of this kind could be excluded.  
The chalcones X and DMX are yellowish compounds, which absorb slightly at 450 
nm. This inherent absorption may interfere with the absorption at 450 nm of the formazan 
product formed after incubation with the WST1 reagent. We found that X and DMX 
interfered with the absorbance of WST1 at the monitoring wavelength, hence, experimental 
values were corrected for the measured absorptions of these compounds at 450 nm. 
92
LIES DELMULLE 155x240 - 148 blz - INDESIGN.indd   104 05-11-2007   15:55:12
  
93 
 
5.6.2. Estrogenic activity assay 
5.6.2.1. Growth-stimulatory assay 
The effect of the hop-derived prenylflavonoids on the MCF7/6 breast cancer cells was 
determined to assess the estrogenic potencies of the compounds. As the MCF7/6 breast cancer 
cell line served as an estrogen-responsive reference control model in the proliferation assays 
(see 5.4.1 and 5.6.1), first results of the influence of the compounds on the growth of this cell 
line were already obtained. However, the growth-stimulatory effects observed required further 
investigations, since a strong growth-stimulatory effect for 8PN on this estrogen-responsive 
breast cancer cell line was expected, as 8PN has been characterized as a highly potent 
phytoestrogen.
3
 Therefore, the MCF-7/6 breast cancer cells were incubated with 17-estradiol 
(1 fM to 1 M) or 8PN (1 fM to 1 M) at varying concentrations of steroid-free, dextran-
coated, charcoal-treated FBS and varying incubation times, in order to establish the most 
favorable conditions to reproduce a growth stimulatory dose-response curve.  
A pronounced growth-stimulatory effect for 8PN was observed after three days of 
incubation with a concentration of 2% steroid-free, dextran-coated, charcoal-treated FBS. 
This effect was noted for 17-estradiol, when the experimental media did not contain steroid-
free, dextran-coated, charcoal-treated FBS. Figure 5.11 illustrates the growth-stimulatory 
effects of both compounds on MCF7/6 cells carried out under the specific conditions as 
determined for each compound separately.  
The calculated EC50 values for growth stimulation of 17-estradiol and 8PN were 9.3 
± 0.5 pM and 4.2 ± 1.3 nM, respectively, indicating that 8PN is about 500 times weaker in 
stimulating growth as compared to 17-estradiol. However, the comparison is not reliable, 
because of the different conditions used in both assays.  We were able to confirm the biphasic 
dose-response curve for 8PN, which had been found indeed for all compounds in the cell 
proliferation assays (see: 5.6.1). At a concentration of 100 nM, maximum growth stimulation 
was achieved and the growth-stimulatory effect diminished at higher concentrations to finally 
result in a growth-inhibitory effect from a concentration of 10 M. 
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Figure 5.11: Growth-stimulatory effect of 17-estradiol (E2) and 8-prenylnaringenin (8-PN) on MCF-7/6 
breast cancer cells. Materials and Methods, see: 5.3 and 5.4.2.1, respectively. 
A further study aimed at observing potential inhibitory effects of X known for its 
potent cancer chemopreventive activities,
17 
on the growth-stimulatory effect of 8PN on 
MCF7/6 breast cancer cells. MCF7/6 cells were incubated with three concentrations of 8PN 
(1, 10 or 100 nM) that were effective in growth stimulation (Figure 5.11) and X was added in 
varying concentrations ranging from 100 nM to 200 M. The results are illustrated in figure 
5.12. 
It was concluded that X inhibited the growth-stimulatory effect of 8PN at 
concentrations between 1 M and 5 M. Concentrations above 5 M exhibited a growth-
inhibitory effect as compared to the control (100%). Moreover, at a concentration of 0.1 M 
X has an additional growth-stimulatory effect leading to an increased growth stimulation as 
was observed for 8PN. These findings are in accordance with the biphasic dose-response 
curves observed for X on MCF7/6 breast cancer cells in the cell proliferation assays (see: 
5.6.1). 
94
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Figuur 5.12: Effect of xanthohumol (X) on the growth stimulation of  8-prenylnaringenin (8PN) on MCF-
7/6 breast cancer cells. Materials and Methods, see: 5.3 and 5.4.2.1, respectively. 
5.6.2.2. Recombinant yeast estrogen screen (YES) 
The YES was used to investigate the binding capacity of the compounds to the 
estrogen receptor alpha (ER) and their potency to subsequently stimulate a signal-
transduction cascade resulting in secretion of -galactosidase. 17-Estradiol served as a 
positive control. X and IX exhibited very weak activities, hence, the incubation times in the 
YES assay needed to be prolonged to five to six days in order to detect a dose response above 
the detection limit. Under these conditions, EC50 values can not be used for direct comparison 
of the estrogenic activities and, thus, relative potencies were determined. The results are 
presented in table 5.1.  
The EC50 value of 214 pM for 17-estradiol after three days of incubation 
demonstrates the high sensitivity of the assay. From the relative potencies observed, it can be 
concluded that the estrogenic activity of 8PN determined by the YES was approximately 300-
fold lower than that of 17-estradiol, but 10-, 50-, and 10,000-fold higher than the activities of 
DMX, 6PN, and X/IX, respectively. Furthermore, the relative induction efficiencies indicate 
that, when compared to the full agonist 17-estradiol, 8PN, 6PN, and DMX produce a 
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maximum response and, thus, may behave as full agonists on ER. Conversely, X and IX 
could not give rise to a maximum response, which may suggest that they behave as partial 
agonists on ER. 
Table 5.1: EC50 values, relative potencies (RP) and relative induction efficiencies (RIE) 
of hop-derived prenylflavonoids in the recombinant yeast estrogen screen (n>3 
independent experiments). Materials and Methods, see: 5.3 and 5.4.2.2, respectively. 
Compound EC50
a
 (95% CI) (mol/L) RP
a
 RIE
b
 
17-estradiol* 2.14E-10 (1.49E-10-3.08E-10) 1 100 
8PN* 6.3E-08 (1.4E-08-2.8E-07) 3.1E-03 (9.2E-04-1.0E-02) 111.6 (7.8) 
6PN* 3.6E-06 (1.3E-06-1.0E-05) 6.6E-05 (3.3E-05-1.3E-04) 106.6 (15.5) 
DMX* 6.9E-07 (2.5E-07-1.9E-06) 3.0E-04 (2.1E-04-4.4E-04) 108.7 (14.3) 
X** 7.6E-05 (2.3E-05-2.5E-04) 3.5E-07 (6.9E-08-1.7E-06) 64.8 (36.7) 
IX** 7.2E-05 (3.0E-05-1.7E-04) 3.7E-07 (1.1E-07-1.2E-06) 63.3 (18.6) 
Abbreviations: CI: confidence interval; 8PN: 8-prenylnaringenin; 6PN: 6-prenylnaringenin; DMX: 
desmethylxanthohumol; X: xanthohumol; IX: isoxanthohumol; 
a
geometric mean; 
b
arithmetic mean (standard 
deviation); * 3 days of incubation; ** 5-6 days of incubation. 
  
5.6.3. Determination of the cell seeding density 
5.6.3.1. Cell proliferation assay 
Cells had to be seeded into flat-bottomed 96-well tissue culture plates at a certain 
density. Not all cell lines grew at the same rate and significant differences in cell densities 
could have been expected after 48 h of incubation time. Since the endpoints of the WST1 and 
SRB assays are determined by color formation (measured at the appropriate wavelength), it 
was important to confirm that measurements were within the lineair absorbance ranges for all 
cell lines. Therefore, the seeding density for each cell line was determined from ‘blank’ 
curves by seeding the cells at various concentrations (MCF7/6, MDA-MB-231, PC-3, DU145, 
and HBME: 1,000 cells/well to 10,000 cells/well; LNCaP.FGC: 20,000 cells/well to 200,000 
cells/well) and incubating them during the same time as proposed for the in vitro assays. Cell 
viability or protein content was measured using the WST1 assay or the SRB assay, 
respectively (see: 5.4.1.1 and 5.4.1.2, respectively). 
For each cell line, the innoculum (seeding concentration) that produced a color 
intensity within the linear range with an appropriate cell density for stimulation or inhibition 
of proliferation was established. 
96
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Figure 5.13 illustrates the ‘blank’ curves for PC-3 for which color formation was 
measured using the WST1 assay (A) and the SRB assay (B).  
The results show that the absorbances measured with the WST1 assay are higer than 
those for the same cell concentrations in the SRB assay. It was preferred to use an innoculum 
of 6,000 cells/well for the prostate cancer cell line PC-3 with the WST1 and the SRB assays. 
Similarly, the innocula for the other cell lines were determined to be 2,000 cells/well for 
MCF-7/6, 3,000 cells/well for DU145, 10,000 cells/well for MDA-MB-231, 17,000 cells/well 
for LNCaP.FGC, and 6,000 cells/well for HBME. 
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Figure 5.13: ‘Blank’ curves for PC-3 prostate cancer cells (A: WST1 assay, B: SRB assay). 
Materials and Methods, see: 5.3 and 5.4.3.1, respectively. 
5.6.3.2. Growth-stimulatory assay 
For the growth-stimulatory assay, ‘blank’ curves for MCF7/6 breast cancer cells were 
obtained to determine the innoculum and the concentration of steroid-free, dextran-coated 
charcoal-treated FBS (DCC-FBS) needed to observe proliferation stimulation. Therefore, 
varying concentrations of MCF7/6 breast cancer cells (from 500 cells/well to 10,000 
cells/well) were incubated with experimental medium containing varying concentrations of 
DCC-FBS (0 %; 2 % or 5 %). The protein content was measured after an incubation time of 
72 h using the SRB assay (see: 5.4.1.2). Figure 5.14 illustrates the ‘blank’ curve for the 
MCF-7/6 breast cancer cell line. 
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Figure 5.14: Blank curve for MCF7/6 breast cancer cells using the SRB assay. DCC-FBS: Dextran-coated 
charcoal-stripped foetal bovine serum. Materials and Methods, see: 5.3 and 5.4.3.2, respectively. 
The dose-response curve obtained using experimental medium without DCC-FBS is 
linear over a broad range, but absorbances are rather low. The absorbances obtained from the 
experiments using experimental medium supplemented with 2% and 5% DCC-FBS cover the 
linear range, but the values are higher leading to a more sensitive reading. From these results, 
experimental medium supplemented with 0% and 2% DCC-FBS were chosen for further 
experiments, and the preferred innocula were determined to be 5,000 cells/well and 10,000 
cells/well, respectively, giving possibilities for  proliferation that can be measured within the 
linear area of absorption after the proposed incubation time of 72 h (see: 5.4.3.2).  
5.6.4. Determination of the presence of ER and ER mRNA transcripts by RT-PCR 
5.6.4.1. RNA extraction 
Total RNA extracts were prepared from the breast cancer cell lines MCF7/6, and 
MDA-MB-231, and from the prostate cancer cell lines PC-3, DU145 and LNCaP.FGC, using 
the RNeasy Mini Kit. Results showed that it was necessary to add the DNase-solution to the 
RNeasy mini column before washing and eluting the RNA. The RNA concentrations in the 
extracts were measured with the Beckman DU-600 UV-Vis Diode Array Spectrometer. Table 
5.2 shows the results of the RNA concentration measurements. 
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Table 5.2: Results of the RNA concentration measurements. Materials and Methods, 
see: 5.3 and 5.4.4.1, respectively. 
  Absorbance Absorbance 260/280 Dilution factor RNA concentration 
  (260 nm) (280 nm)     (μg/mL) 
Extract           
PC-3 0,7742 0,3537 2,19 10 309,66 
DU 145 0,9398 0,4362 2,15 10 375,91 
LNCaP 1,0299 0,4978 2,07 10 411,95 
MCF7/6 0,7354 0,3346 2,20 10 294,17 
MDA-MB-231 0,7081 0,3528 2,01 10 283,26 
5.6.4.2. Development of selective oligonucleotide primers 
For each estrogen receptor, two different sets of primers were developed using the 
programs ‘primer 3’ and ‘clonewin’. The cDNA sequences of ER and ER were copied from 
the ‘NCBI’ and ‘Ensembl’ site and ‘blasting’ those two sequences gave a 99% match. All four 
sets of primers were examined for their selectivities using the option ‘blast’ on the NCBI site. 
The sequences of the primers for both estrogen receptors are illustrated in figure 5.15. The 
positions of the primers on the cDNA sequence of ER and ER are shown in figure 5.16 
and 5.17, respectively.  
ER-alpha ER-beta
FP1 5´- ACGGACCATGACCATGACCCT -3´ 5´- TTCCCAGCAATGTCACTAACT -3´
RP1 5´- GGTGGCTGGACACATATAGT -3´ 5´- CTCTTTGAACCTGGACCAGTA -3´
FP2 5´- GCTCCTTTAATTGGTGACTTGG -3´ 5´- CCTATGTAGACAGCCACCATGA -3´
RP2 5´- AGGGAGGGCTTTCTTTTGTAAC -3´ 5´- AAAAGGCCTTACATCCTTCACA-3´  
Figure 5.15: Sequences of the primers for ER and ER (FP1: Forward primer from primer set 1, RP1: 
Reversed primer from primer set 1, FP2: Forward primer from primer set 2, RP2: Reversed primer from 
primer set 2). Materials and Methods, see: 5.3 and 5.4.4.2, respectively. 
 
 
GTCGGGTCGCCCGGCTTCACCGGACCCGCAGGCTCCCGGGGCAGGGCCGGGGCCAGAGCTCGCGTGTCGGCGGGACAT 
GCGCTGCGTCGCCTCTAACCTCGGGCTGTGCTCTTTTTCCAGGTGGCCCGCCGGTTTCTGAGCCTTCTGCCCTGCGGGGA 
CACGGTCTGCACCCTGCCCGCGGCCACGGACCATGACCATGACCCTCCACACCAAAGCATCTGGGATGGCCCTACTGC 
ATCAGATCCAAGGGAACGAGCTGGAGCCCCTGAACCGTCCGCAGCTCAAGATCCCCCTGGAGCGGCCCCTGGGCGAGG 
TGTACCTGGACAGCAGCAAGCCCGCCGTGTACAACTACCCCGAGGGCGCCGCCTACGAGTTCAACGCCGCGGCCGCCG 
CCAACGCGCAGGTCTACGGTCAGACCGGCCTCCCCTACGGCCCCGGGTCTGAGGCTGCGGCGTTCGGCTCCAACGGCCT 
GGGGGGTTTCCCCCCACTCAACAGCGTGTCTCCGAGCCCGCTGATGCTACTGCACCCGCCGCCGCAGCTGTCGCCTTTC 
CTGCAGCCCCACGGCCAGCAGGTGCCCTACTACCTGGAGAACGAGCCCAGCGGCTACACGGTGCGCGAGGCCGGCCCG 
CCGGCATTCTACAGGCCAAATTCAGATAATCGACGCCAGGGTGGCAGAGAAAGATTGGCCAGTACCAATGACAAGGGA 
AGTATGGCTATGGAATCTGCCAAGGAGACTCGCTACTGTGCAGTGTGCAATGACTATGCTTCAGGCTACCATTATGGAG 
TCTGGTCCTGTGAGGGCTGCAAGGCCTTCTTCAAGAGAAGTATTCAAGGACATAACGACTATATGTGTCCAGCCACCAA 
CCAGTGCACCATTGATAAAAACAGGAGGAAGAGCTGCCAGGCCTGCCGGCTCCGTAAATGCTACGAAGTGGGAATGAT 
GAAAGGTGGGATACGAAAAGACCGAAGAGGAGGGAGAATGTTGAAACACAAGCGCCAGAGAGATGATGGGGAGGGC 
AGGGGTGAAGTGGGGTCTGCTGGAGACATGAGAGCTGCCAACCTTTGGCCAAGCCCGCTCATGATCAAACGCTCTAAG 
AAGAACAGCCTGGCCTTGTCCCTGACGGCCGACCAGATGGTCAGTGCCTTGTTGGATGCTGAGCCCCCGATACTCTATT 
CCGAGTATGATCCTACCAGACCCTTCAGTGAAGCTTCGATGATGGGCTTACTGACCAACCTGGCAGACAGGGAGCTGGT 
TCACATGATCAACTGGGCGAAGAGGGTGCCAGGCTTTGTGGATTTGACCCTCCATGATCAGGTCCACCTTCTAGAATGT 
GCCTGGCTAGAGATCCTGATGATTGGTCTCGTCTGGCGCTCCATGGAGCACCCAGGGAAGCTACTGTTTGCTCCTAACT 
TGCTCTTGGACAGGAACCAGGGAAAATGTGTAGAGGGCATGGTGGAGATCTTCGACATGCTGCTGGCTACATCATCTC 
GGTTCCGCATGATGAATCTGCAGGGAGAGGAGTTTGTGTGCCTCAAATCTATTATTTTGCTTAATTCTGGAGTGTACAC 
ATTTCTGTCCAGCACCCTGAAGTCTCTGGAAGAGAAGGACCATATCCACCGAGTCCTGGACAAGATCACAGACACTTTG 
ATCCACCTGATGGCCAAGGCAGGCCTGACCCTGCAGCAGCAGCACCAGCGGCTGGCCCAGCTCCTCCTCATCCTCTCCC 
ACATCAGGCACATGAGTAACAAAGGCATGGAGCATCTGTACAGCATGAAGTGCAAGAACGTGGTGCCCCTCTATGACC 
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TGCTGCTGGAGATGCTGGACGCCCACCGCCTACATGCGCCCACTAGCCGTGGAGGGGCATCCGTGGAGGAGACGGACC 
AAAGCCACTTGGCCACTGCGGGCTCTACTTCATCGCATTCCTTGCAAAAGTATTACATCACGGGGGAGGCAGAGGGTTT 
CCCTGCCACGGTCTGAGAGCTCCCTGGCTCCCACACGGTTCAGATAATCCCTGCTGCATTTTACCCTCATCATGCACCAC 
TTTAGCCAAATTCTGTCTCCTGCATACACTCCGGCATGCATCCAACACCAATGGCTTTCTAGATGAGTGGCCATTCATTT 
GCTTGCTCAGTTCTTAGTGGCACATCTTCTGTCTTCTGTTGGGAACAGCCAAAGGGATTCCAAGGCTAAATCTTTGTAAC 
AGCTCTCTTTCCCCCTTGCTATGTTACTAAGCGTGAGGATTCCCGTAGCTCTTCACAGCTGAACTCAGTCTATGGGTTGG 
GGCTCAGATAACTCTGTGCATTTAAGCTACTTGTAGAGACCCAGGCCTGGAGAGTAGACATTTTGCCTCTGATAAGCAC 
TTTTTAAATGGCTCTAAGAATAAGCCACAGCAAAGAATTTAAAGTGGCTCCTTTAATTGGTGACTTGGAGAAAGCTAGG 
TCAAGGGTTTATTATAGCACCCTCTTGTATTCCTATGGCAATGCATCCTTTTATGAAAGTGGTACACCTTAAAGCTTTTA 
TATGACTGTAGCAGAGTATCTGGTGATTGTCAATTCATTCCCCCTATAGGAATACAAGGGGCACACAGGGAAGGCAGA 
TCCCCTAGTTGGCAAGACTATTTTAACTTGATACACTGCAGATTCAGATGTGCTGAAAGCTCTGCCTCTGGCTTTCCGGT 
CATGGGTTCCAGTTAATTCATGCCTCCCATGGACCTATGGAGAGCAGCAAGTTGATCTTAGTTAAGTCTCCCTATATGA 
GGGATAAGTTCCTGATTTTTGTTTTTATTTTTGTGTTACAAAAGAAAGCCCTCCCTCCCTGAACTTGCAGTAAGGTCAGC 
TTCAGGACCTGTTCCAGTGGGCACTGTACTTGGATCTTCCCGGCGTGTGTGTGCCTTACACAGGGGTGAACTGTTCACTG 
TGGTGATGCATGATGAGGGTAAATGGTAGTTGAAAGGAGCAGGGGCCCTGGTGTTGCATTTAGCCCTGGGGCATGGAG 
CTGAACAGTACTTGTGCAGGATTGTTGTGGCTACTAGAGAACAAGAGGGAAAGTAGGGCAGAAACTGGATACAGTTCT 
GAGGCACAGCCAGACTTGCTCAGGGTGGCCCTGCCACAGGCTGCAGCTACCTAGGAACATTCCTTGCAGACCCCGCAT 
TGCCCTTTGGGGGTGCCCTGGGATCCCTGGGGTAGTCCAGCTCTTCTTCATTTCCCAGCGTGGCCCTGGTTGGAAGAAG 
CAGCTGTCACAGCTGCTGTAGACAGCTGTGTTCCTACAATTGGCCCAGCACCCTGGGGCACGGGAGAAGGGTGGGGAC 
CGTTGCTGTCACTACTCAGGCTGACTGGGGCCTGGTCAGATTACGTATGCCCTTGGTGGTTTAGAGATAATCCAAAATC 
AGGGTTTGGTTTGGGGAAGAAAATCCTCCCCCTTCCTCCCCCGCCCCGTTCCCTACCGCCTCCACTCCTGCCAGCTCATT 
TCCTTCAATTTCCTTTGACCTATAGGCTAAAAAAGAAAGGCTCATTCCAGCCACAGGGCAGCCTTCCCTGGGCCTTTGCT 
TCTCTAGCACAATTATGGGTTACTTCCTTTTTCTTAACAAAAAAGAATGTTTGATTTCCTCTGGGTGACCTTATTGTCTGT 
AATTGAAACCCTATTGAGAGGTGATGTCTGTGTTAGCCAATGACCCAGGTGAGCTGCTCGGGCTTCTCTTGGTATGTCTT 
GTTTGGAAAAGTGGATTTCATTCATTTCTGATTGTCCAGTTAAGTGATCACCAAAGGACTGAGAATCTGGGAGGGCAAA 
AAAAAAAAAAAAGTTTTTATGTGCACTTAAATTTGGGGACAATTTTATGTATCTGTGTTAAGGATATGTTTAAGAACAT 
AATTCTTTTGTTGCTGTTTGTTTAAGAAGCACCTTAGTTTGTTTAAGAAGCACCTTATATAGTATAATATATATTTTTTTG 
AAATTACATTGCTTGTTTATCAGACAATTGAATGTAGTAATTCTGTTCTGGATTTAATTTGACTGGGTTAACATGCAAAA 
ACCAAGGAAAAATATTTAGTTTTTTTTTTTTTTTTTGTATACTTTTCAAGCTACCTTGTCATGTATACAGTCATTTATGCC 
TAAAGCCTGGTGATTATTCATTTAAATGAAGATCACATTTCATATCAACTTTTGTATCCACAGTAGACAAAATAGCACT 
AATCCAGATGCCTATTGTTGGATACTGAATGACAGACAATCTTATGTAGCAAAGATTATGCCTGAAAAGGAAAATTATT 
CAGGGCAGCTAATTTTGCTTTTACCAAAATATCAGTAGTAATATTTTTGGACAGTAGCTAATGGGTCAGTGGGTTCTTTT 
TAATGTTTATACTTAGATTTTCTTTTAAAAAAATTAAAATAAAACAAAAAAAAATTTCTAGGACTAGACGATGTAATAC 
CAGCTAAAGCCAAACAATTATACAGTGGAAGGTTTTACATTATTCATCCAATGTGTTTCTATTCATGTTAAGATACTACT 
ACATTTGAAGTGGGCAGAGAACATCAGATGATTGAAATGTTCGCCCAGGGGTCTCCAGCAACTTTGGAAATCTCTTTGT 
ATTTTTACTTGAAGTGCCACTAATGGACAGCAGATATTTTCTGGCTGATGTTGGTATTGGGTGTAGGAACATGATTTAA 
AAAAAAACTCTTGCCTCTGCTTTCCCCCACTCTGAGGCAAGTTAAAATGTAAAAGATGTGATTTATCTGGGGGGCTCAG 
GTATGGTGGGGAAGTGGATTCAGGAATCTGGGGAATGGCAAATATATTAAGAAGAGTATTGAAAGTATTTGGAGGAAA 
ATGGTTAATTCTGGGTGTGCACCAGGGTTCAGTAGAGTCCACTTCTGCCCTGGAGACCACAAATCAACTAGCTCCATTT 
ACAGCCATTTCTAAAATGGCAGCTTCAGTTCTAGAGAAGAAAGAACAACATCAGCAGTAAAGTCCATGGAATAGCTAG 
TGGTCTGTGTTTCTTTTCGCCATTGCCTAGCTTGCCGTAATGATTCTATAATGCCATCATGCAGCAATTATGAGAGGCTA 
GGTCATCCAAAGAGAAGACCCTATCAATGTAGGTTGCAAAATCTAACCCCTAAGGAAGTGCAGTCTTTGATTTGATTTC 
CCTAGTAACCTTGCAGATATGTTTAACCAAGCCATAGCCCATGCCTTTTGAGGGCTGAACAAATAAGGGACTTACTGAT 
AATTTACTTTTGATCACATTAAGGTGTTCTCACCTTGAAATCTTATACACTGAAATGGCCATTGATTTAGGCCACTGGCT 
TAGAGTACTCCTTCCCCTGCATGACACTGATTACAAATACTTTCCTATTCATACTTTCCAATTATGAGATGGACTGTGGG 
TACTGGGAGTGATCACTAACACCATAGTAATGTCTAATATTCACAGGCAGATCTGCTTGGGGAAGCTAGTTATGTGAAA 
GGCAAATAGAGTCATACAGTAGCTCAAAAGGCAACCATAATTCTCTTTGGTGCAGGTCTTGGGAGCGTGATCTAGATTA 
CACTGCACCATTCCCAAGTTAATCCCCTGAAAACTTACTCTCAACTGGAGCAAATGAACTTTGGTCCCAAATATCCATC 
TTTTCAGTAGCGTTAATTATGCTCTGTTTCCAACTGCATTTCCTTTCCAATTGAATTAAAGTGTGGCCTCGTTTTTAGTCA 
TTTAAAATTGTTTTCTAAGTAATTGCTGCCTCTATTATGGCACTTCAATTTTGCACTGTCTTTTGAGATTCAAGAAAAATT 
TCTATTCTTTTTTTTGCATCCAATTGTGCCTGAACTTTTAAAATATGTAAATGCTGCCATGTTCCAAACCCATCGTCAGTG 
TGTGTGTTTAGAGCTGTGCACCCTAGAAACAACATATTGTCCCATGAGCAGGTGCCTGAGACACAGACCCCTTTGCATT 
CACAGAGAGGTCATTGGTTATAGAGACTTGAATTAATAAGTGACATTATGCCAGTTTCTGTTCTCTCACAGGTGATAAA 
CAATGCTTTTTGTGCACTACATACTCTTCAGTGTAGAGCTCTTGTTTTATGGGAAAAGGCTCAAATGCCAAATTGTGTTT 
GATGGATTAATATGCCCTTTTGCCGATGCATACTATTACTGATGTGACTCGGTTTTGTCGCAGCTTTGCTTTGTTTAATG 
AAACACACTTGTAAACCTCTTTTGCACTTTGAAAAAGAATCCAGCGGGATGCTCGAGCACCTGTAAACAATTTTCTCAA 
CCTATTTGATGTTCAAATAAAGAATTAAACT 
 
Figure 5.16: Positioning of the developed primers on the cDNA sequence of the human ER (Primerset 1: 
yellow, Primerset 2: green). Transitions between the different exons are marked by transition from black 
to blue. Materials and Methods, see: 5.3 and 5.4.4.2, respectively. 
 
 
TTTCAGTTTCTCCAGCTGCTGGCTTTTTGGACACCCACTCCCCCGCCAGGAGGCAGTTGCAAGCGCGGAGGCTGCGAGA 
AATAACTGCCTCTTGAAACTTGCAGGGCGAAGAGCAGGCGGCGAGCGCTGGGCCGGGGAGGGACCACCCGAGCTGCG 
ACGGGCTCTGGGGCTGCGGGGCAGGGCTGGCGCCCGGAGCCTGAGCTGCAGGAGGTGCGCTCGCTTTCCTCAACAGGT 
GGCGGCGGGGCGCGCGCCGGGAGACCCCCCCTAATGCGGGAAAAGCACGTGTCCGCATTTTAGAGAAGGCAAGGCCG 
GTGTGTTTATCTGCAAGCCATTATACTTGCCCACGAATCTTTGAGAACATTATAATGACCTTTGTGCCTCTTCTTGCAAG 
GTGTTTTCTCAGCTGTTATCTCAAGACATGGATATAAAAAACTCACCATCTAGCCTTAATTCTCCTTCCTCCTACAACTG 
CAGTCAATCCATCTTACCCCTGGAGCACGGCTCCATATACATACCTTCCTCCTATGTAGACAGCCACCATGAATATCCA 
GCCATGACATTCTATAGCCCTGCTGTGATGAATTACAGCATTCCCAGCAATGTCACTAACTTGGAAGGTGGGCCTGGTC 
GGCAGACCACAAGCCCAAATGTGTTGTGGCCAACACCTGGGCACCTTTCTCCTTTAGTGGTCCATCGCCAGTTATCACA 
TCTGTATGCGGAACCTCAAAAGAGTCCCTGGTGTGAAGCAAGATCGCTAGAACACACCTTACCTGTAAACAGAGAGAC 
ACTGAAAAGGAAGGTTAGTGGGAACCGTTGCGCCAGCCCTGTTACTGGTCCAGGTTCAAAGAGGGATGCTCACTTCTG 
CGCTGTCTGCAGCGATTACGCATCGGGATATCACTATGGAGTCTGGTCGTGTGAAGGATGTAAGGCCTTTTTTAAAAGA 
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AGCATTCAAGGACATAATGATTATATTTGTCCAGCTACAAATCAGTGTACAATCGATAAAAACCGGCGCAAGAGCTGC 
CAGGCCTGCCGACTTCGGAAGTGTTACGAAGTGGGAATGGTGAAGTGTGGCTCCCGGAGAGAGAGATGTGGGTACCGC 
CTTGTGCGGAGACAGAGAAGTGCCGACGAGCAGCTGCACTGTGCCGGCAAGGCCAAGAGAAGTGGCGGCCACGCGCC 
CCGAGTGCGGGAGCTGCTGCTGGACGCCCTGAGCCCCGAGCAGCTAGTGCTCACCCTCCTGGAGGCTGAGCCGCCCCA 
TGTGCTGATCAGCCGCCCCAGTGCGCCCTTCACCGAGGCCTCCATGATGATGTCCCTGACCAAGTTGGCCGACAAGGAG 
TTGGTACACATGATCAGCTGGGCCAAGAAGATTCCCGGCTTTGTGGAGCTCAGCCTGTTCGACCAAGTGCGGCTCTTGG 
AGAGCTGTTGGATGGAGGTGTTAATGATGGGGCTGATGTGGCGCTCAATTGACCACCCCGGCAAGCTCATCTTTGCTCC 
AGATCTTGTTCTGGACAGGGATGAGGGGAAATGCGTAGAAGGAATTCTGGAAATCTTTGACATGCTCCTGGCAACTACT 
TCAAGGTTTCGAGAGTTAAAACTCCAACACAAAGAATATCTCTGTGTCAAGGCCATGATCCTGCTCAATTCCAGTATGT 
ACCCTCTGGTCACAGCGACCCAGGATGCTGACAGCAGCCGGAAGCTGGCTCACTTGCTGAACGCCGTGACCGATGCTTT 
GGTTTGGGTGATTGCCAAGAGCGGCATCTCCTCCCAGCAGCAATCCATGCGCCTGGCTAACCTCCTGATGCTCCTGTCC 
CACGTCAGGCATGCGAGTAACAAGGGCATGGAACATCTGCTCAACATGAAGTGCAAAAATGTGGTCCCAGTGTATGAC 
CTGCTGCTGGAGATGCTGAATGCCCACGTGCTTCGCGGGTGCAAGTCCTCCATCACGGGGTCCGAGTGCAGCCCGGCA 
GAGGACAGTAAAAGCAAAGAGGGCTCCCAGAACCCACAGTCTCAGTGA 
 
Figure 5.17: Positioning of the developed primers on the cDNA sequence of the human ER (Primerset 1: 
yellow, Primerset 2: green). Transitions between the different exons are marked by transition from black 
to blue. Materials and Methods, see: 5.3 and 5.4.4.2, respectively. 
The programs ‘primer 3’ and ‘clonewin’ give additional necessary information about 
the exact positions of the primers on the cDNA strand and the positions of the primers 
regarding the different exons and introns. Table 5.3 gives an overview of this information. 
From the positions of the primers on the cDNA strand, the length of the primers and the 
length of the introns which lie in-between the exons, the length of the amplicon that is formed 
in the RT-PCR reaction from the mRNA template as well as from the possibly genomic DNA 
present could be calculated. These programs also propose for each set of primers an optimum 
annealing temperature, however, these temperatures had to be optimized experimentally by 
using the thermogradient method.  
Table 5.3 Features of the sets of primers 
FP RP FP RP FP RP FP RP
Position on cDNA (bp) 356 1015 2580 2964 591 829 522 914
Length of primer (bp) 21 20 22 22 21 21 22 22
Position on exon 1 3 8 8 2 3 2 3
Intron in between (length in bp)
Annealing temperature (ºC)
Length of amplicon for 
mRNA template (bp)
Length of amplicon for 
genomic DNA template (bp)
ER-beta
Primerset 1
406
ER-alpha
Primerset 1 Primerset 2
1-2 (34232)     
2-3 (37867)
59
 / 
60
679
72777 406
Primerset 2
2-3 (2470) 2-3 (2470)
55 57
259 414
2884 2329
 
From the information given in table 5.3, it could be concluded that all proposed 
primers have an optimum length for stable binding and selectivity, which is around 20 bp. 
The amplicon formed lies within the acceptable range for RT-PCR. Primerset 2 for ER 
seemed not being able to distinguish between a signal derived from the transcription of the 
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mRNA template and that derived from the transcription of the genomic DNA template that 
could be present. This primerset is, therefore, not appropriate to perform the RT-PCR 
reaction. The other sets of primers lie on different exons and, therefore, result in two different 
amplicon signals after transcription of the mRNA template and the genomic DNA template 
that could be present.  
5.6.4.3. The RT-PCR reaction and gel electrophoresis 
Two human breast cancer cell lines MCF-7/6 and MDA-MB-231 and three human 
prostate cancer cell lines PC-3, DU145, and LNCaP.FGC were screened for the presence of 
the mRNA-transcripts of the ER and ER using RT-PCR. For each receptor, two sets of 
primers were used. The -actin positive control for the RT-PCR reaction included in all RT-
PCR reactions proved to be positive, thereby confirming that the optimized RT-PCR 
conditions (quantities of reagents used in the reaction mixture, temperature settings for the 
thermogradient method, duration of the different steps) were efficient. The control of the 
presence of genomic DNA for all cell extracts (mixture without MulVRTase) proved to be 
negative. Primer set 2 for ER, which could not distinguish between mRNA and genomic 
DNA signals, was also tested along the different RT-PCR reactions performed.  
To determine the optimum annealing temperature, the four sets of primers were 
examined on all cell extracts using the thermogradient method. The results showed that the 
optimum annealing temperatures for the primer sets of ER and ER were 50°C and 65°C, 
respectively. It could be concluded that the primer set, which gave most selective and efficient 
results for both receptors, was primer set 1. The fixed temperature method was repeated for 
primer set 1 from ER and ER on the breast and prostate cancer cell extracts and the results 
are shown in table 5.4.  
Table 5.4: Results of the screening for the presence of the mRNA transcripts of the ER 
and ER in the human breast cancer cell lines MCF-7/6 and MDA-MB-231, and the 
human prostate cancer cell lines PC-3, DU145, and LNCaP.FGC.  
MCF7/6 MDA-MB-231 PC-3 DU145 LNCaP.FGC
ER-alpha  +++  +  ++  +  ++ 
ER-beta  ++  +++  +++  +  + 
 
MCF7/6 demonstrated a very strong signal for ER and only a weak, but positive 
signal for ER. In contrast, MDA-MB-231 showed a strong signal for ER and a very weak 
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signal for ER. PC-3 gave a very strong signal for ER and only a weak, but positive signal 
for ER. LNCaP.FGC showed a signal for ER, which was stronger than for ER. DU145 
was positive for both ER and ER, but the signals were weak in both cases. 
5.7. Discussion 
Polyphenols are abundant micronutrients in our diet and evidence for their role in the 
prevention of degenerative diseases such as cancer and cardiovascular diseases is emerging. 
The hop plant proved to be a rich source of particular polyphenols notably prenylflavonoids. 
The main dietary source of hop-derived prenylflavonoids is through consumption of beer and 
their content can be up to 4 mg/L. A number of anticancer-linked biological activities have 
been ascribed to individual prenylflavonoids, including antioxidant properties
38
, inhibition of 
human cytochrome P450 enzymes,
39
 and induction of quinone reductase
40
.  Miranda et al. 
investigated the ability of X, DMX, and IX, as well as some minor prenylflavonoids present 
in hops, to inhibit the proliferation of human breast cancer (MCF-7), colon cancer (HT-29), 
and ovarian cancer (A2780) cell lines in vitro.
16
 A dose-dependent growth inhibition of MCF-
7 cells was observed for X and IX with IC50 values of 13.3 M and 15.3 M, respectively, 
after two days of exposure. X exhibited an even more pronounced growth-inhibitory effect 
against A2780 ovarian cancer cells (IC50 of 0.52 M). On the other hand, the viability of 
HT29 colon cancer cells was not affected by X and IX. DMX was the least active in breast 
cancer MCF-7 cells. The flavanone 8PN proved to inhibit angiogenesis with an IC50 of 
between 3 and 10 M using bovine microvascular endothelial cells derived from the adrenal 
cortex (BME cells) and from the thoracic aorta (BAE cells).
20
 
Proliferation assays using human cancer cell lines are commonly recognized 
procedures to examine compounds of various sources for their potential anticarcinogenic 
properties. In this study, we used the cell proliferation reagent WST-1 and the SRB assay to 
determine the relative potencies of the hop-derived prenylflavonoids in inhibiting the growth 
of cancer cells and in assessing the sensitivities of the different cell lines to these compounds. 
More specifically, we aimed at getting detailed insights into the effects of the chalcones X and 
DMX, and the flavanones IX, 8PN, and 6PN on the proliferation of different types of prostate 
carcinoma cells (PC-3, DU145, LNCaP.FGC). In parallel, the hop-derived prenylflavonoids 
were exposed to the breast cancer cell lines MCF7/6 and MDA-MB-231, which served as 
estrogenic reference models. Each of these cell lines represents a different stage of the disease 
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and a different hormonal status and response, because of the varying expression profiles of 
the estrogen receptors alpha (ER) and beta (ER).41,42,43,44,45,46 By means of RT-PCR, we 
determined the presence of the ER and ER mRNA transcripts in all cell lines. Furthermore, 
we assayed the antiproliferative properties of the hop-derived prenylflavonoids on a human 
bone marrow endothelial cell line (HBME) to search for potential antiangiogenic activities.
 
The WST1 assay is a colorimetric assay based on the cellular reduction of WST1 to a 
formazan product by the mitochondrial dehydrogenases of viable cells. It is adequate for the 
quantification of cell viability, cell proliferation or cytotoxicity. It had been shown previously 
that compounds with intrinsic reductive potential such as kaempferol can interact with the dye 
of the proliferation assay leading to false positive results.
31
 The hop-derived prenylflavonoids 
studied, however, did not interact with the WST1 reagent. The SRB assay provides a sensitive 
method for measuring drug cytotoxicity in culture. The dye binds to the proteins of cells 
thereby providing a sensitive index of the cellular protein content, which is directly correlated 
to the number of cells in culture. Thus, a growth-stimulatory or growth-inhibitory effect is 
evident.  
X proved to be the most potent compound in inhibiting the growth of all cell lines 
(except for LNCaP.FGC), with IC50 values of 3.2 ± 1.2 M for HBME, 12.3 ± 1.1 M for 
DU145, 12.4 ± 1.1 M for MCF-7/6, 13.2 ± 1.1 m for PC-3, and 36.3 ± 1.1 M for MDA-
MB-231. In particular, X was highly potent in suppressing the growth of the endothelial cells 
(IC50 of 3.2 ± 1.2 M) suggesting that X may be an efficient antiangiogenic agent. 6PN had 
the most pronounced growth inhibitory effect on PC-3 (IC50 of 18.4 ± 1.2 M), followed by 
DU145, MCF-7/6, HBME, and MDA-MB-231 (IC50 of 29.1 ± 1.1 M, 32.6 ± 1.0 M, 39.8 ± 
1.0 M, and 65.1 ± 1.0 M, respectively). 8PN showed pronounced antiproliferative effects 
on PC-3, LNCaP.FGC, and DU145 (IC50 of 33.5 ± 1.0, 42.8 ± 1.2, and IC50 of 43.1 ± 1.2 M, 
respectively). IX was the second most active growth inhibitor for HBME with an IC50 of 29.4 
± 1.1 M. The compound showed activities on prostate cancer cells comparable to those of 
8PN (IC50 of 45.2 ± 1.1 M on PC-3 and 47.4 ± 1.1 M on DU145) but, was more efficient 
on MCF-7/6 breast cancer cells (IC50 of 32.9 ± 1.1 M) and proved to be the most potent 
inhibitor of LNCaP.FGC prostate cancer cells with an IC50 of 34.4 ± 1.0 M. DMX was the 
least active compound in all cell lines (data are missing for the LNCaP.FGC cell line).  
All prenylflavonoids showed a biphasic dose-response behavior on MCF-7/6 breast 
cancer cells, stimulating growth at low concentrations and inhibiting growth at higher 
104
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concentrations. However, a stronger growth-stimulatory effect for 8PN on this estrogen-
responsive breast cancer cell line was expected, as 8PN has been characterized as a highly 
potent phytoestrogen.
3
 Therefore, growth-stimulatory experiments were performed on the 
MCF7/6 cells. The calculated EC50 values for growth stimulation of 17-estradiol and 8PN 
were 9.3 ± 0.5 pM and 4.2 ± 1.3 nM, respectively, indicating that 8PN is about 500 times 
weaker in stimulating growth as compared to 17-estradiol. However, the comparison is not 
reliable, because of the different conditions used in both assays. At a concentration of 100 
nM, maximum growth stimulation was achieved and the growth-stimulatory effect diminished 
at higher concentrations to finally result in a growth-inhibitory effect from a concentration of 
10 M. The well-described potent cancer chemopreventive activities of X inspired us to 
investigate whether X could inhibit the strong growth-stimulatory effect of 8PN on MCF7/6 
breast cancer cells. X did inhibit the growth-stimulatory effect of 8PN at concentrations 
between 1 M and 5 M. Concentrations above 5 M exhibited a growth-inhibitory effect as 
compared to the control (100%). At a concentration of 0.1 M, X had an additional growth-
stimulatory effect leading to an increased growth stimulation as was observed for 8PN. On 
LNCaP.FGC prostate cancer cells, X and 6PN showed a biphasic dose-response behavior 
stimulating growth at low concentrations and inhibiting growth at higher concentrations. IX 
and 8PN, which are the most potent inhibitors for the growth of this cell line, inhibited growth 
at concentrations that led to stimulation by X and 6PN.  
As the inhibitory effects of the prenylflavonoids on cancer cells may be mediated 
through hormonal - in particular estrogenic - mechanisms,  it was important to additionally 
assess the estrogenic activity using an estrogen-inducible yeast screening assay (yeast 
estrogen screen; YES)
18
 and to assess the hormonal status of the cell lines used. In the YES, X 
and IX were almost inactive, while 6PN behaved as a weak estrogen and DMX and 8PN 
revealed potent estrogenic activities. However, it should be noted that the high activity of 
DMX could contribute to its instability and subsequent conversion to a mixture of 8PN and 
6PN (60% conversion after 48 h incubation at 37°C, data not shown). Therefore, activities 
found for DMX should be interpreted with great caution. Milligan et al. found similar dose-
response curves with the YES, but results obtained with the Ishikawa Var I assay gave a 
different ranking of the estrogenic activity (from high to low): 8PN >> DMX > IX > 6PN > 
X.
3,47
 The difference in activity for IX in the YES (almost no activity) compared to the 
Ishikawa Var I assay (weak estrogenic activity) could be explained by a possible metabolic 
conversion of IX to 8PN in the endometrial cells used in the latter assay. In the cell lines 
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applied in the present study, IX may also have been metabolized to 8PN and this feature 
should also be taken into account when interpreting the results. 
The inhibitory effects of the hop-derived prenylflavonoids on cancer cells may be 
mediated through hormonal mechanisms, as seems to be evidenced by the antiproliferative 
activities on the breast cancer cells MCF7/6 and MDA-MB-231 that are inversely correlated 
to increasing estrogenic activities. Indeed, considering the potential metabolic conversion of 
IX into 8PN and the instability of DMX, the estrogenic activities in the YES (from high to 
low) were: 8PN >> DMX > 6PN > IX > X, while the antiproliferative effects on MCF-7/6 and 
on MDA-MB-231 cells were (from high to low): X > 6PN > IX > 8PN > DMX. The pattern 
of responses observed with the two prostate cancer cell lines PC-3 and DU145 was (from high 
to low): X > 6PN > 8PN > IX > DMX showing on their turn an inverse correlation to 
increasing estrogenic activities. This could be explained by the preferential binding of X and 
6PN to the ER which is suggested to be predominantly antiproliferative. However, the 
pattern of response observed with LNCaP.FGC cells (IX > 8PN > X > 6PN) demonstrated no 
correlation with the estrogenic activity. Nevertheless, no quantitative relation between the 
estrogenic potency as measured in the YES and the antiproliferative effect could be 
established. 
The observed variations in sensitivities between the different types of cancer cells may 
be attributed to the varying expression profiles of the ER and ER. Although there are 
contradictory literature reports in this respect,
42,48,49,50,43 
it is accepted that MDA-MB-231 
cells express only low levels of ER- and MCF-7/6 cells express high levels of ER and low 
levels of ER.41,42,43 Moreover, MCF-7/6 and MDA-MB-231 cells express qualitatively the 
same ER-isoforms.44 The expression profiles of both estrogen receptors remain controversial 
in prostate cancer cells. Maruyama et al.
45
 demonstrated the expression of ER and ER in 
PC-3 prostate cancer cells. Lau et al.
46
 confirmed these results and showed exclusive 
expression of ER mRNA in DU145 and LNCaP prostate cancer cells. However, Ito et al.51 
reported also an exclusive expression of ER mRNA for PC-3 prostate cancer cells. Because 
of the controversy regarding the presence of the human estrogen receptors in the commonly 
used cancer cell lines, we examined the presence of the mRNA transcripts of the ER and 
ER in the human breast cancer cell lines MCF-7/6 and MDA-MB-231, and in the human 
prostate cancer cell lines PC-3, DU145, and LNCaP.FGC, by RT-PCR. 
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We found that all cell lines demonstrated positive signals for the ER and ER 
transcripts, with the strongest signal for ER in the MCF7/6 breast cancer cell line and the 
strongest signal for ER in the PC-3 and MDA-MB-231 cells. The results must be interpreted 
with caution, because the RT-PCR technique was not quantitative. The intensities of the 
signals can be compared, but only when submitted to the same RT-PCR reaction and even 
then, there are still events that make comparison of signals questionable. The experiments 
were repeated three times in exactly identical conditions and the order of cell lines submitted 
to a particular RT-PCR reaction were always respected. It can safely be concluded that ER is 
most abundant in MCF7/6 breast cancer cells and ER is most abundant in PC-3 prostate 
cancer and MDA-MB-231 breast cancer cells.  
These results are in accordance with the literature regarding the presence of ER and 
ER for MCF7/6 and ER for MDA-MB-231. The presence of an ER transcript for MDA-
MB-231 was demonstrated in this study, albeit expressed lower than ER. For prostate cancer 
cells, our results are in accordance with the findings of Maruyama et al. and Lau et al. for PC-
3 prostate cancer cells. However, for DU145 and LNCaP.FGC, we demonstrated that these 
prostate cancer cell lines express both receptor subtypes. The explanation of this difference 
can be found in the difference between the variants of these cell lines that are not always 
identified within the materials of a study. Moreover, depending on the culture conditions and 
media provided to the growth of the culture, the characteristics of cells can change while 
adapting themselves to the particular conditions.  
If we correlate the findings of this study with the observed antiproliferative activities, 
it is difficult to explain why breast cancer MCF7/6 cells were found to be more sensitive to 
the hop-derived prenylflavonoids than MDA-MB-231 cells. Both cell lines express ER in 
comparable amounts, however, ER is much more abundant in the MCF7/6 breast cancer 
cells, rendering the latter more sensitive to estrogenic stimulation. Biphasic effects on MCF-
7/6 cells (noted here) have been observed for the soy-derived phytoestrogen genistein, which 
exhibited a dose-dependent growth-stimulatory effect at low concentrations, followed by a 
growth-inhibitory effect at higher concentrations on MCF-7 cells, while, under similar 
conditions, only a dose-dependent growth-inhibitory effect was observed on MDA-MB-231 
cells.
52
 The responses of different types of breast cancer cells to genistein were found to be 
cell-type specific and were attributed to a heterogeneous spectrum of mechanisms associated 
with growth modulation that involve more than only hormone-related effects. Indeed, in our 
LIES DELMULLE 155x240 - 148 blz - INDESIGN.indd   119 05-11-2007   15:55:18
  
108 
 
study, the observed sensitivity differences between MCF-7 and MDA-MB-231 cells could, 
other then a result of differences in ER-expression levels, be a result of a different ER-
mediated response to the compounds with varying estrogenic activities. Remarkably, the 
observed growth-stimulatory effects on MCF-7/6 cells in this study are most pronounced for 
X, which is almost devoid of estrogenic activity, whereas the potent phytoestrogen 8PN was 
less active in growth stimulation, evidencing that other than ER-mediated effects could be 
involved. 
No obvious differences in sensitivities between the prostate cancer cells PC-3 and 
DU145 were noted and our findings confirm indeed that both receptor subtypes are present in 
both cell lines, the difference in ER expression profiles being less obvious as compared to the 
breast cancer cells.  
There is strong evidence that, for the prostate cancer cell lines, the presence of ER is 
significant with regard to the regulation of proliferation. Peach et al. demonstrated that 17-
estradiol inhibited transcription via ER, but activated transcription when signalling through 
ER.53 Additionally, studies in cell culture found that ER inhibited ER-transcriptional 
activity at subsaturating levels of 17-estradiol and decreased overall sensitivity of the cells to 
estrogens.
54
 A differential response of 17-estradiol was also observed in the immature uterus 
of ER-knockout (BERKO) mice, which exhibited an enhanced response to 17-estradiol, 
compared with the wild-type, ER-positive mice. If transcriptional activity reflects the 
mitogenic effects of the ER, these studies and the finding that older ER-null mice develop 
prostatic hyperplasia
55
 suggest that ER is predominantly antiproliferative. The corollary is 
that loss of ER, in conjunction with other unknown molecular events, may promote cell 
proliferation and, possibly, carcinogenesis. This hypothesis is compatible with the findings by 
Horvarth et al., who demonstrated that loss of ER expression is associated with progression 
from normal prostate epithelium to prostate cancer.
56
 Furthermore, the growth-inhibitory 
effects of the pure anti-estrogen ICI on DU145 prostate cancer cells were reversed by ER-
antisense oligonucleotides, which supports the notion that the observed antiproliferative 
activity on DU145 cells is mediated via an ER-signalling mechanism.46 Our findings show 
indeed that 8PN, with a high affinity and activity on ER, was less active in inhibiting the 
proliferation on PC3 and DU145 prostate cancer cells compared to X and 6PN which were 
proved to have more affinity for ER. 
108
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Interpretation of the observed results on LNCaP.FGC prostate cancer cells is complex. 
Even though ER is present in larger amounts than the antiproliferative ER, the most potent 
estrogenic compounds IX and 8PN prove to be very potent proliferation inhibitors for this cell 
line. On the other hand, a growth-stimulatory effect is observed for X and 6PN, which have 
very low or low estrogenic activity, respectively. These results presume the presence of non-
hormonal effects, however, this complex situation is probably also affected by the special 
features of the LNCaP.FGC prostate cancer cell line. The clone FGC is a LNCaP variant 
expressing two androgen-controlled pathways, namely, the induction of cell proliferation and 
the proliferative shutoff.
57
 Using this clone, biphasic dose-responses are observed after 
treatment with androgens. Moreover, the androgen receptor (AR) of this cell line contains a 
mutation at amino acid 868 in the ligand-binding domain, which increases the affinity of the 
receptor for estrogens, progestins, and even some anti-androgens thereby leading to greatly 
enhanced agonistic effects on the receptor.
58,59
 This explains why compounds such as the hop-
derived prenylflavonoids could bind to the AR, thereby resulting in a biphasic dose-response. 
To fully understand the observed effects on this cell line, further specific research will need to 
be done. 
All these findings and the facts that inhibitory properties were observed across all cell 
lines and that a direct correlation between estrogenic and antiproliferative activities for 
prostate cancer cells seemed to be absent, suggest that additional non-genomic mechanisms 
may be involved. So et al. examined the inhibition of proliferation of human breast cancer 
MCF-7/6 cells by flavonoids in the presence and in the absence of an excess of 17-estradiol. 
Only the inhibition of cell proliferation by genistein was reversed by the competing estrogens, 
hence, the antiproliferative activities of other flavonoids seemed to involve different 
mechanisms.
60
 Besides estrogen receptor-related actions, phytoestrogens may exert their 
activities by interacting with some of the key enzymes in sex steroid production such as 
aromatase, 17-hydroxysteroid dehydrogenase, and 5-reductase or by other, non-hormonal 
functions including induction of apoptosis, inhibition of tyrosine kinase, protein kinase C, and 
DNA topoisomerase II or by their antioxidant properties.
61
 Further research on the effect of 
prenylflavonoids from hops on non-genomic mechanisms seems necessary. 
The more efficient growth stimulation of X on MCF-7/6 cells as compared to 8PN 
could also be due to the formation of estrogenically active metabolites. Until now, very little 
is known on metabolism of hop-derived prenylflavonoids. It was reported that X is converted 
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to four metabolites by isosafrole/beta-naphthoflavone-induced rat liver microsomes and two 
major glucuronides were found with either rat or human liver microsomes.
62,63
 8PN is 
converted into at least twelve metabolites by human liver microsomes, the most abundant 
ones being oxidized within the prenyl group.
64
 With the exception of the reported human 
cyclooxygenase-2 inhibitory activity for 5,7,4’-trihydroxy-8-(2-hydroxy-3-methylbut-3-
enyl)flavanone, an isomer of 8PN, and the estrogenic 8-prenylapigenine, a C-ring 
dehydrogenated analog of 8PN, it remains uncertain whether these oxidation and conjugation 
products possess well-defined biological activities.  
Previous studies on structure-activity relationships of chalcones indicated that their 
potencies to inhibit proliferation of colon cancer cells (CCL 220.1) was dependent on the 
number and the positions of hydroxyl groups in the chalcone nucleus.
65
 Furthermore, the 
presence of an ,-double bound, hydroxylation at the 2’- or 3’-positions of the B-ring, and 
the absence of a prenyl group appeared important for antiproliferative activity in ovarian 
cancer cells.
66
 Analysis of the effects in the series used in the present study reveals that the 
methoxy group at the 6’-position in the A-ring of X is essential, since a hydroxy group at this 
position (as in DMX) abolishes the strong inhibitory capacity for all cell lines. This 
phenomenon has also been observed by Miranda et al. for chalcones X and DMX on breast 
cancer (MCF-7) cells and colon cancer (HT-29) cells, but not on ovarian cancer (A2780) 
cells.
16
 
In the same study, Miranda et al. showed that conversion of a chalcone to a flavanone 
(X to IX) resulted in reduced antiproliferative activities for X on MCF-7 and A2780 cells. Our 
observations indicate comparable activities for X, except for the LNCaP.FGC cell line, which 
shows different results at all levels probably due to the sensitive AR receptor. Conversion of 
the chalcone DMX to the flavanones 8PN and 6PN, however, resulted in increased activities. 
It should be noted that DMX is unstable giving rise to 8PN and 6PN. Therefore, activities 
found for DMX should be interpreted with great caution and the effect of DMX is probably 
the sum of the effects of 8PN and 6PN separately.  
5.8. Conclusions 
Antiproliferative activities of xanthohumol and 6-prenylnaringenin were found to be 
strongest for the breast cancer cells MCF-7/6 and MDA-MB-231, and the prostate cancer 
cells PC-3 and DU145, while, on LNCaP.FGC, these compounds first exerted a strong 
110
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induction of cell proliferation followed by a proliferation shut-off. 8-Prenylnaringenin, a 
compound that has previously been identified as a potent phytoestrogen, demonstrated weaker 
antiproliferative effects on prostate cancer cell lines PC-3 and DU145, confirming the 
proposed importance of the ER receptor in the antiproliferative activity of prostate cancer 
cells. However, on LNCaP.FGC prostate cancer cells 8PN demonstrated a more potent 
growth inhibition. Isoxanthohumol exhibited activities on prostate cancer cells PC-3 and 
DU145 comparable to those of 8-prenylnaringenin, but was more effective on LNCaP.FGC 
and MCF-7/6 breast cancer cells. Desmethylxanthohumol was the least active compound in 
all cell lines. The observed stimulatory effect on MCF-7/6 breast cancer cells and 
LNCaP.FGC prostate cancer cells is exerted in the low micromolar range. No quantitative 
relation between the estrogenic potencies as measured in the YES and antiproliferative effects 
could be concluded. The strong antiproliferative activity of xanthohumol in endothelial cells 
suggests potential antiangiogenic activity compromising tumor growth and metastasis. Further 
research on the non-genomic effects of the hop-derived prenylflavonoids is necessary to 
understand the mechanisms of action and to confirm whether these compounds may be 
efficient in the chemoprevention of breast and prostate cancers.   
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6. Mechanistic insights on antiproliferation and cytotoxicity of 
hop-derived prenylflavonoids 
Antiproliferative activities of five hop-derived prenylflavonoids, xanthohumol (X), 
desmethylxanthohumol (DMX), isoxanthohumol (IX), 8-prenylnaringenin (8PN), and 6-
prenylnaringenin (6PN), on human prostate cancer cells (PC-3, DU145 and LNCaP.FGC), 
were evidenced in part of our study.
67
  
In this respect, we aimed to obtain insights into the underlying mechanisms by which 
the compounds in view of their potential applications influence the pathogenesis of prostate 
cancer (PC). These investigations were performed at the laboratory of Prof. Dr. P. 
Vandenabeele, Ghent University-UGent, Faculty of Sciences, Flanders Interuniversity 
Institute for Biotechnology, Department for Molecular Biomedical Research, Molecular 
Signalling and Cell Death Unit, Ghent, Belgium. 
6.1. Purpose 
The observed antiproliferative effects of the hop-derived prenylflavonoids on the 
prostate cancer cells may involve different mechanisms. The observed dose-dependent 
decrease in cell viability as determined with the WST1 proliferation assay could be ascribed 
to the interaction of the hop-derived prenylflavonoids with the cell cycle resulting in a cell 
division delay. On the other hand, the compounds could have induced cell death in an 
apoptotic or necrotic way. It is also possible that viability assays such as the WST1 
proliferation assay, which is based on the measurement of mitochondrial enzyme activity, 
could have produced false-positive results, since the mitochondrial enzymes from cells 
undergoing apoptosis remain active until the last phase of the cell death process. Therefore, it 
was necessary to perform more detailed research into the effects of the hop-derived 
prenylflavonoids at the cell level. 
To limit the extensive manipulations due to the various compounds and cell lines, we 
limited our research to the effects of the compounds on cell mechanisms using the human 
prostate cancer cell lines PC-3 and DU145. The LNCaP.FGC cell line was not further 
examined, because of practical problems with this highly sensitive and difficult-to-manipulate 
cell culture. The chalcone DMX was not further tested because of its instability. 
112
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6.2. Introduction 
Prostate cancer is the most invasive and frequently diagnosed malignancy and the 
second leading cause of cancer related deaths in the United States.
68
 Most prostate cancers are 
generally slow-growing malignancies and present themselves as mixtures of androgen-
dependent and androgen-independent cells during the clinical diagnosis.
69,70
 Age and 
hormones are known factors influencing the incidence of prostate cancer and hormone-
dependent cancer cells initially respond to androgen withdrawal by undergoing apoptosis. 
However, patients with advanced or metastatic prostate cancer develop hormone refractory 
status that becomes fatal because of the growth of androgen-independent tumor cells and the 
emergence of tumor clones. Therefore, cancer chemotherapy aimed at causing cell death in 
metastatic prostate cancer is necessary and urgent for clinical treatment.  
Apoptosis is a form of physiological cell death essential to normal tissue development 
and homeostasis.
71
 After receiving an apoptotic death stimulus, cells first enter a signalling 
phase followed by the final degradation phase, in which apoptosis is identifiable by chromatin 
condensation, cell shrinkage, caspases activation, membrane lipid rearrangement, DNA 
fragmentation, and cell fragmentation through formation of ‘apoptotic bodies’.
72
 It is now 
well-evident that apoptosis occurs through two main pathways in cells responsive to apoptotic 
stimuli, namely extrinsic and intrinsic apoptosis signaling.
73,74
 The extrinsic or cytoplasmic 
pathway is triggered through the Fas death receptor, a member of the tumor necrosis factor 
(TNF) receptor superfamily. The intrinsic or mitochondrial pathway leads, when stimulated, 
to the release of cytochrome-c from the mitochondria and activation of the death signal. Both 
pathways converge to a final common pathway involving activation of a cascade of caspases, 
starting with the activation of pro-caspase 3, leading to the morphologic manifestations of 
apoptosis and finally resulting in death of the cell.
75
 
A wide variety of natural substances have been recognized to possess the ability to 
induce apoptosis in various cancerous cells.
76
 Induction of apoptosis by hop bitter acids in 
HL-60 human leukemia cell lines has been demonstrated by Chen et al.
77
 and Tobe et al.
78
  
We investigated the kinetics of the time-dependent antiproliferative activities of four 
hop-derived prenylflavonoids and studied the treated cells morphologically for typical 
apoptotic features. Furthermore, the effect of the inhibition of caspases was determined and 
the activation of pro-caspase-3 and the caspase-3 activities were measured.  
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6.3. Materials 
6.3.1. Hop-derived prenylflavonoids 
The hop-derived prenylflavonoids X, IX, 8PN, and 6PN were isolated and purified 
from spent hops as described in chapter 4. 
6.3.2. Chemicals 
HEPES was purchased from Sigma-Aldrich (Bornem, Belgium). Solvents (HPLC 
grade) were from Biosolve (Valkenswaard, The Netherlands). Cell culture media, L-
glutamine, non-essential amino acids (NEAA), penicillin (10,000 IU/ml), and streptomycin 
(10,000 g/ml), foetal bovine serum (FBS), and sodium pyruvate were obtained from 
Invitrogen (Merelbeke, Belgium). The pan-caspase inhibitor was purchased from Enzyme 
Systems Products (Dublin, California, USA). The caspase-3-like substrate acetyl(Ac)-DEVD-
AMC was obtained from the Peptide Iinstitute (Osaka, Japan). Rabbit polyclonal antibodies 
against caspase-3/CPP32 were purchased from BioSource (Nivelles, Belgium), the anti-rabbit 
secondary antibody horseradish peroxidase conjugate was derived by Amersham Biosciences 
(Roosendaal, Netherlands), and the ‘chemiluminescence reagent plus’ was purchased from 
Nycomed Amersham place (Buckinghamshire, United Kingdom). 
6.3.3. Cells and culture media 
Two established human epithelial cancer cell lines from prostatic (PC-3, DU145) 
origin were obtained from the American Type Culture Collection (ATCC, Rockville, 
Maryland, USA). Cells were maintained in cell-specific media at 37°C in a humidified 
atmosphere of 5% carbon dioxide. The cells were passed at 70% confluency (i.e., two or three 
times a week). To reduce potential variations of cell characteristics, cells were used within 10 
passages for all experiments.  
Cells were cultured in a Dulbecco’s Modified Eagle’s Medium DMEM/F12 (Ham) 1:1 
(Dubecco’s Mem Nut Mix F–12 (HAM)) with L–glutamine (365,00 mg/L) and 15 mM 
HEPES. This medium was supplemented with 10% foetal bovine serum (FBS) and antibiotic 
agents (penicillin 10,000 IU/ml and streptomycin 10,000 g/ml).  
114
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Experiments with DU145 cells were performed in DMEM without phenol red; 
experiments with PC-3 cells were performed in phenol red-free RPMI 1640. Both media were 
supplemented with 10% steroid-free, dextran-coated, charcoal-treated FBS, and 1% antibiotic 
agents (penicillin 10,000 IU/mL and streptomycin 10,000 g/mL). In addition, 2 mM L-
glutamine, 0.1 mM NEAA, and 1 mM sodium pyruvate were added to the DMEM medium 
and 1 mM sodium pyruvate and 10 mM HEPES were added to the RPMI 1640 medium.   
6.3.4. Dextran-coated charcoal-stripped FBS 
The preparation of dextran-coated charcoal-stripped FBS was performed as described 
in the methods used for the investigation of the antiproliferative, cytotoxic, antiangiogenic, 
and estrogenic properties of hop-derived prenylflavonoids (see: 5.3.5). 
6.4. Methods 
6.4.1. Time dependent cell survival assay 
WST1 tetrazolium is a slightly reddish substrate, which is cleaved to its water-soluble 
formazan product under catalysis by succinate dehydrogenase complex II of the inner 
mitochondrial membrane, an enzyme involved in the oxidative phosphorylation. In death or 
dying cells, the damaged mitochondria are affected in their capacity to cleave significant 
amounts of WST1 tetrazolium to its formazan product. Therefore, this assay measures both 
cytostatic as well as cytotoxic effects. For the description of the WST1 tetrazolium assay we 
refer to 5.4.1.1. The WST1 tetrazolium assay was performed in a kinetic way to determine the 
incubation time necessary for the compounds to exert their effects on the human prostate 
cancer cell lines.  
Cells were seeded into flat-bottomed 96-well tissue culture plates (Falcon, Beckton 
Dickinson, Grenoble, France) at a density of 6,000 cells/well for DU145 and 10,000 cells/well 
for PC-3 in 100 l experimental growth medium. After 24 h, the cells (20-30% confluent) 
were exposed to culture media containing 100 M or 200 M of the hop-derived 
prenylflavonoids for 2, 4, 6, 8, 10, 12 and 14 h. All experiments included a solvent control. 
The experiments were repeated three times with three replicas per condition. At the end of 
each incubation period, cell viability was measured using the 4-[3-(4-iodophenyl)-2-(4-
nitrophenyl)-2H-5-tetrazolio]-1,3-benzene (WST1) assay (Roche Diagnostics, Vilvoorde, 
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Belgium) according to the manufacturer’s instructions. The average absorbance of each 
treated well was compared with the average absorbance of each control well to give a 
percentage of the control proliferation ([value/control]x100). As X and DMX absorb slightly 
at 450 nm, their experimental absorbance values at various concentrations were corrected for 
the respective blank absorbances from wells containing experimental medium and X or DMX 
at various concentrations, in the absence of the WST1 reagent. 
6.4.2. Morphological analysis 
Using a classic phase contrast and a digital modulator contrast (DIC) light microscope 
cells undergoing cell death after incubation with the hop-derived prenylflavonoids were 
examined for the specific morphological changes associated with the various cell death 
processes. Classic phase contrast technique gives information about cell granularity and cell 
content, while the DIC technique gives more information about the cell surface. The use of 
both techniques allows to detect all possible changes at cell level.  
Cells were seeded into flat-bottomed 6-well tissue culture plates (Falcon) at a density 
of 200,000 cells/well. After 24 h, the cells were exposed to culture media containing 200 M 
of the hop-derived prenylflavonoids. All experiments included a solvent control. After 
treatment for 0.5, 1, 1.5, 2, 12, and 24 h, respectively, cell changes were studied 
microscopically and photographs were taken using a phase-contrast microscope at 200x 
magnification. 
6.4.3. Apoptosis inhibition with zVAD-fmk 
zVAD-fmk (N-Benzyloxycarbonyl-Val-Ala-Asp(O-Me)-fluoromethyl ketone) is a 
broad range (pan-)caspase inhibitor. Caspases are a family of cysteine aspartate-specific 
proteases. They are activated either via proximity-induced autoproteolysis or by cleavage via 
upstream proteases in an intracellular cascade resulting in several biochemical responses 
giving rise to apoptosis. If apoptosis is induced by the tested compounds, inhibition of the 
capsases by zVAD-fmk should result in changes in cell viability, which can be measured by 
the WST-1 tetrazolium assay. 
Cells were seeded into flat-bottomed 96-well tissue culture plates (Falcon) at a density 
of 6,000 cells/well for DU145 and 10,000 cells/well for PC-3 in 100 l experimental growth 
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medium. After 24 h, the cells (20-30% confluent) were exposed to culture media containing 
25 M zVAD-fmk for 2 h. After 2 h, cells were exposed for 18 h to culture media containing 
a serial dilution of the hop-derived prenylflavonoids prepared in ethanol from a 200 mM stock 
solution to a final ethanol concentration of 0.1 % in each well. All experiments included a 
solvent control and a zVAD-fmk control. Further manipulations were identical to those 
described for the time-dependent cell survival assays. 
6.4.4. Western blot analysis of caspase 3-activity 
Caspases are synthesized as zymogens consisting of a prodomain of variable length, 
followed by a p20 and p10 unit that contain the residues essential for substrate recognition 
and catalytic activity. The net result of these proteolytic activities is the separation of the 
prodomain from the p20 and p10 subunits. Proteolytic activation of procaspases leads to the 
appearance of typical p20 and p10 subunits, therefore, the proteolytic activation state of 
caspases can be examined by Western Blotting. If caspases are activated by the tested 
compounds, cleavage of these enzymes should be detected by the Western blot technique. 
Cells were seeded into flat-bottomed 6-well tissue culture plates (Falcon) at a density 
of 200,000 cells/well in 1,200 L experimental medium. After 24 h, cells were exposed to 
experimental medium containing 200 M of the hop-derived prenylflavonoids for 15, 30, 60, 
90, and 120 min, respectively, resulting in a final volume of 1,500 L/well. All experiments 
included a solvent control. At regular time intervals (15, 30, 60, 90, 120 min), cells were 
collected in an eppendorf tube by scraping and centrifuged for 5 min at 1,100 rpm at 4°C. The 
culture medium was gently aspirated, cells were washed with 1 mL cold phosphate-buffered 
saline (8 g/L NaCl, 0.2 g/L KCl, 2.89 g/L Na2HPO4.12H2O, 0.2 g/L KH2PO4) and centrifuged 
for 5 min at 1,100 rpm at 4°C. PBS was aspirated and cells were lysed in 100 L caspase lysis 
buffer (1 % Nonidet P-40, 10 mM Tris-HCl, pH 7.4, 10 mM NaCl, 3 mM MgCl2, 1 mM 
phenylmethylsulfonyl fluoride, 0.3 mM aprotinin, 1 mM leupeptin), and left on ice for 10 
min. Lysates were cleared by centrifuging at 14,000 rpm for 5 min, 1:5 volume of a 5 x 
Leammli buffer (312.5 mM Tris-HCl, pH 6.8, 10% SDS, 50% glycerol and 20% -mercapto-
ethanol) was added to the remaining cytosol and boiled for 5-10 min at 98°C. For Western 
blot analysis, equal amounts (15 L/lane) were separated on 10% SDS-polyacrylamide gels 
and transferred to a nitrocellulose membrane (Schleicher & Schuell Bioscience, 
s’Hertogenbosch, The Netherlands). The membrane was incubated with a 1:1,500 dilution 
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from rabbit anti-caspase-3/CPP32 polyclonal primary antibody (BioSource, Nivelles, 
Belgium). Anti-rabbit secondary antibody horseradish peroxidase conjugate (1:4,000) 
(Amersham Biosciences, Roosendaal, the Netherlands) was used to detect and visualize with 
chemiluminescence Renaissance reagent (PerkinElmer Life Sciences, Vienna, Austria). 
6.4.5. Analysis of caspase activity using fluorogenic substrates 
The measurement of the actual activity of caspases can be examined with the use of 
fluorogenic substrates for caspases. These substrates contain the minimal amino acid 
composition corresponding with the cleavage-site of a typical substrate, coupled to 7-amino-
4-methylcoumarin (AMC) or 7-amino-4-trifluoromethylcoumarin (AFC). Acetyl(Ac)-DEVD-
AMC (7-amino-4-methylcoumarin, N-acetyl-L-aspartyl-Lglutamyl-L-valyl-l-aspartic acid 
amide) is a fluorogenic substrate for caspase-3 derived from the caspase-3 cleavage site in 
poly ADP ribosyl polymerase (PARP). The hydrolysis of the peptide substrate results in the 
release of free fluorescent AMC or AFC which can be measured with a fluorometer.  
Cell lysates were prepared as described for the Western blot analysis of caspase-3 
activation. Glutathione was added to the lysis buffer in a final concentration of 1 mM. After 
lysis, cells were left for 10 min on ice. Cell debris was removed by centrifuging the lysate for 
5 min at 14,000 rpm and caspase activity was measured by incubating 10 L of the cell lysate 
with 50 M of the fluorogenic substrate Ac-DEVD-AMC in 150 L CFS-buffer (10 mM 
HEPES-NaOH, pH 7.4, 220 mM mannitol, 68 mM sucrose, 2 mM NaCL, 2.5 mM KH2PO4, 
0.5 mM EGTA, 2 mM MgCl2, 5 mM sodium pyruvate, 0.1 mM phenylmethylsulfonyl 
fluoride, 1 mM dithiothreitol). The release of fluorescent AMC was monitored for 1 h at 37°C 
at 2 min time intervals with a fluorometer (CytoFluor, PerSeptive Biosystems, Cambridge, 
Massachusetts, USA) using a filter with an excitation wavelength of 360 nm and a filter with 
an emission wavelength of 460 nm. 
6.5. Results 
6.5.1. Time-dependent cell survival assay 
The time-dependent effects of the hop-derived prenylflavonoids X, IX, 6PN, and 8PN 
on cell viability were investigated. Human prostate cancer cell lines PC-3 and DU145 were 
treated with 100 M or 200 M X, IX, 8PN or 6PN. After varying incubation times, cell 
118
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viability was measured with the WST-1 proliferation assay. As shown in Figure 6.1, all 
compounds reduced cell viability for at least 50% after 2 h of incubation when added to the 
cells in a concentration of 200 M. Treatment with 100 M significantly reduced cell 
viability albeit to a smaller extent, except for 8PN and 6PN, which did not significantly 
reduce cell viability in DU145 prostate cancer cells. Longer incubation times (until 14 h) did 
not result in enhanced reduction, while treatment for 14 h with 100 M resulted in a gradual, 
but small decline of the cell viability (data not shown).  
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Figure 6.1. Effects of hop-derived prenylflavonoids on cell viability. PC-3 (A) and DU145 (B) cells were 
treated with either 100 M or 200 M X, IX, 8PN or 6PN for 2 h. Cell viability was measured with the 
WST-1 assay. Materials and Methods, see: 6.3 and 6.4.1, respectively. Data are represented as means ± SE 
for three determinations (X: xanthohumol, IX: isoxanthohumol, 8PN: 8-prenylnaringenin, 6PN: 6-
prenylnaringenin). 
 
6.5.2. Morphological analysis 
Morphologic analysis was effected on PC-3 and DU145 prostate cancer cells treated 
with 200 M X, IX, 8PN or 6PN. Figure 6.2 and 6.3 illustrate the morphological changes 
observed in the cells after 12 h and 24 h of incubation. Shorter incubation times did not alter 
the morphology of the cells compared to the control (illustrations not shown). Complete cell 
death occurred after 24 h of incubation. Typical apoptotic changes could not be observed for 
any compound, neither in PC-3 cells, nor in DU145 cells during the complete incubation time 
of 24 h. However, formation of vacuoles was evident after 12 h of treatment with IX and 6PN 
in PC-3 cells, and with IX, 8PN, and 6PN in DU145 cells. 
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Figure 6.2 Effect of hop-derived prenylflavonoids on cell morphology in PC-3 cells. The cells were treated 
with 200 M X, IX, 8PN or 6PN and pictures were taken after the indicated incubation times using a 
phase-contrast microscope at 200x magnification. Materials and Methods, see: 6.3 and 6.4.2, respectively. 
Data shown are from a representative experiment repeated three times with similar results (X: 
xanthohumol, IX: isoxanthohumol, 8PN: 8-prenylnaringenin, 6PN: 6-prenylnaringenin). 
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Figure 6.3 Effect of hop-derived prenylflavonoids on cell morphology in DU145 cells. The cells were 
treated with 200 M X, IX, 8PN or 6PN and pictures were taken after the indicated incubation times 
using a phase-contrast microscope at 200x magnification. Materials and Methods, see: 6.3 and 6.4.2, 
respectively. Data shown are from a representative experiment repeated three times with similar results 
(X: xanthohumol, IX: isoxanthohumol, 8PN: 8-prenylnaringenin, 6PN: 6-prenylnaringenin). 
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6.5.3. Apoptosis inhibition with zVAD-fmk 
We investigated the effect of the broad range pan-caspase inhibitor zVAD-fmk (N-
benzyloxycarbonyl-Val-Ala-Asp(OMe) fluoromethyl ketone) on the time-dependent 
reduction of cell viability caused by X, IX, 8PN or 6PN. PC-3 and DU145 prostate cancer cell 
lines were treated with 25 M zVAD-fmk for 2 h. After incubation, cells were exposed to 
varying concentrations of the hop-derived prenylflavonoids for 18 h and cell viability was 
measured with the WST-1 proliferation assay. As shown in figure 6.4, complete inhibition of 
caspases by zVAD-fmk did not change cell viability expressed as the amount of cell death for 
PC-3 or DU145 cells. However, with DU145 prostate cancer cells, we measured elevated 
values of cell viability as a function of the concentrations of 8PN and 6PN suggesting a partial 
protection from cell death.  Administration of 25 M zVAD-fmk for 2 h on PC-3 or DU145 
prostate cancer cells was not toxic for the cells. 
6.5.4. Analysis of caspase activity 
To demonstrate whether treatment with the hop-derived prenylflavonoids could result 
in the cleavage of pro-caspase-3, we exposed PC-3 and DU145 cells to 200 M X, IX, 8PN or 
6PN for 15, 30, 60, 90, and 120 min, respectively, harvested cell lysates (see: 6.4.4), and 
determined the cleavage of pro-caspase-3 in a time-dependent manner by Western blot 
analysis using specific antibodies. Within the same experimental model, cell lysates were 
harvested (see: 6.4.5) and Ac-DEVD-AMC, a fluorogenic substrate, was used to determine 
the activity of caspase-3 by monitoring the release of fluorescent AMC. As shown in figure 
6.5, no activation of pro-caspase-3 could be detected in treated PC-3 prostate cancer cells. The 
same observations were made for DU145 prostate cancer cells (data not shown). Consistent 
with these results, no activity of caspase-3 could be measured by fluorometric analysis (data 
not shown). 
122
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Figure 6.4: Concentration-dependent effects of zVAD-fmk on the cytotoxicity in PC-3 (A) and DU145 (B) 
cells. Cells were treated for 2 h with 25 M zVAD-fmk. Then, cells were treated with varying 
concentrations of X, IX, 8PN or 6PN for 18 h. Cell viability was measured with the WST-1 assay. 
Materials and Methods, see: 6.3 and 6.4.3, respectively. Data are represented as means ± SE for three 
determinations (X: xanthohumol, IX: isoxanthohumol, 8PN: 8-prenylnaringenin, 6PN: 6-
prenylnaringenin). 
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Figure 6.5: Time-dependent cleavage of pro-caspase-3 in PC-3 prostate cancer cells. Cells were treated at 
the indicated times with 200 M X, IX, 8PN or 6PN and processing of pro-caspase-3 was detected by 
Western Blot analysis using specific antibodies. Materials and Methods, see: 6.3 and 6.4.4, respectively.  
(X: xanthohumol, IX: isoxanthohumol, 8PN: 8-prenylnaringenin, 6PN: 6-prenylnaringenin). 
6.6. Discussion 
Prostate cancer constitutes a major and escalating worldwide health problem. 
Androgen deprivation therapy continues to be the mainstay for metastatic disease. The aim of 
our research program is to examine the effects of hop-derived prenylflavonoids on the growth 
of prostate cancer cells and the mechanisms that are involved in these growth-modulating 
effects. Previous studies with X, IX, 8PN, and 6PN demonstrated dose-dependent 
antiproliferative activities on prostate cancer cells PC-3 and DU145.
67
 In the present study, 
we investigated the mechanism involved by monitoring apoptotic phenomena. Apoptosis is a 
physiological process by which cells are removed when an agent damages their DNA.
79
 
Apoptosis represents a discrete manner of cell death that differs from necrotic cell death and 
is regarded as an efficient way to eliminate damaged cells.
80
 Aberrant control of the balance 
of cell numbers may arise from malignant transformation and induction of apoptosis in 
transformed cell populations suppresses the development of cancer. Agents that can modulate 
apoptosis may be able to affect the steady-state cell population, which may be useful in the 
management and therapy of cancer.
81
 Despite the acquired insights into the necrotic and 
autophagic cell death processes,
82,83
 until now, no general biochemical features have been 
described for the detection of necrosis. Necrotic cell death is, therefore, usually concluded 
124
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from typical morphological features, loss of membrane integrity, and absence of any apoptotic 
feature. 
We investigated the time-dependent cell viability with the WST1 proliferation assay 
and found that exposure of the PC-3 and DU145 prostate cancer cells to 200 M of the hop-
derived prenylflavonoids produced at least 50% cell death after 2 h. From these results, it 
could be concluded that, if apoptosis is the induced process of cell death, early apoptotic 
features should be detectable within 2 h of cell exposure to a concentration of 200 M of the 
compounds.  
Using a phase-contrast light microscope, cells undergoing cell death after incubation 
with the hop-derived prenylflavonoids were examined for specific morphological changes 
associated with the various cell death processes. None of the compounds showed specific 
apoptotic morphological features. Interestingly, cell death occurred only after 12 h of 
incubation, while, in the time-dependent cell viability assay, a reduction of cell viability of at 
least 50% was observed already after 2 h. This could suggest that the compounds change 
mitochondrial activity in an early phase leading to cell death only at a later stage. Another 
interesting observation was the formation of vacuoles in the DU145 prostate cancer cell line 
for IX and 6PN, and in the PC-3 prostate cancer cell line for IX, 6PN, and 8PN. Formation of 
these vacuoles could suggest the occurrence of autophagy. Autophagic cell death is a type of 
programmed cell death, which is characterized by the accumulation of autophagic vacuoles 
and the absence of caspase activation.
84,85,86
 Cell death characterized by a combination of 
apoptotic and autophagic features is frequently observed and making a clear-cut difference 
between them is difficult.
87,88
 Autophagy is a cell-survival mechanism during nutrient 
starvation
89,90
 that supplies vital components until conditions improve. This process is 
characterized by the formation of double or multiple membrane–bound autophagosomes that 
engulf cytoplasmic material. After maturation, autophagosomes fuse with lysosomes to digest 
the sequestered material. Autophagy was recently established as a novel tumor suppression 
mechanism.
91
 Autophagy might exert its tumor suppression function at the subcellular level 
by removing defective cytoplasmic components such as damaged mitochondria. In addition, it 
might function at the cellular level by helping the orderly removal of damaged cells. Previous 
studies indicated that autophagy is compromised in human breast, ovarian, and prostate 
cancers.
91
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Treatment with the caspase inhibitor zVAD-fmk did not rescue prostate cancer cells 
from the time-dependent reduction of cell viability caused by hop-derived prenylflavonoids 
suggesting that apoptosis is not the induced mechanism of cell death. However, in DU145 
prostate cancer cells, we measured elevated values of cell viability as a function of the 
concentrations of 8PN and 6PN indicating partial protection from cell death. These results 
also suggest possible involvement of caspases in the cell-death process activated by 8PN and 
6PN.   
Activation of caspases, a family of cysteine proteases that specifically cleave at 
aspartic acid residues, is central to the execution of apoptosis.
92,93
 We investigated the 
activation and activity of caspase-3, which is considered to play a central role in many types 
of stimuli-induced apoptosis.
94,95 
No cleavage or activation of caspase-3 could be 
demonstrated for all compounds investigated. 
6.7. Conclusions 
There is no evidence for induction of apoptotic cell death in prostate cancer cells PC-3 
and DU145 upon treatment with the hop-derived prenylflavonoids X, IX, 8PN, and 6PN. 
However, considering the formation of vacuoles in PC-3 prostate cancer cells when treated 
with IX and 6PN, and in DU145 prostate cancer cells when treated with IX, 6PN, and 8PN, it 
is suggested that autophagy is induced, which could consequently lead to cell death in this 
model. Therefore, IX, 8PN, and 6PN appear to be promising candidates for further 
investigation in prostate anticancer therapy.  
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CONCLUSIONS 
This research project has resulted in the first insights into the chemopreventive or 
therapeutic properties of the hop-derived prenylflavonoids xanthohumol (X), 
desmethylxanthohumol (DMX), isoxanthohumol (IX), 8-prenylnaringenin (8PN), and 6-
prenylnaringenin (6PN) on prostate cancer.  
The compounds were found to inhibit the proliferation of the human prostate cancer 
cells PC-3, DU145, and LNCaP.FGC in a dose-dependent manner. Antiproliferative activities 
of X and 6PN were found to be strongest for prostate cancer cells PC-3 and DU145, while, on 
LNCaP.FGC, these compounds first exerted a strong induction of cell proliferation followed 
by a proliferation shut-off. 8PN, a hop-derived prenylflavanone which has previously been 
identified as a highly potent phytoestrogen, showed weaker antiproliferative effects on 
prostate cancer cell lines PC-3 and DU145, confirming the proposed importance of the ER 
receptor in the antiproliferative activity of prostate cancer cells. However, on LNCaP.FGC 
prostate cancer cells 8PN demonstrated a more potent growth inhibition. IX exhibited 
activities on prostate cancer cells PC-3 and DU145 comparable to those of 8PN, but it was 
more effective on LNCaP.FGC cells. DMX was the least active compound in all cell lines. 
The observed stimulatory effect on LNCaP.FGC prostate cancer cells is exerted in the low 
micromolar range and could result from the stimulatory activity of X and 6PN through a 
mutated androgen receptor. The effect of the prenylflavonoids on early-stage prostate cancer 
(LNCaP.FGC) proved to be different compared to late-stage prostate cancer (PC-3 and 
DU145) and this should be considered when considering the possible protective effects 
regarding prostate cancer development and progression. No quantitative relation between the 
estrogenic potency as measured in the recombinant yeast estrogen screen and antiproliferative 
effects could be concluded. The strong antiproliferative activity of X in endothelial cells 
suggests potential antiangiogenic activity compromising tumor growth and metastasis. 
Further research into the underlying mechanisms of growth inhibition revealed that 
there was no evidence for induction of apoptotic cell death in prostate cancer cells PC-3 and 
DU145 upon treatment with the hop-derived prenylflavonoids X, IX, 8PN, and 6PN. 
However, considering the formation of vacuoles in PC-3 prostate cancer cells when treated 
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with IX and 6PN, and in DU145 prostate cancer cells when treated with IX, 6PN, and 8PN, it 
is suggested that autophagy is induced, which could consequently lead to cell death in this 
model.  
It can be concluded that the hop-derived prenylflavonoids X, IX, 8PN, and 6PN appear 
to be promising candidates for further investigation in prostate anticancer therapy and 
chemoprevention, especially in the final stages. 
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SUMMARY 
Benign prostate hypertrophy (BPH) and prostate cancer (PC) are highly common 
among aging men causing bothersome symptoms or developing into life-threatening diseases. 
Whereas the treament and relief of BPH has noticeably progressed, the treatment of invasive 
prostate cancer has remained elusive. Phytoestrogens could influence hormone-dependent 
diseases including BPH and PC by their varying bioactivities. Hop (Humulus lupulus L.) 
contains a number of prenylflavonoids, with 5 representatives most interesting for their 
bioactivities: xanthohumol (X), desmethylxanthohumol (DMX), isoxanthohumol (IX), 8-
prenylnaringenin (8PN), and 6-prenylnaringenin (6PN). 
This research project has focused on the investigation of the chemopreventive or 
therapeutic properties of the hop-derived prenylflavonoids X, DMX, IX, 8PN, and 6PN on 
PC. We aimed to get insights in how the hop-derived prenylflavonoids influence the 
pathogenesis of PC and in how the underlying mechanisms operate. Therefore, a series of in 
vitro experiments was set up using the well-established human prostate cancer cell lines 
LNCaP.FGC, PC-3, and DU145.  
The investigation of the growth-influencing properties revealed that X proved to be the 
most potent compound in inhibiting the growth of all cell lines (except for the LNCaP.FGC 
cell line) with IC50 values of 12.3 ± 1.1 M for DU145, and 13.2 ± 1.1 m for PC-3. 6PN 
was, for all cell lines (except for the LNCaP.FGC cell line), the second most active growth 
inhibitor showing most significant effects on PC-3 cells (IC50 of 18.4 ± 1.2 M), followed by 
DU145 (IC50 of 29.1 ± 1.1 M). 8PN, a compound that has been previously identified as a 
potent phytoestrogen, showed weaker antiproliferative effects on PC-3 and DU145 but proved 
the be more potent on LNCaP.FGC prostate cancer cells (IC50 of 33.5 ± 1.0, 43.1 ± 1.2 M 
and IC50 of 42.8 ± 1.2, respectively). IX showed activities on prostate cancer cells comparable 
to those of 8PN (IC50 of 45.2 ± 1.1 M on PC-3 and 47.4 ± 1.1 M on DU145) and proved to 
be the most potent inhibitor of LNCaP.FGC prostate cancer cells with an IC50 of 34.4 ± 1.0 
M. DMX was the least active compound in all the cell lines. On LNCaP.FGC prostate cancer 
cells, X and 6PN showed a biphasic dose-response behavior stimulating growth at low 
concentration and inhibiting growth at higher concentrations. IX and 8PN, which are the most 
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potent inhibitors for the growth of this cell line, inhibited growth at the same concentrations 
where X and 6PN stimulated it.  
The recombinant yeast estrogen screen (YES) was used to investigate the binding 
capacity of the compounds to the estrogen receptor alpha (ER) and their potency to 
subsequently stimulate a signal-transduction cascade resulting in secretion of -galactosidase. 
The estrogenic activity of 8PN determined by YES was approximately 300-fold lower than 
that of 17-estradiol, but 10-, 50- and 10,000-fold higher than the activities of DMX, 6PN, 
and X/IX, respectively. Furthermore, 8PN, 6PN, and DMX behaved as full agonists, while X 
and IX behaved as partial agonists on ER. Growth-stimulatory experiments using human 
breast cancer cells MCF7/6 confirmed the estrogenic potency of 8PN (EC50 value for growth 
stimulation of 4.2 ± 1.3 nM). No quantitative relation between the estrogenic potencies and 
the proliferative or antiproliferative effects could be established. 
Furthermore, the prenylflavonoids X, DMX, IX, 8PN, and 6PN were examined in 
vitro for their antiangiogenic activities on a human bone marrow endothelial cell line 
(HBME). Chalcone X proved to be a very potent inhibtor of the growth of HBME endothelial 
cells with an IC50 value of 3.2 ± 1.2 M.  IX and 6PN were the second most active growth 
inhibitors with IC50 values of 29.4 ± 1.1 M and 39.8 ± 1.0 M, respectively. 8PN and DMX 
were the least active growth inhibitors with IC50 values of 77.1 ± 1.0 M and 72.7 ± 1.0 M, 
respectively. These preliminary results strongly suggest that X could be a promising 
antiangiogenic agent. 
Further research into the mechanisms by which cell death was induced revealed that 
all compounds induced cell death in the absence of caspase-3 activation and typical apoptotic 
morphological features. The general pan-caspase inhibitor zVAD-fmk could not protect this 
form of cell death. In addition, we observed the formation of vacuoles in PC-3 cells treated 
with IX and 6PN, and in DU145 cells treated with IX, 8PN, and 6PN, which could suggest the 
induction of autophagy and consequent cell death.  
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SAMENVATTING 
Goedaardige prostaathypertrofie (‘benign prostate hypertrophy”, BPH) en 
prostaatkanker (‘prostate cancer’, PC) zijn veel voorkomende aandoeningen van de prostaat 
bij oudere mannen, gepaard gaande met onaangename symptomen en mogelijke ontwikkeling 
tot levensbedreigende situaties. Waar behandeling en onderdrukking van de symptomen van 
BPH reeds in een gevorderd stadium van ontwikkeling zijn, verkeert behandeling van 
invasieve PC nog in een beginfase. Fyto-oestrogenen kunnen, omwille van hun breed 
spectrum aan bio-activiteiten, hormoon-afhankelijke aandoeningen, zoals BPH en PC 
beïnvloeden. Hop (Humulus lupulus L.) is rijk aan prenylflavonoïden, waarvan 5 
componenten zeer interessante bio-activiteiten vertonen: xanthohumol (X), 
desmethylxanthohumol (DMX), isoxanthohumol (IX), 8-prenylnaringenine (8PN) en 6-
prenylnaringenine (6PN). 
Dit onderzoeksproject omvat de studie van de chemopreventieve en/of therapeutische 
eigenschappen van de prenylflavonoïden X, DMX, IX, 8PN en 6PN uit hop bij PC. Onze 
doelstelling was inzicht te verkrijgen in de wijze, waarop de prenylflavonoïden uit hop de 
pathogenese van PC kunnen beïnvloeden, en in de onderliggende mechanismen, die hierbij 
een rol spelen. Daartoe werden een reeks in vitro experimenten uitgevoerd, gebruik makende 
van de gevestigde prostaatkankercellijnen  LNCaP.FGC, PC-3 en DU145. 
Het onderzoek naar de potentiële groei-beïnvloedende eigenschappen toonde aan dat 
X de krachtigste groeiremmer was voor alle cellijnen (behalve voor de LNCaP.FGC cellijn) 
met IC50 waarden van 12.3 ± 1.1 M voor DU145 en 13.2 ± 1.1 m voor PC-3. 6PN was, 
voor alle cellijnen (behalve voor de LNCaP.FGC cellijn), de tweede krachtigste groeiremmer 
en vertoonde de sterkste werking bij PC-3 cellen (IC50 van 18.4 ± 1.2 M), gevolgd door 
DU145 (IC50 van 29.1 ± 1.1 M). 8PN, een zeer sterk fyto-oestrogeen, vertoonde een 
zwakker antiproliferatief effect bij PC-3 and DU145, maar bleek een sterker groeiremmend 
effect te vertonen bij LNCaP.FGC prostaatkankercellen (IC50 van 33.5 ± 1.0, 43.1 ± 1.2 M
en IC50 van 42.8 ± 1.2, respectievelijk). IX vertoonde vergelijkbare activiteiten bij 
prostaatkankercellen met deze van 8PN (IC50 van 45.2 ± 1.1 M bij PC-3 en 47.4 ± 1.1 M
bij DU145) en was de krachtigste groeiremmer van LNCaP.FGC prostaatkankercellen met 
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een IC50 van 34.4 ± 1.0 M. DMX was de minst actieve verbinding bij alle onderzochte 
cellijnen. Bij LNCaP.FGC vertoonden X en 6PN een bifasisch dosis-responsgedrag met 
groeistimulatie bij lage concentraties en groeiremming bij hogere concentraties. IX en 8PN, 
de sterkste groeiremmers voor deze cellijn, inhibeerden de groei bij dezelfde concentraties, 
waarbij X en 6PN de groei stimuleerden.  
De recombinante oestrogene gistassay (‘yeast estrogen screen’, YES) werd gebruikt 
om de bindingscapaciteit van de verbindingen aan de oestrogeen receptor alfa (ER) te 
onderzoeken, samen met hun stimulatie van de erop volgende signaaltransductiecascade, 
resulterend in de afscheiding van  -galactosidase. De oestrogene activiteit van 8PN volgens 
YES bleek ongeveer 300-maal geringer te zijn dan deze van 17-oestradiol, doch 10-, 50- en 
10,000-maal krachtiger dan de activiteiten van, respectievelijk, DMX, 6PN en X/IX. 
Bovendien gedroegen 8PN, 6PN en DMX zich als volle agonisten, waar X en IX fungeerden 
als partiële agonisten ten opzichte van ER. Groeistimulerende experimenten bij MCF7/6 
borstkankercellen bevestigden de sterke oestrogene activiteit van 8PN (EC50 waarde voor 
groeistimulatie van 4.2 ± 1.3 nM). Er werd geen kwantitatief verband gevonden tussen de 
oestrogene werking en de proliferatieve of antiproliferatieve effecten.  
De in vitro anti-angiogene eigenschappen van de prenylflavonoïden X, DMX, IX, 8PN 
en 6PN werden onderzocht aan de hand van een humane beenmerg endotheliale cellijn 
(HBME). Chalcon X bleek een zeer krachtige groeiremmer te zijn voor de HBME 
endotheliale cellen met een IC50 waarde van 3.2 ± 1.2 M.  IX en 6PN waren actieve groei-
inhibitoren met IC50 waarden van, respectievelijk, 29.4 ± 1.1 M en 39.8 ± 1.0 M. 8PN en 
DMX waren de minst actieve groeiremmers met IC50 waarden van, respectievelijk, 77.1 ± 1.0 
M en 72.7 ± 1.0 M. Deze resultaten geven reeds een sterk vermoeden dat X een 
veelbelovende anti-angiogene verbinding zou kunnen zijn. 
Verder onderzoek naar de mechanismen van celdoodinductie toonden aan dat de 
prenylflavonoïden celdood induceerden in afwezigheid van caspase-3 activatie en typische 
apoptotische morfologische kenmerken. De algemene pan-caspase inhibitor zVAD-fmk kon 
de cellen niet beschermen tegen deze vorm van celdood. Bovendien hebben we de vorming 
van vacuolen bij de PC-3 cellen waargenomen na behandeling met IX en 6PN, en bij de 
DU145 cellen na behandeling met IX, 8PN en 6PN, wat inductie van autofagie gevolgd door 
celdood suggereert.  
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